Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE I)E CETTE DEMANDE OU CE BREVETS
COMPRI~:ND PLUS D'UN TOME.
CECI EST ~.E TOME 1 DE 2
NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des
Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.
THIS IS VOLUME 1 OF 2
NOTE: For additional vohxmes please contact the Canadian Patent Oi~ice.
CA 02542121 2006-04-07
SPECIFICATION
GENOMICALLY MODIFIED CELL NEUTRALIZED TO SERUM-FREE SYSTEM
Technical Field
The present invention relates to a cell in which a genomic gene encoding an
enzyme relating to a sugar chain modification in which 1-position of fucose is
bound to
6-position of N-acetylglucosamine in the reducing end through a-bond in a
complex
type N-glycoside-linked sugar chain is knocked out, wherein the cell is
naturalized in a
medium containing no serum (hereinafter referred to as "serum-free medium"),
and a
process for producing a glycoprotein composition, such as an antibody, by
using the cell.
Background Art
Hanai et al. have reported that addition of fucose to N-acetylglucosamine in
the reducing end in N-glycoside-linked sugar chains of an antibody decreases
antibody-
dependent cellular cytotoxic activity (ADCC activity) of the antibody to
fiftieth
[WO00/61739, J. Biol. Chem., 278, 3466 (2003)]. These reports show that the
sugar
chain structure plays a considerably important role in the effector function
of human
IgGI subclass antibodies, and that a change in the sugar chain structure
results in a
2 0 change in the pharmacological activity relating to the effector function.
In general, most of glycoproteins including antibodies applicable to
medicaments are prepared by using genetic recombination techniques, and are
produced
by using, as a host cell, an animal cell such as Chinese hamster ovary tissue-
derived
CHO cell. However, since sugar chain structures of expressed glycoproteins are
2 5 different depending on the host cell, a sugar chain having the- most
suitable
pharmacological activity is not always added to the glycoprotein under the
present
situation.
Particularly, when addition of fucose to N-acetylglucosamine in the
reducing end in the N-glycoside-linked sugar chain greatly reduces the
pharmacological
3 0 activity like the case of an antibody, it is essential to properly prepare
and provide an
antibody molecule having a sugar chain structure which is not modified with
fucose for
the purpose of providing patients with a high quality medical treatment.
Accordingly,
it has been desired to develop techniques for controlling the sugar chain
structure of a
glycoprotein.
3 5 The sugar chain structure of a glycoprotein is regulated by sugar chain
genes
which are genes encoding a glycosyltransferase which synthesizes the sugar
chain and a
-1-
CA 02542121 2006-04-07
glycolytic enzyme which degrades the sugar chain. Also, it is regulated by
genes
encoding proteins capable of carrying out functions such as biosynthesis of an
intracellular sugar nucleotide which becomes the donor of a saccharide to the
sugar
chain and transfer thereof to the Golgi body. A possibility has been shown
that the
sugar chain structure of a glycoprotein produced by the host cell can be
controlled by
introducing a gene relating to the modification of these sugar chains into a
host cell, or
mutating them.
Attempts have been made to modify the sugar chain structure of a produced
glycoprotein by introducing a gene encoding an enzyme relating to the
modification of a
sugar chain. Specifically, it has been reported that 1) it is possible to
produce a protein
in which sialic acid is added in large numbers to the non-reducing end of its
sugar chain
by introducing rat (3-galactoside a2,6-sialyltransferase into CHO cell [J.
Biol. Chem.,
261, 13848 (1989)], 2) it is possible to express an H antigen (Fuc a.l-2Gal
(31-) in which
fucose (hereinafter referred also to as Fuc) is added to the non-reducing end
of its sugar
chain, by introducing human (3-galactoside 2-a-fucosyltransferase into mouse L
cell
[Science, 252, 1668 (1991)], and 3) it is possible to produce an antibody
having a high
addition ratio of N-acetylglucosamine at the bisecting of N-glycoside-linked
sugar chain
by producing the antibody using CHO cell into which [31,4-N-acetylglucosamine
transferase III (GnTIll) is introduced [Glycobiology, 5, 813 (1995),
W099/54342]. It
2 0 has been reported that, when an antibody was expressed using CHO cell into
which
GnTIII was introduced, it showed 16 times higher ADCC activity than the
antibody
expressed by the parent cell line. However, over-expression of GnTIII or (31,4-
N-
acetylglucosamine transferase V (GnTV) showed toxicity upon CHO cell.
The mutants in which the activity of a gene relating to the modification of a
2 5 sugar chain is changed have been obtained, for example, as clones showing
resistance to
a lectin such as WGA (wheat-germ agglutinin derived from T. vulgaris), ConA
(concanavalin A derived from C. ensiformis), RIC (a toxin derived from R.
communis),
L-PHA (leukoagglutinin derived from P. vulgaris), LCA (lentil agglutinin
derived from
L. culinaris), PSA (pea lectin derived from P. sativum) or the like [Somatic
Cell Mol
30 Genet., 12, 51 (1986)]. A case has been reported in which a glycoprotein in
which a
produced sugar chain structure is changed is produced by using such a mutant,
as the
host cell, in which the activity of a gene relating to the modification of a
sugar chain
was changed. Examples include a report on the production of an antibody having
a
high mannose type sugar chain structure using a CHO cell mutant clone in which
the
35 activity of N-acetylglucosamine transferase I (GnTI) was deleted [J.
Immunol., 160,
3393 (1998)].
-2-
CA 02542121 2006-04-07
In addition, a case has been reported on expression of an antibody having a
sugar chain structure in which sialic acid is not added to the non-reducing
end in the
sugar chains or expression of an antibody without addition of galactose
thereto, using a
CMP-sialic acid transporter- or UDP-galactose transporter-deficient clone, but
expression of an antibody having ef~ector activity improved to a degree
suitable for
appliccation to a medicament has not been succeeded [J. Immunol., 160, 3393
(1998)].
Under such a situation, it has been reported that an antibody having high
ADCC activity and is highly suitable for application to a medicament can be
produced
by using, as the host cell, a clone having decreased activity of GDP-mannose
4,6
dehydratase, an enzyme capable of catalyzing a dehydration reaction to convert
GDP
mannose into GDP-4-keto,6-deoxy-GDP-mannose [WO00/61739; J. Biol. Chem., 277,
26733 (2002)]. In these reports, as the host cell, a lectin-resistant clone
which can
recognize a sugar chain structure in which 1-position of fucose is bound to 6-
position of
N-acetylglucosamine in the reducing end in complex type N-glycoside-linked
sugar
chains through a.-bond, such as clone CHO-AAL which is resistant to AAL (a
lectin
derived from Aleuria aurantia), clone CHO-LCA which is resistant to LCA
(lentil
agglutinin derived from L. culinaris) or clone Lec 13 is used as the host
cell. In
addition to these, PLR1.3 established as a PSA (pea lectin derived from P.
sativum)
resistant mutant of a mouse leukemia-derived clone BW 5147 is also known as a
clone
2 0 having decreased activity of GDP-mannose 4,6-dehydratase [J. Biol. Chem.,
255, 9900
(1980)].
However, since each of these clones is not a complete gene deficient clone,
it is difficult to completely make a sugar chain structure, which is a cause
of showing
high ADCC activity by the antibody. Namely it is difficult to completely
inhibit
2 5 addition of fucose to the N-acetylglucosamine in the reducing erid in
complex type N-
glycoside-linked sugar chains. Particularly, since mutant clones such as
PLR1.3 and
Lecl3 are obtained by randomly introducing mutation through a mutagen
treatment, it
cannot always be said that they have properties suited as clones to be used in
the
production of pharmaceutical preparations. On the other hand, there has been
no
3 0 reports in which attempts to produce a glycoprotein such as an antibody
using a clone
prepared by disrupting a target gene alone on purpose, wherein an enzyme gene
concerned in the sugar chain modification of the host cell is used as the
target were
made.
In addition, when serum is present in the culture medium in producing a
3 5 physiologically active protein such as a glycoprotein by an animal cell or
a recombinant
animal cell, the difference in serum lots exerts serious influence upon the
cell yield and
-3-
CA 02542121 2006-04-07
productivity, and it is necessary to take into consideration a possibility of
causing
contamination of the final purified product with pathogenic microorganism such
as
virus or prion. Accordingly, when a physiologically active protein is produced
using
an animal cell in order to apply it to a medicament, it is preferable to
culture the cell
using a medium containing no serum.
Disclosure of the Invention
An object of the present invention is to provide a cell in which a genomic
gene relating to a sugar chain modification in which 1-position of fucose is
bound to
6-position of N-acetylglucosamine in the reducing end through a,-bond in a
complex
type N-glycoside-linked sugar chain is knocked out, wherein the cell is
naturalized in a
medium containing no serum; a process for producing a glycoprotein composition
using
the cell; and a glycoprotein composition produced by the process. The cell of
the
present invention is useful for producing a glycoprotein composition such as
an
antibody composition which has a modified sugar chain structure and is useful
in
pharmaceutical development.
The present invention relates to the following (1) to (27):
(1) A cell in which a genomic gene encoding an enzyme relating to a sugar
chain modification in which 1-position of fucose is bound to 6-position of N
2 0 acetylglucosamine in the reducing end through oc-bond in a complex type N-
glycoside
linked sugar chain is knocked out, wherein the cell is naturalized in a serum-
free
medium.
(2) The cell according to the above (I), wherein all of alleles on a genome
encoding an enzyme relating to modification of a sugar chain in which 1-
position of
2 5 fucose is bound to 6-position of N-acetylglucosatnine in the reducing end
through a-
bond in a complex type N-glycoside-linked sugar chain are knocked out, and
wherein
the cell is naturalized in a serum-free medium.
(3) The cell according to the above (1) or (2), wherein an exon region
containing an initiation codon of the genomic gene encoding an enzyme relating
to
3 0 modification of a sugar chain in which 1-position of fucose is bound to 6-
position of N-
acetylglucosamine in the reducing end through a-bond in a complex type N-
glycoside-
linked sugar chain is deleted, and wherein the cell is naturalized in a serum-
free medium.
(4) The cell according to any one of the above (1) to (3), wherein the enzyme
relating to modification of a sugar chain in which 1-position of fucose is
bound to 6-
3 5 position of N-acetylglucosamine in the reducing end through oc-bond in a
complex type
N-glycoside-linked sugar chain is a-1,6-fucosyltransferase.
-4-
CA 02542121 2006-04-07
(5) The cell according to the above (4), wherein the a-1,6-fucosyltransferase
is
a protein encoded by a DNA selected from the following (a) or (b):
(a) a DNA comprising the nucleotide sequence represented by SEQ ID NO:1;
(b) a DNA which hybridizes with a DNA consisting of the nucleotide sequence
represented by SEQ 1D NO:1 under stringent conditions and encodes a protein
having
a-1,6-fucosyltransferase activity.
(6) The cell according to the above (4), wherein the a-1,6-fucosyltransferase
is
a protein selected from the group consisting of the following (a), (b) and
(c):
(a) a protein comprising the amino acid sequence represented by SEQ >D NO:S;
(b) a protein consisting of an amino acid sequence in which one or more amino
acids) is/are deleted, substituted, inserted and/or added in the amino acid
sequence
represented by SEQ B7 NO:S and having a-1,6-fucosyltransferase activity;
(c) a protein consisting of an amino acid sequence which has at least 80%
amino acid sequence homology to the amino acid sequence represented by SEQ B7
NO:S and having a-1,6-fucosyltransferase activity.
(7) The cell according to any one of the above (1) to (6), which is resistant
to a
lectin which recognizes a sugar chain structure in which 1-position of fucose
is bound to
6-position of N-acetylglucosamine in the reducing end through a-bond in a
complex
type N-glycoside-linked sugar chain.
2 0 (8) The cell according to the above (7), wherein said resistance is
resistance in
which the cell survives at a higher ratio than a cell in which the genomic
gene has not
been knocked out when the cells are cultured in a medium containing the lectin
which
recognizes a sugar chain structure in which 1-position of fucose is bound to 6-
position
of N-acetylglucosamine in the reducing end through a-bond in a complex type N
2 5 glycoside-linked sugar chain.
(9) The cell according to any one of the above (1) to (7), wherein the serum-
free
medium is a protein-free medium.
(10) The cell according to any one of the above (1) to (9), which comprises a
gene encoding a glycoprotein.
3 0 ( 11 ) The cell according to the above ( 10), wherein the glycoprotein is
a
glycoprotein having no sugar chain structure in which 1-position of fucose is
bound to
6-position of N-acetylglucosamine in the reducing end through a-bond in a
complex
type N-glycoside-linked sugar chain.
( 12) The cell according to the above ( 10) or ( 11 ), wherein the
glycoprotein is an
3 5 antibody.
-5-
CA 02542121 2006-04-07
(13) The cell according to the above (12), wherein the antibody belongs to an
IgG class.
(14) A process for producing a glycoprotein composition, which comprises using
the cell according to any one of the above (1) to (13).
(15) A process for producing a glycoprotein composition, which comprises
culturing the cell according to any one of the above ( 1 ) to ( 13) in a
medium to form and
accumulate the glycoprotein composition in the culture, and recovering and
purifying
the glycoprotein composition from the culture.
(16) The process for producing a glycoprotein composition according to the
above (14) or (15), wherein the process is carried out by batch culture, fed-
batch culture
or perfusion culture.
( 17) The process according to any one of the above ( 14) to ( 16), wherein at
least
one selected from a nutrient factor and a physiologically active substance is
added to the
medium during culturing.
(18) The process according to the above (17), wherein the nutrient factor is
at
least one selected from a glucose, an amino acid and a vitamin.
( 19) The process according to the above ( 17), wherein the physiologically
active
substance is at least one selected from an insulin, an insulin-like growth
factor,
transferrin and albumin.
2 0 (20) The process according to any one of the above ( 14) to ( 19), wherein
the
glycoprotein composition is an antibody composition.
(21) A method for naturalizing a cell in which a genomic gene encoding an
enzyme relating to a sugar chain modification in which 1-position of fucose is
bound to
6-position of N-acetylglucosamine in the reducing end through oc-bond in a
complex
2 5 type N-glycoside-linked sugar chain is knocked out in a serum-free medium,
which
comprises inoculating the cell into a medium for naturalization to give a cell
density of
1 x 105 to 1 x 106 cells/ml.
(22) A method for obtaining a clone in which a genomic gene encoding an
enzyme relating to a sugar chain modification in which 1-position of fucose is
bound to
3 0 6-position of N-acetylglucosamine in the reducing end through a-bond in a
complex
type N-glycoside-linked sugar chain is knocked out, which comprises
naturalizing the
cell in a serum-free medium by the method according to the above (21), and
then
cloning the cell.
(23) A cell in which a genomic gene encoding an enzyme relating to a sugar
35 chain modification in which 1-position of fucose is bound to 6-position of
N
acetylglucosamine in the reducing end through a,-bond in a complex type N-
glycoside
-6-
CA 02542121 2006-04-07
linked sugar chain is knocked out, wherein the cell is naturalized in a serum-
free
medium, which is obtainable by the method according to the above (21).
(24) A clone in which a genomic gene encoding an enzyme relating to a sugar
chain modification in which 1-position of fucose is bound to 6-position of N
acetylglucosamine in the reducing end through a-bond in a complex type N-
glycoside
linked sugar chain is knocked out, wherein the clone is naturalized in a serum-
free
medium, which is obtainable by the method according to the above (22).
(25) The method according to the above (21) or (22), wherein the serum-free
medium is a protein-free medium,
(26) The cell according to the above (23), wherein the serum-free medium is a
protein-free medium.
(27) The clone according to the above (24), wherein the serum-free medium is a
protein-free medium.
The present invention is described below in detail. This application is
based on the priority of Japanese patent application No. 2003-350166 filed on
October 9,
2003, and the entire contents of the specification and the drawings in the
patent
application are incorporated hereinto by reference.
The cell of the present invention in which a genomic gene encoding an
2 0 enzyme relating to a sugar chain modification in which 1-position of
fucose is bound to
6-position of N-acetylglucosamine in the reducing end through oc-bond in a
complex
type N-glycoside-linked sugar chain is knocked out, wherein the cell is
naturalized in a
serum-free medium (hereinafter referred to as the cell of the present
invention) includes
a cell in which a genomic gene is modified so as to delete the activity of an
enzyme
relating to a sugar chain modification in which 1-position of fucose is bound
to
6-position of N-acetylglucosamine in the reducing end through a-bond in a
complex
type N-glycoside-linked sugar chain (hereinafter referred to as the a-1,6-
fucose
modifying enzyme).
In the present invention, modification of genome so as to delete the activity
of the oc-1,6-fucose modifying enzyme means that mutation is introduced into
an
expression-controlling region of the gene so as to delete the expression of
the enzyme,
or that mutation is introduced into an amino acid sequence of the gene so as
to delete
the function of the enzyme. Introduction of the mutation means that
modification of a
nucleotide sequence such as deletion, substitution, insertion and/or addition
is carried
3 5 out in the nucleotide sequence on the genome. Complete inhibition of the
expression
or function of the modified genomic gene is called "knocked out". Examples in
which
CA 02542121 2006-04-07
a genomic gene is knocked out include a case in which the gene as the target
is
completely or partially deleted from the genome. Specific examples include
deletion
of a genomic region of exon containing at least an initiation codon from the
chromosome or deletion of all of alleles in the gene encoding the a-1,6-fucose
modifying enzyme.
Accordingly, the cell of the present invention includes a cell in which all of
alleles on a genome encoding the a-1,6-fucose modifying enzyme are knocked out
or a
cell in which an exon region containing at least an initiation codon of the
enzyme,
wherein the cell is naturalized in a serum-free medium.
The a-1,6-fucose modifying enzyme means an enzyme relating to a sugar
chain modification in which 1-position of fucose is bound to 6-position of N-
acetylglucosamine in the reducing end through a-bond in a complex type N-
glycoside-
linked sugar chain. The enzyme relating to a sugar chain modification in which
1-
position of fucose is bound to 6-position of N-acetylglucosamine in the
reducing end
through a-bond in a complex type N-glycoside-linked sugar chain also includes
an
enzyme having influence on the reaction.
Specific examples of the a-1,6-fucose modifying enzyme include a-1,6-
fucosyltransferase, a-L-fucosidase and the like.
Furthermore, the enzyme having influence on the reaction in which 1-
2 0 position of fucose is bound to 6-position of N-acetylglucosamine in the
reducing end
through a-bond in a complex type N-glycoside-linked sugar chain also includes
an
enzyme having influence on the above a-1,6-fucose modifying enzyme activity or
influence on structure of a substance which is used as a substrate of the
enzyme.
In the present invention, the a-1,6-fucosyltransferase includes a protein
2 5 encoded by a DNA of the following (a), (b), (c), (il), (e), (f), (g) or
(h); a protein of the
following (i), (j), (k), (1), (m), (n), (o), (p), (q), (r), (s) or (t), and
the like:
(a) a DNA comprising the nucleotide sequence represented by SEQ m NO: l;
(b) a DNA comprising the nucleotide sequence represented by SEQ >17 N0:2;
(c) a DNA comprising the nucleotide sequence represented by SEQ lD N0:3;
3 0 (d) a DNA comprising the nucleotide sequence represented by SEQ ID N0:4;
(e) a DNA which hybridizes with a DNA consisting of the nucleotide sequence
represented by SEQ >D NO:I under stringent conditions and encodes a protein
having
a-1,6-fucosyltransferase activity;
(f) a DNA which hybridizes with a DNA consisting of the nucleotide sequence
3 5 represented by SEQ ID N0:2 under stringent conditions and encodes a
protein having
a-1,6-fucosyltransferase activity;
_g_
CA 02542121 2006-04-07
(g) a DNA which hybridizes with a DNA consisting of the nucleotide sequence
represented by SEQ >D N0:3 under stringent conditions and encodes a protein
having
a-1,6-fucosyltransferase activity;
(h) a DNA which hybridizes with a DNA consisting of the nucleotide sequence
represented by SEQ >I7 N0:4 under stringent conditions and encodes a protein
having
a-1,6-fucosyltransferase activity;
(i) a protein comprising the amino acid sequence represented by SEQ >D NO:S;
(j) a protein comprising the amino acid sequence represented by SEQ >D N0:6;
(k) a protein comprising the amino acid sequence represented by SEQ >D N0:7;
(1) a protein comprising the amino acid sequence represented by SEQ >D N0:8;
(m) a protein consisting of an amino acid sequence in which one or more amino
acids) is/are deleted, substituted, inserted and/or added in the amino acid
sequence
represented by SEQ >D NO:S and having a-1,6-fucosyltransferase activity;
(n) a protein consisting of an amino acid sequence in which one or more amino
acids) is/are deleted, substituted, inserted andlor added in the amino acid
sequence
represented by SEQ >D N0:6 and having a-1,6-fucosyltransferase activity;
(o) a protein consisting of an amino acid sequence in which one or more amino
acids) is/are deleted, substituted, inserted and/or added in the amino acid
sequence
represented by SEQ >D N0:7 and having a-1,6-fucosyltransferase activity;
2 0 (p) a protein consisting of an amino acid sequence in which one or more
amino
acids) is/are deleted, substituted, inserted and/or added in the amino acid
sequence
represented by SEQ B7 N0:8 and having a-1,6-fucosyltransferase activity;
(q) a protein consisting of an amino acid sequence which has 80% or more
homology to the amino acid sequence represented by SEQ 1D NO:S and having a-
1,6
2 5 fucosyltransferase activity;
(r) a protein consisting of an amino acid sequence which has 80% or more
homology to the amino acid sequence represented by SEQ >D N0:6 and having a-
1,6-
fucosyltransferase activity;
(s) a protein consisting of an amino acid sequence which has 80% or more
30 homology to the amino acid sequence represented by SEQ D7 N0:7 and having a-
1,6
fucosyltransferase activity;
(t) a protein consisting of an amino acid sequence which has 80% or more
homology to the amino acid sequence represented by SEQ ID N0:8 and having a-
1,6-
fucosyltransferase activity.
35 Also, the DNA encoding the a-1,6-fucosyltransferase includes a DNA
comprising the nucleotide sequence represented by SEQ ID NO:1, 2, 3 or 4 and a
DNA
-9-
CA 02542121 2006-04-07
which hybridizes with the DNA consisting of the nucleotide sequence
represented by
SEQ m NO:1, 2, 3 or 4 under stringent conditions and encodes an amino acid
sequence
having a,-1,6-fucosyltransferase activity.
In the present invention, a DNA which hybridizes under stringent conditions
is a DNA obtained, e.g., by a method such as colony hybridization, plaque
hybridization
or Southern blot hybridization using a DNA consisting of the nucleotide
sequence
represented by SEQ m NO:1, 2, 3 or 4 or a partial fragment thereof as the
probe, and
specifically includes a DNA which can be identified by carrying out
hybridization at
65°C in the presence of 0.7 to 1.0 M sodium chloride using a filter to
which colony- or
plaque-derived DNAs are immobilized, and then washing the filter at
65°C using 0.1 to
2 x SSC solution (composition of the 1 x SSC solution comprising 150 mM sodium
chloride and 15 mM sodium citrate). The hybridization can be carried out in
accordance with the methods described, e.g., in Molecular Cloning, A
Laboratory
Manual, Second Edition, Cold Spring Harbor Laboratory Press (1989)
(hereinafter
referred to as "Molecular Cloning, Second Edition"), Current Protocols in
Molecular
Biology, John Wiley & Sons, 1987-1997 (hereinafter referred to as "Current
Protocols
in Molecular Biology"); DNA Cloning l: Core Techniques, A Practical Approach,
Second Edition, Oxford University (1995); and the like. The hybridizable DNA
includes a DNA having at least 60% or more, preferably 70% or more, more
preferably
2 0 80% or more, still more preferably 90% or more, far more preferably 95% or
more, and
most preferably 98% or more, of homology with the nucleotide sequence
represented by
SEQ m NO: l, 2, 3 or 4.
In the present invention, the protein consisting of an amino acid sequence in
which one or more amino acids) is/are deleted, substituted, inserted and/or
added in the
amino acid sequence represented by SEQ m NO:S, 6, 7 or 8 and having a.-1,6
fucosyltransferase activity can be obtained, e.g., by introducing a site-
directed mutation
into a DNA encoding a protein consisting of the amino acid sequence
represented by
SEQ m NO:S, 6, 7 or 8, respectively, using the site-directed mutagenesis
described, e.g.,
in Molecular Cloning, Second Edition; Current Protocols in Molecular Biology;
Nucleic Acids Research, 10, 6487 (1982); Proc. Natl. Acad. Sci. USA, 79, 6409
(1982);
Gene, 34, 315 (1985); Nucleic Acids Research, 13, 4431 (1985); Proc. Natl.
Acad. Sci.
USA, 82, 488 (1985); and the like. The number of amino acids to be deleted,
substituted, inserted and/or added is one or more, and the number is not
particularly
limited, but is a number which can be deleted, substituted or added by a known
technique such as the above-described site-directed mutagenesis, e.g., it is 1
to several
tens, preferably 1 to 20, more preferably 1 to 10, and most preferably 1 to 5.
- 10-
CA 02542121 2006-04-07
Also, in the present invention, the protein consisting of an amino acid
sequence which has 80% or more homology to the amino acid sequence represented
by
SEQ >D NO:S, 6, 7 or 8 and having a-1,6-fucosyltransferase activity is a
protein having
at least 80% or more homology, preferably 85% or more homology, more
preferably
90% or more homology, still more preferably 95% or more homology, far more
preferably 97% or more homology, and most preferably 99% or more homology, to
the
protein consisting of the amino acid sequence represented by SEQ >D NO:S, 6, 7
or 8,
when calculated by using an analyzing software such as BLAST [J. Mol. Biol.,
215, 403
( 1990)], FASTA [Methods in Enrymology, 183, 63 ( 1990)] or the like.
As a method for obtaining the cell of the present invention, any technique
can be used, so long as the genome of interest can be modified. However,
genetic
engineering techniques are preferred. Examples include:
(a) a gene disruption technique which comprises targeting at a gene encoding
the a-1,6-fucose modifying enzyme,
(b) a technique for introducing mutation into a gene encoding the a-1,6-fucose
modifying enzyme, and the like.
Furthermore, the cell of the present invention can be obtained by using a
method for selecting a clone resistant to a lectin which recognizes a sugar
chain
structure in which 1-position of fucose is bound to 6-position of N-
acetylglucosamine in
2 0 the reducing end through a-bond in a complex type N-glycoside-linked sugar
chain.
The cell which is resistant to the lectin means a cell in which growth is not
inhibited in the presence of a lectin at an effective concentration. The
effective
concentration is equal to or higher than a concentration in which the cell
before the
genomic gene is knocked out (hereinafter also referred to as the parent cell)
cannot
2 5 normally grow, and is a concentration which is preferably similar to, more
preferably 2
to 5 times, still more preferably 10 times, and most preferably 20 times or
more, higher
than the concentration in which the cell before the genomic gene is knocked
out cannot
normally grow.
In the present invention, the effective concentration of a lectin which does
3 0 not inhibit the growth can be decided depending on the cell line, and is
generally 10
~g/ml to 10 mg/ml, preferably 0.5 to 2.0 mg/ml.
As the lectin which recognizes a sugar chain structure in which 1-position of
fucose is bound to 6-position of N-acetylglucosamine in the reducing end
through a-
bond in a complex type N-glycoside-linked sugar chain, any lectin can be used,
so long
3 5 as it can recognize the sugar chain structure. Examples include a Lens
culinaris lectin
LCA (lentil agglutinin derived from Lens culinaris), a pea lectin PSA (pea
lectin
-11-
CA 02542121 2006-04-07
derived from Pisum sativum), a broad bean lectin VFA (agglutinin derived from
Vicia
faba), an Aleuria aurantia lectin AAL (lectin derived from Aleuria aurantia)
and the
like.
The cell of the present invention may be any cell, so long as it can express a
glycoprotein. Examples include a yeast, an animal cell, an insect cell, a
plant cell and
the like, and specific examples include cells described in the item 2 below.
The animal
cell includes a CHO cell derived from a Chinese hamster ovary tissue, a rat
myeloma
cell line YB2/3HL.P2.G11.16Ag.20 cell, a mouse myeloma cell line NSO cell, a
mouse
myeloma cell line SP2/0-Agl4 cell, a BHK cell derived from a Syrian hamster
kidney
tissue, an antibody producing-hybridoma cell, a human leukemia cell line
Namalwa cell,
an embryonic stem cell, a fertilized egg cell and the like. Preferable
examples include
the above myeloma cell and hybridoma cell used for producing a glycoprotein
such as
an antibody composition, a host cell for producing a humanized antibody and a
human
antibody, an embryonic stem cell and fertilized egg cell for preparing a non-
human
transgenic animal which produces a human antibody, a plant cell for preparing
a
transgenic plant which produces a humanized antibody and a human antibody, and
the
like.
The cell before the genomic gene is knocked out is a cell before a method
for knocking out a genomic gene encoding the a,-1,6-fucose modifying enzyme is
2 0 applied. The cell before the genomic gene is knocked out is not
particularly limited,
and includes, as NSO cell before the genomic gene is knocked out, NSO cells
described
in literatures such as BIOlTECHNOLOGY, 10, 169 (1992) and Biotechnol. Bioeng.,
73,
261 (2001). Further examples include NSO cell line (RCB 0213) registered at
RIKEN
Cell Bank, The Institute of Physical and Chemical Research, sub-cell lines
obtained by
2 5 naturalizing these cell lines in serum-free media, and the like.
SP2/0-Agl4 cell before the genomic gene is knocked out includes SP2/0-
Agl4 cells described in literatures such as J. Immunol., 126, 317 (1981),
Nature, 276,
269 ( 1978) and Human Antibodies and Hybridomas, 3, 129 ( 1992). Further
examples
include SP2/0-Agl4 cell (ATCC CRL-1581) registered at ATCC, sub-cell lines
30 obtained by naturalizing these cell lines in serum-free media (ATCC CRL-
1581.1), and
the like.
CHO cell derived from Chinese hamster ovary tissue before the genomic
gene is knocked out includes CHO cells described in literatures such as
,lournal of
Experimental Medicine, 108, 945 ( 1958), Proc. Natl. Acad. Sci. USA, 60, 1275
( 1968),
35 Genetics, S5, 513 (1968), Chromosoma, 41, 129 (1973), Methods in Cell
Science, 18,
115 ( 1996), Radiation Research, 148, 260 ( 1997), Proc. Natl. Acad. Sci. USA,
77, 4216
- 12-
CA 02542121 2006-04-07
(1980), Proc. Natl. Acad. Sci. USA, 60, 1275 (1968), Cell, 6, 121 (1975) and
Molecular
Cell Genetics, Appendix I, II (p. 883-900). Further examples include cell line
CHO-
Kl (ATCC CCL-61), cell line DUXB11 (ATCC CRL-9096) and cell line Pro-5 (ATCC
CRL-1781) registered at ATCC, commercially available cell line CHO-S (Cat #
11619
of Life Technologies), sub-cell lines obtained by naturalizing these cell
lines in serum-
free media, and the like.
A rat myeloma cell line YB2/3HL.P2.G11.16Ag.20 cell before the genomic
gene is knocked out includes cell lines established from Y3/Ag1.2.3 cell (ATCC
CRL-
1631). Specific examples include YB2/3HL.P2.G11.16Ag.20 cell described in
literatures such as J. Cell. Biol., 93, 576 (1982) and Methods Enzymol., 73B,
1 (1981).
Further examples include YB2/3HL.P2.G11.16Ag.20 cell (ATCC CRL-1662)
registered
at ATCC, sub-cell lines obtained by naturalizing these cell lines in serum-
free media,
and the like.
In the cell of the present invention, among the enzymes relating to the sugar
chain structure of a glycoprotein such as an antibody, an enzyme relating to
the
modification of fucose is inactivated. Accordingly, in the cell of the present
invention
prepared by introducing a gene encoding a glycoprotein, the produced
glycoprotein is
not modified with fucose, so that a glycoprotein composition having high
physiological
activity can be produced stably by serum-free culturing.
2 0 The glycoprotein composition having high physiological activity includes a
glycoprotein composition having improved affinity with a receptor, a
glycoprotein
composition having improved half life in blood, a glycoprotein composition in
which its
tissue distribution after administration into blood is changed, and a
glycoprotein
composition in which its interaction with a protein necessary for expressing
2 5 pharmacological activity is improved.
Accordingly, any glycoprotein composition is included in the glycoprotein
composition of the present invention, so long as it is a glycoprotein
composition in
which the produced protein has a sugar chain structure modified with fucose,
when it is
produced by a cell before the genomic gene is knocked out. Examples include an
3 0 antibody, erythropoietin, thrombopoietin, tissue type plasminogen
activator,
prourokinase, thrombomodulin, antithrombin III, protein C, blood coagulation
factor
VII, blood coagulation factor VIII, blood coagulation factor IX, blood
coagulation
factor X, blood coagulation factor XII, gonadotropic hormone, thyroid-
stimulating
hormone, epidermal growth factor (EGF), hepatocyte growth factor (HGF),
keratinocyte
35 growth factor, activin, bone formation factor, stem cell factor (SCF),
interferon a,,
interferon (3, interferon y, interleukin 2, interleukin 6, interleukin 10,
interleukin 11,
-13-
CA 02542121 2006-04-07
soluble interleukin 4 receptor, tumor necrosis factor a, DNase I,
galactosidase, a-
glucosidase, glucocerebrosidase and the like.
Specific examples of the glycoprotein having remarkably improved
physiological activity by having a sugar chain structure which is not modified
with
fucose include an antibody composition.
Accordingly, the cell of the present invention produces an antibody
composition having higher ADCC activity than the antibody composition produced
by
the cell before the genomic gene is knocked out.
Also, the cell of the present invention produces an antibody composition
having a higher ratio of sugar chains in which fucose is not bound to N-
acetylglucosamine in the reducing end in the sugar chains, among the total
complex
type N-glycoside-linked sugar chains bound to the Fc region contained in the
antibody
composition, than the cell before the genomic gene is knocked out.
The antibody composition is a composition which comprises an antibody
molecule having a complex type N-glycoside-linked sugar chain in the Fc
region.
The antibody is a tetramer in which two molecules of each of two kinds of
polypeptide chains, a heavy chain and a light chain, are respectively
associated. Each
of about a quarter of the N-terminal side of the heavy chain and about a half
of the N-
terminal side of the light chain (more than 100 amino acids for each) is
called variable
2 0 region which is rich in diversity and directly relates to the binding to
an antigen. The
greater part of the moiety other than the variable region is called constant
region.
Based on homology with the constant region, antibody molecules are classified
into
classes IgG, IgM, IgA, IgD and IgE.
Also, the IgG class is further classified into subclasses IgGl to IgG4 based
2 5 on homology with the constant region.
The heavy chain is classified into four immunoglobulin domains VH, CH1,
CH2 and CH3 from its N-terminal side, and a highly flexible peptide region
called
hinge region is present between CHl and CH2 to divide CH1 and CH2. A
structural
unit comprising CH2 and CH3 after the hinge region is called Fc region to
which N-
3 0 glycoside-linked sugar chain is bound and is also a region to which an Fc
receptor, a
complement and the like are bound (Immunology Illustrated, the Original, 5th
edition,
published on February 10, 2000, by Nankodo; Handbook of Antibody Technology
(Kotai Kogaku Nyumon), 1 st edition on January 25, 1994, by Chijin Shokan).
Sugar chains which binds to a glycoprotein such as an antibody are roughly
3 5 classified into two types, namely a sugar chain which binds to asparagine
(N-glycoside-
linked sugar chain) and a sugar chain which binds to serine or threonine (O-
glycoside-
-14-
CA 02542121 2006-04-07
linked sugar chain), based on the binding form to the protein moiety. The N
glycoside-linked sugar chains have a common core structure shown by the
following
formula (I) [Biochemical Experimentation Method 23 -Method for Studying
Glycoprotein Sugar Chain (Gakujutsu Shuppan Center), edited by Reiko Takahashi
(1989)].
Formula (I):
~Fuc a 1
~Gai /31 -~ 4GIcNAc ~ 1 '> 2Man CY 1
6 6
~GIcNAc ~ 1 ~ 4~n S t ~ 4GIcNAc S 1 -~ 4GIcNAc
3
~Gal S 1 .~ 4GIcNAc S 1 '> 2Man a 1
In formula (I), the sugar chain terminus which binds to asparagine is called a
reducing end, and the opposite side is called a non-reducing end.
The N-glycoside-linked sugar chain includes a sugar chain having the core
structure represented by formula (I) and specifically includes a high mannose
type sugar
chain in which mannose alone binds to the non-reducing end of the core
structure; a
complex type sugar chain which the non-reducing end side of the core structure
has one
or plurality of parallel branches of galactose-N-acetylglucosamine
(hereinafter referred
to as "Gal-GIcNAc") and the non-reducing end side of Gal-GIcNAc further has a
structure of sialic acid, bisecting N-acetylglucosamine or the like; a hybrid
type sugar
chain in which the non-reducing end side of the core structure comprises
branches of
both of the high mannose type and complex type; and the like.
Since the Fc region in the antibody molecule has positions to which N
2 0 glycoside-linked sugar chains are separately bound, two sugar chains are
bound per one
antibody molecule. The N-glycoside-linked sugar chains which bind to antibody
molecules may be any sugar chains containing the core structure represented by
the
above formula (I). A number of combinations of sugar chains are present for
the two
N-glycoside-linked sugar chains which bind to the antibody.
2 5 Accordingly, the antibody composition which is prepared by using the cell
of the present invention may comprise an antibody molecule having the same
sugar
-15-
CA 02542121 2006-04-07
chain structure or an antibody molecule having different sugar chain
structures, so long
as the effect of the present invention is obtained. The thus prepared antibody
composition is preferably an antibody composition having a higher ratio of
sugar chains
in which fucose is not bound to N-acetylglucosamine in the reducing end in the
sugar
chains, among the total N-glycoside-linked sugar chains bound to the Fc region
contained in the antibody composition, is higher than the antibody composition
produced by the parent cell before the genomic gene is knocked out.
The ratio of sugar chains in which fucose is not bound to N
acetylglucosamine in the reducing end in the sugar chain among the total
complex type
N-glycoside-linked sugar chains bound to the Fc region contained in the
antibody
composition is a ratio of the number of sugar chains in which fucose is not
bound to N-
acetylglucosamine in the reducing end in the sugar chains to the total number
of the
complex type N-glycoside-linked sugar chains bound to the Fc region contained
in the
composition.
The sugar chain in which fucose is not bound to N-acetylglucosamine in the
reducing end in a complex type N-glycoside-linked sugar chain is a sugar chain
in
which fucose is not bound to N-acetylglucosamine in the reducing end through a-
bond
in a complex type N-glycoside-linked sugar chain. Specifically, it is a sugar
chain in
which 1-position of fucose is not bound to 6-position of N-acetylglucosamine
through
2 0 a-bond in a complex type N-glycoside-linked sugar chain.
The ratio of sugar chains in which fucose is not bound to N-
acetylglucosamine in the reducing end in the sugar chain among the total
complex type
N-glycoside-linked sugar chains bound to the Fc region contained in the
antibody
composition of the present invention is preferably 20% or more, more
preferably 30%
2 5 or more, still more preferably 40% or more, particularly preferably 50% or
more, and
most preferably 100%.
The antibody composition having higher ADCC activity than the antibody
composition produced by the cell before the genomic gene is knocked out
includes
those in which, among total complex type N-glycoside-linked sugar chains bound
to the
3 0 Fc region contained in the antibody composition, the ratio of sugar chains
in which
fucose is not bound to N-acetylglucosamine in the reducing end in the sugar
chain is
higher than the ratio in an antibody composition produced by the cell before
the
genomic gene is knocked out. Examples include an antibody composition in which
the
ratio is at least 2 times, preferably at least 3 times, more preferably at
least 5 times, and
3 5 still more preferably 10 times or higher. An antibody composition in which
all of
complex type N-glycoside-linked sugar chains bound to the Fc region contained
in the
- 16-
CA 02542121 2006-04-07
antibody composition are sugar chains in which 1-position of fucose is not
bound to 6-
position of N-acetylglucosamine in the reducing end in the sugar chain is most
preferred.
The antibody composition having a ratio of sugar chains in which fucose are
not bound to N-acetylglucosamine in the reducing end in the sugar chain of
100% or the
antibody composition in which all of complex type N-glycoside-linked sugar
chains
bound to the Fc region contained in the antibody composition are sugar chains
in which
1-position of the fucose is not bound to 6-position of N-acetylglucosamine in
the
reducing end contains those in which fucose is in such a degree that it cannot
be
substantially detected by the sugar chain analysis described in the following
item 6.
The degree that it cannot be substantially detected means that it is equal to
or below the
detection limit in the measurement.
In the antibody composition obtained by the present invention, when the
ratio of sugar chains in which fucose is not bound to N-acetylglucosamine in
the
reducing end, among the total compelx type N-glycoside-linked sugar chains
bound to
the Fc region, is higher than that of an antibody composition produced by the
cell before
the genomic gene is knocked out, the antibody composition obtained in the
present
invention has higher ADCC activity than the antibody composition comprising
the
antibody molecule produced by the parent cell.
The ADCC activity is cytotoxic activity in which an antibody bound to a
2 0 cell surface antigen existed on a tumor cell and the like in the living
body activates an
effector cell through binding an Fc receptor existing on the antibody Fc
region and
effector cell surface and thereby injure the tumor cell and the like
[Monoclonal
Antibodies: Principles and Applications, Wiley-Liss, Inc., Chapter 2.1
(1955)]. The
effector cell includes a killer cell, a natural killer cell, an activated
macrophage and the
2 5 like.
The ratio of sugar chains in which fucose is not bound to
N-acetylglucosamine in the reducing end in the sugar chain contained in the
composition which comprises an antibody molecule having complex type N-
glycoside-
linked sugar chains in the Fc region can be determined by releasing the sugar
chain
3 0 from the antibody molecule by using a known method such as hydrazinolysis,
enzyme
digestion or the like [Biochemical Experimentation Methods 23 - Method for
Studying
Glycoprotein Sugar Chain (Japan Scientific Societies Press), edited by Reiko
Takahashi
(1989)], carrying out fluorescence labeling or radioisotope labeling of the
released sugar
chain and then separating the labeled sugar chain by chromatography. Also, the
35 released sugar chain can also be analyzed and determined by the HI'AED-PAD
method
[J. Liq. Chromatogr., 6, 1577 (1983)]. Also, the antibody of the present
invention is
- 17-
CA 02542121 2006-04-07
preferably an antibody which recognizes a tumor-related antigen, an antibody
which
recognizes an allergy- or inflammation-related antigen, an antibody which
recognizes
cardiovascular disease-related antigen, an antibody which recognizes an
autoimmune
disease-related antigen or an antibody which recognizes a viral or bacterial
infection-
s related antigen are exemplified below, and preferably belongs to an IgG
class.
The antibody which recognizes a tumor-related antigen includes anti-GD2
antibody [Anticancer Res., 13, 331 (1993)], anti-GD3 antibody [Cancer Immunol.
Immunother., 36, 260 (1993)], anti-GM2 antibody [CancerRes., 54, 1511 (1994)],
anti-
HER2 antibody [Proc. Natl. Acac~ Sci. USA, 89, 4285 (1992)], anti-CD52
antibody
[Nature, 332, 323 (1998)], anti-MAGE antibody [British J. Cancer, 83, 493
(2000)],
anti-HM1.24 antibody [Molecular Immunol., 36, 387 (1999)], anti-parathyroid
hormone-related protein (PTHrP) antibody [Cancer, 88, 2909 (2000)], anti-FGFB
antibody [Proc. Natl. Acad. Sci. USA, 86, 9911 ( 1989)], anti-basic fibroblast
growth
factor antibody, anti-FGF8 receptor antibody [J Biol. Chem., 265, 16455
(1990)], anti-
basic fibroblast growth factor receptor antibody, anti-insulin-like growth
factor antibody
[J. Neurosci. Res., 40, 647 (1995)], anti-insulin-like growth factor receptor
antibody [J
Neurosci. Res., 40, 647 (1995)], anti-PMSA antibody [J Urology, 160, 2396
(1998)],
anti-vascular endothelial cell growth factor antibody [Cancer Res., 57, 4593
(1997)],
anti-vascular endothelial cell growth factor receptor antibody [Oncogene, 19,
2138
(2000)], anti-CA125 antibody, anti-17-lA antibody, anti-integrin ocv(33
antibody, anti-
CD33 antibody, anti-CD22 antibody, anti-HL,A antibody, anti-HLA-DR antibody,
anti-
CD20 antibody, anti-CD 19 antibody, anti-EGF receptor antibody [Immunology
Today,
21, 403 (2000)], anti-CD10 antibody [American Journal of Clinical Pathology,
113, 374
(2000)] and the like.
The antibody which recognizes an allergy- or inflammation-related antigen
includes anti-interleukin 6 antibody [Immunol. Rev., 127, 5 (1992)], anti-
interleukin 6
receptor antibody [Molecular Immunol., 31, 371 (1994)], anti-interleukin 5
antibody
[Immunol. Rev., 127, 5 (1992)], anti-interleukin 5 receptor antibody and anti-
interleukin
4 antibody [Cytokine, 3, 562 (1991)], anti-interleukin 4 receptor antibody [J.
Immunol.
Meth., 217, 41 (1998)], anti-tumor necrosis factor antibody [Hybridoma, 13,
183
(1994)], anti-tumor necrosis factor receptor antibody [Molecular Pharmacol.,
58, 237
(2000)], anti-CCR4 antibody [Nature, 400, 776 (1999)], anti-chemokine antibody
[J
Immuno. Meth., 174, 249 (1994)], anti-chemokine receptor antibody [J Exp.
Med., 186,
1373 ( 1997)], anti-IgE antibody, anti-CD23 antibody, anti-CD 11 a antibody
[Immunology Today, 21, 403 (2000)], anti-CRTH2 antibody [J Immunol., 162, 1278
- 18-
CA 02542121 2006-04-07
(1999)], anti-CCR8 antibody (W099/25734), anti-CCR3 antibody (IJS6207155) and
the
like.
The antibody which recognizes a cardiovascular disease-related antigen
includes anti-GpIIb/IIIa antibody [J. Immunol , 152, 2968 ( 1994)], anti-
platelet-derived
growth factor antibody [Science, 253, 1129 (1991)], anti-platelet-derived
growth factor
receptor antibody [J. Biol. Chem., 272, 17400 (1997)], anti-blood coagulation
factor
antibody [Circulation, 101, 1158 (2000)] and the like.
The antibody which recognizes an antigen relating to autoimmune diseases
(psoriasis, rheumarthritis, Crohn's diseases, colitis ulcerosa, systemic
erythematodes,
multiple sclerosis, etc.) includes an anti-auto-DNA antibody [Immunol.
Letters, 72, 61
(2000)], anti-CD 11 a antibody, anti-ICAM3 antibody, anti-CD80 antibody, anti-
CD2
antibody, anti-CD3 antibody, anti-CD4 antibody, anti-integrin x.4(37 antibody,
anti-
CD40L antibody, anti-IL-2 receptor antibody [Immunology Today, 21, 403
(2000)], and
the like.
The antibody which recognizes a viral or bacterial infection-related antigen
includes anti-gp 120 antibody [Structure, 8, 385 (2000)], anti-CD4 antibody
[J.
Rheumatology, 25, 2065 (1998)], anti-CCR4 antibody, anti-Vero toxin antibody
[J. Clin.
Microbiol., 37, 396 (1999)], , and the like.
The antibody molecule may be any antibody molecule, so long as it
2 0 comprises the Fc region of an antibody. Examples include an antibody, an
antibody
fragment, a fusion protein comprising an Fc region, and the like.
The antibody is a protein which is produced in the living body by immune
reaction as a result of exogenous antigen stimulation and has an activity to
specifically
bind to the antigen. Examples include an antibody secreted by a hybridoma cell
2 5 prepared from a spleen cell of an animal immunized with an antigen; an
antibody
prepared by a genetic recombination technique, namely an antibody obtained by
introducing an antibody gene-inserted antibody expression vector into a host
cell; and
the like. Specific examples include an antibody produced by a hybridoma, a
humanized antibody, a human antibody and the like.
3 0 A hybridoma is a cell which is obtained by cell fusion between a B cell
obtained by immunizing a non-human mammal with an antigen and a myeloma cell
derived from mouse, rat or the like and can produce a monoclonal antibody
having the
desired antigen specificity.
The humanized antibody includes a human chimeric antibody, a human
3 5 CDR-grafted antibody and the like.
- 19-
CA 02542121 2006-04-07
A human chimeric antibody is an antibody which comprises a heavy chain
variable region (hereinafter referred to as "HV" or "VH", as the variable
region being
referred to as V region) and a light chain variable region (hereinafter
referred to as "LV"
or "VL", as the light region being referred to as L region), both of a non-
human animal
antibody, a human antibody heavy chain constant region (hereinafter also
referred to as
"CH") and a human antibody light chain constant region (hereinafter also
referred to as
"CL"). The non-human animal may be any animal such as mouse, rat, hamster,
rabbit
or the like, so long as a hybridoma can be prepared therefrom.
The human chimeric antibody can be produced by obtaining cDNAs
encoding VH and VL from a monoclonal antibody-producing hybridoma, inserting
them into an expression vector for host cell having genes encoding human
antibody CH
and human antibody CL to thereby construct a vector for expression of human
chimeric
antibody, and then introducing the vector into a host cell to express the
antibody.
The CH of human chimeric antibody may be any CH, so long as it belongs
to human immunoglobulin (hereinafter referred to as "hIg"). Those belonging to
the
hIgG class are preferred and any one of the subclasses belonging to the hIgG
class, such
as hIgGl, hIgG2, hIgG3 and hIgG4, can be used. Also, as the CL of human
chimeric
antibody, any CL can be used, so long as it belongs to the hIg class, and
those belonging
to the K class or ~, class can also be used.
2 0 A human CDR-grafted antibody is an antibody in which amino acid
sequences of CDRs of VH and VL of a non-human animal antibody are grafted into
appropriate positions of VH and VL of a human antibody.
The human CDR-grafted antibody can be produced by constructing cDNAs
encoding V regions in which CDRs of VH and VL of a non-human animal antibody
are
2 5 grafted into CDRs of VH and VL of a human antibody, respectively inserting
them into
an expression vector for host cell having genes encoding human antibody CH and
human antibody CL to thereby construct a human CDR-grafted antibody expression
vector, and then introducing the expression vector into a host cell to express
the human
CDR-grafted antibody.
3 0 The CH of human CDR-grafted antibody may be any CH, so long as it
belongs to the hIg. Those belonging to the hIgG class are preferred and any
one of the
subclasses belonging to the hIgG class, such as hIgGl, hIgG2, hIgG3 and hIgG4,
can be
used. Also, as the CL of human CDR-grafted antibody, any CL can be used, so
long
as it belongs to the hIg class, and those belonging to the K class or ~, class
can also be
3 5 used.
-20-
CA 02542121 2006-04-07
A human antibody is originally an antibody naturally existing in the human
body, but it also includes antibodies obtained from a human antibody phage
library, a
human antibody-producing transgenic non-human animal and a human antibody-
producing transgenic plant, which are prepared based on the recent advance in
genetic
engineering, cell engineering and developmental engineering techniques.
Regarding the antibody existing in the human body, a lymphocyte capable
of producing the antibody can be cultured by isolating a human peripheral
blood
lymphocyte, immortalizing it by infecting with EB virus or the like and then
cloning it,
and the antibody can be purified from the culture.
The human antibody phage library is a library in which antibody fragments
such as Fab, single chain antibody and the like are expressed on the phage
surface by
inserting a gene encoding an antibody prepared from a human B cell into a
phage gene.
A phage expressing an antibody fragment having the desired antigen binding
activity
can be recovered from the library based on its binding activity to an antigen-
immobilized substrate. The antibody fragment can be converted further into a
human
antibody molecule comprising two full H chains and two full L chains by
genetic
engineering techniques.
A human antibody-producing transgenic non-human animal is a non-human
animal in which a human antibody gene is introduced into cells. Specifically,
a human
2 0 antibody-producing transgenic animal can be prepared by introducing a
human antibody
gene into embryonic stem cell of a mouse, transplanting the embryonic stem
cell into an
early stage embryo of other mouse and then developing it. The human antibody-
producing transgenic non-human animal can also be prepared by introducing a
human
antibody gene into a fertilized egg of an animal and developing it. Regarding
the
2 5 preparation method of a human antibody from the human antibody-producing
transgenic
non-human animal, the human antibody can be formed and accumulated in a
culture by
obtaining a human antibody-producing hybridoma by a hybridoma preparation
method
usually carried out in non-human mammals and then culturing it.
The transgenic non-human animal includes cattle, sheep, goat, pig, horse,
3 0 mouse, rat, fowl, monkey, rabbit and the like.
Also, in the present invention, it is preferred that the antibody is an
antibody
which recognizes a tumor-related antigen, an antibody which recognizes an
allergy- or
inflammation-related antigen, an antibody which recognizes cardiovascular
disease-
related antigen, an antibody which recognizes an autoimmune disease-related
antigen or
3 5 an antibody which recognizes a viral or bacterial infection-related
antigen, and a human
antibody which belongs to the IgG class is preferred.
-21-
CA 02542121 2006-04-07
An antibody fragment is a fragment which comprises at least a part of Fc
region of the above antibody. The Fc region is CH2 region and CH3 region,
which is a
region at the C-terminal of H chain of an antibody, and includes a natural
type and a
mutant type. The part of Fc region is preferably a fragment which comprises
CH2
region, and more preferably region which comprises aspartic acid at position 1
existing
in the CH2 region.. The Fc region of the IgG class is from Cys at position 226
to the
C-terminal or from Pro at position 230 to the C-terminal according to the
numbering of
EU Index of Kabat et al. [Sequences of Proteins of Immunological Interest, 5~'
Ed.,
Public Health Service, National Institutes of Health, Bethesda, MD. (1991)].
The
antibody fragment includes an H chain monomer, an H chain dimer and the like.
A fusion protein comprising a part of Fc region may be any fusion protein
so long as it is a protein in which an antibody comprising the Fc region of an
antibody
or the antibody fragment is fused with a protein such as an enzyme or a
cytokine
(hereinafter referred to as "Fc fusion protein").
The present invention is explained below in detail.
1. Preparation of cell of the present invention
The cell of the present invention can be prepared by the following
techniques.
(1) Gene disruption technique which comprises targeting gene encoding enzyme
The cell of the present invention can be prepared by using a gene disruption
technique by targeting a genomic gene encoding the a.-1,6-fucose modifying
enzyme.
The oc-1,6-fucose modifying enzyme includes oc-1,6-fucosyltransferase, a-L-
fucosidase
2 5 and the like:
The gene disruption method may be any method, so long as it can disrupt
the gene of the target enzyme. Examples include a homologous recombination
method,
an RNA-DNA oligonucleotide (RDO) method, a method using retrovirus, a method
using transposon, and the like. The methods are specifically described below.
(a) Preparation of the cell of the present invention by homologous
recombination
The cell of the present invention can be produced by modifying a target
gene on chromosome through a homologous recombination technique for targeting
at a
gene encoding the oc-1,6-fucose modifying enzyme.
3 5 The target gene on the chromosome can be modified by using a
chromosome engineering method described in Manipulating the Mouse Embryo, A
-22-
CA 02542121 2006-04-07
Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press (1994)
(hereinafter referred to as "Manipulating the Mouse Embryo, A Laboratory
Manual");
Gene Targeting, A Practical Approach, IRL Press at Oxford University Press
(1993);
Biomanual Series 8, Gene Targeting, Preparation of Mutant Mice using ES Cells,
Yodo-sha (1995) (hereinafter referred to as "Preparation of Mutant Mice using
ES
Cells"); or the like, for example, as follows.
A cDNA encoding the oc-1,6-fucose modifying enzyme is prepared.
Based on the nucleotide sequence of the obtained cDNA, a genomic DNA
encoding the a-1,6-fucose modifying enzyme is prepared.
Based on the nucleotide sequence of the genomic DNA, a target vector is
prepared for homologous recombination of a target gene to be modified (e.g.,
structural
gene of the a.-1,6-fucose modifying enzyme, or a promoter gene).
The cell of the present invention can be produced by introducing the
prepared target vector into a host cell and selecting a cell in which
homologous
recombination generated between the target gene and target vector.
As the host cell, any cell such as yeast, an animal cell, an insect cell, a
plant
cell or the like can be used, so long as it has the gene targeting at the oc-
1,6-fucose
modifying enzyme. Examples include cells described in the following item 2.
The method for obtaining a cDNA or a genomic DNA encoding the x,-1,6-
2 0 fucose modifying enzyme includes the method described below.
Preparation method of cDNA:
A total RNA or mRNA is prepared from various host cells.
A cDNA library is prepared from the prepared total RNA or mRNA.
2 5 Degenerative primers are produced based on the known amino acid
sequence of the oc-1,6-fucose modifying enzyme, e.g., known amino acid
sequences
such as human amino acid sequence, and a gene fragment encoding the a.-1,6-
fucose
modifying enzyme is obtained by PCR using the prepared cDNA library as the
template.
A cDNA encoding the a-1,6-fucose modifying enzyme can be obtained by
3 0 screening the cDNA library by using the obtained gene fragment as a probe.
As the mRNA of various host cells, a commercially available product (e.g.,
manufactured by Clontech) may be used or may be prepared from various host
cells as
follows. The method for preparing a total RNA from various host cells includes
the
guanidine thiocyanate-cesium trifluoroacetate method [Methods in Enrymology,
154, 3
35 (1987)], the acidic guanidine thiocyanate phenol chloroform (AGPC) method
-23-
CA 02542121 2006-04-07
[Analytical Biochemistry, 162, 156 (1987); Experimental Medicine (Jikken
Igaku), 9,
193 7 ( 1991 )] and the like.
Furthermore, the method for preparing mRNA as poly(A)+ RNA from a
total RNA includes the oligo(dT)-immobilized cellulose column method
(Molecular
Cloning, Second Edition) and the like.
In addition, mRNA can be prepared by using a kit such as Fast Track
mRNA Isolation Kit (manufactured by Invitrogen), Quick Prep mRNA Purification
Kit
(manufactured by Pharmacia) or the like.
A cDNA library is prepared from the prepared mRNA of various host cells.
The method for preparing cDNA libraries includes the methods described in
Molecular
Cloning, Second Edition; Current Protocols in Molecular Biology; A Laboratory
Manual, Second Edition (1989); and the like, or methods using commercially
available
kits such as Superscript Plasmid System for cDNA Synthesis and Plasmid Cloning
(manufactured by Life Technologies), ZAP-cDNA Synthesis Kit (manufactured by
STRATAGENE) and the like.
As the cloning vector for the preparation of the cDNA library, any vector
such as a phage vector, a plasmid vector or the like can be used, so long as
it is
autonomously replicable in Escherichia coli K12. Examples include ZAP Express
[manufactured by STRATAGENE, Strategies, 5, 58 (1992)], pBluescript II SK(+)
[Nucleic Acids Research, 17, 9494 (1989)], Lambda ZAP II (manufactured by
STRATAGENE), ~,gtl0 and ~,gtl 1 [DNA Cloning, A Practical Approach, 1, 49
(1985)],
~,TriplEx (manufactured by Clontech), ~,ExCell (manufactured by Pharmacia),
pT7T318U (manufactured by Pharmacia), pcD2 [Mol. Cell. Biol., 3, 280 (1983)],
pUCl8 [Gene, 33, 103 (1985)] and the like.
2 5 Any microorganism can be used as the host microorganism for preparing the
cDNA library, and Escherichia coli is preferably used. Examples include
Escherichia
coli XL1-Blue MRF' [manufactured by STRATAGENE, Strategies, S, 81 (1992)],
Escherichia coli C600 [Genetics, 39, 440 (1954)], Escherichia coli Y1088
[Science, 222,
778 (1983)], Escherichia coli Y1090 [Science, 222, 778 (1983)], Escherichia
coli
NM522 [J Mol. Biol., 166, 1 (1983)], Escherichia coli K802 [J. Mol. Biol., 16,
118
(1966)], Escherichia coli JM105 [Gene, 38, 275 (1985)) and the like.
The cDNA library can be used as such in the subsequent analysis, and in
order to obtain a full length cDNA as efficiently as possible by decreasing
the ratio of a
cDNA fragment containing a partial coding sequence, a cDNA library prepared by
using the oligo cap method developed by Sugano et al. [Gene, 138, 171 (1994);
Gene,
200, 149 ( 1997); Protein, Nucleic Acid, Enzyme, 41, 603 ( 1996); Experimental
-24-
CA 02542121 2006-04-07
Medicine (Jikken Igaku), 11, 2491 (1993); cDNA Cloning (Yodo-sha) (1996);
Methods
for Preparing Gene Libraries (Yodo-sha) (1994)] can be used in the following
analysis.
Based on the amino acid sequence of the a,-1,6-fucose modifying enzyme,
degenerative primers specific for the 5'-terminal and 3'-terminal nucleotide
sequences of
a nucleotide sequence presumed to encode the amino acid sequence are prepared,
and
DNA is amplified by PCR [PCR Protocols, Academic Press (1990)] using the
prepared
cDNA library as the template to obtain a gene fragment encoding the a.-1,6-
fucose
modifying enzyme.
It can be confirmed that the obtained gene fragment is a DNA encoding the
a-1,6-fucose modifying enzyme by a method generally used for analyzing a
nucleotide
sequence, such as the dideoxy method of Sanger et al. [Proc. Natl. Acad Sci.
USA, 74,
5463 (1977)], a nucleotide sequence analyzer such as ABI PRISM 377 DNA
Sequencer
(manufactured by PE Biosystems) or the like.
A DNA encoding the a,-1,6-fucose modifying enzyme can be obtained by
carrying out colony hybridization or plaque hybridization (Molecular Cloning,
Second
Edition) to the cDNA or cDNA library synthesized from the mRNA contained in
the
various host cells, using the gene fragment as a DNA probe.
Also, a DNA encoding the a-1,6-fucose modifying enzyme can also be
obtained by carrying out screening by PCR using the cDNA or cDNA library
2 0 synthesized from the mRNA contained in the various host cells as the
template and
using the primers used for obtaining the gene fragment encoding the a,-1,6-
fucose
modifying enzyme.
The nucleotide sequence of the obtained DNA encoding the a,-1,6-fucose
modifying enzyme is analyzed from its terminus and determined by a method
generally
2 5 used for analyzing a nucleotide sequence, such as the dideoxy method of
Sanger et al.
[Proc. Natl. Acad Sci. USA, 74, 5463 (1977)], a nucleotide sequence analyzer
such as
ABI PRISM 377 DNA Sequencer (manufactured by PE Biosystems) or the like.
A gene encoding the a,-1,6-fucose modifying enzyme can also be
determined from genes in data bases by searching nucleotide sequence data
bases such
3 0 as GenBank, EMBL and DDBJ by using a homology retrieving program such as
BLAST based on the determined cDNA nucleotide sequence.
The nucleotide sequence of the gene encoding the oc-1,6-fucose modifying
enzyme includes the nucleotide sequence represented by SEQ ID NO:1, 2, 3 or 4.
The cDNA encoding the a-1,6-fucose modifying enzyme can also be
3 5 obtained by chemically synthesizing it with a DNA synthesizer such as DNA
-25-
CA 02542121 2006-04-07
Synthesizer model 392 manufactured by Perkin Elmer by using the phosphoamidite
method, based on the determined DNA nucleotide sequence.
As an example of the method for preparing a genomic DNA encoding the a-
1,6-fixcose modifying enzyme, the method described below is exemplified.
Preparation method of~enomic DNA:
The method for preparing genomic DNA includes known methods described
in Molecular Cloning, Second Edition; Current Protocols in Molecular Biology;
and the
like. In addition, a genomic DNA encoding the a,-1,6-fucose modifying enzyme
can
also be isolated by using a kit such as Genome DNA Library Screening System
(manufactured by Genome Systems) or Universal GenomeWalkerTM Kits
(manufactured
by CLONTECH).
The nucleotide sequence of the genomic DNA encoding the a-1,6-fucose
modifying enzyme obtained above includes the nucleotide sequence represented
by
SEQ 117 N0:9.
The target vector used in the homologous recombination of the target gene
can be prepared in accordance with a method described in Gene Targeting, A
Practical
Approach, IRL Press at Oxford University Press (1993); Biomanual Series 8,
Gene
Targeting, Preparation of Mutant Mice using ES Cells, Yodo-sha (1995); or the
like.
2 0 The target vector can be used as both a replacement type and an insertion
type.
For introducing the target vector into various host cells, the methods for
introducing recombinant vectors suitable for various cells described in the
following
item 2 can be used.
The method for efficiently selecting a homologous recombinant includes a
2 5 method such as the positive selection, promoter selection, negative
selection or polyA
selection described in Gene Targeting, A Practical Approach, IRL Press at
Oxford
University Press (1993); Biomanual Series 8, Gene Targeting, Preparation of
Mutant
Mice using ES Cells, Yodo-sha (1995); or the like. The method for selecting
the
homologous recombinant of interest from the selected clones includes the
Southern
3 0 hybridization method for genomic DNA (Molecular Cloning, Second Edition),
PCR
[PCR Protocols, Academic Press (1990)], and the like.
A homologous recombinant can be obtained based on the change of the
activity of the oc-1,6-fucose modifying enzyme. The following method is
exemplified
as a method for selecting a transformant.
-26-
CA 02542121 2006-04-07
Method for selecting transformant:
The method for selecting a cell in which the genomic gene encoding the a,-
1,6-fucose modifying enzyme is knocked out includes biochemical methods or
genetic
engineering techniques described in literatures such as New Biochemical
Experimentation Series 3-Saccharides I, Glycoprotein (Tokyo Kagaku Dojin),
edited by
Japanese Biochemical Society (1988); Cell Engineering, Supplement,
Experimental
Protocol Series, Glycobiology Experimental Protocol, Glycoprotein, Glycolipid
and
Proteoglycan (Shujun-shay, edited by Naoyuki Taniguchi, Akemi Suzuki, Kiyoshi
Furukawa and Kazuyuki Sugawara (1996); Molecular Cloning, Second Edition;
Current Protocols in Molecular Biology; and the like. The biochemical method
includes a method in which the enzyme activity is evaluated by using an enzyme-
specific substrate and the like. The genetic engineering technique includes
the
Northern analysis, RT-PCR and the like which measures the amount of mRNA of a
gene encoding the enzyme.
Furthermore, the method for selecting a cell based on morphological change
caused by knocking out the genomic gene encoding the a-1,6-fucose modifying
enzyme
includes a method for selecting a transformant based on the sugar chain
structure of a
produced antibody molecule, a method for selecting a transformant based on the
sugar
chain structure of a glycoprotein on a cell membrane, and the like. The method
for
2 0 selecting a transformant using the sugar chain structure of an antibody-
producing
molecule includes method described in the following item 6. The method for
selecting
a transformant based on the sugar chain structure of a glycoprotein on a cell
membrane
includes a method selecting a clone resistant to a lectin which recognizes a
sugar chain
structure wherein 1-position of fucose is bound to 6-position of N-
acetylglucosamine in
2 5 the reducing end through a.-bond in an N-glycoside-linked sugar chain.
Examples
include a method using a lectin described in Somatic Cell Mol. Genet., 12, 51
(1986).
As the lectin, any lectin can be used, so long as it is a lectin which
recognizes a sugar chain structure in which 1-position of fucose is bound to 6-
position
of N-acetylglucosamine in the reducing end through a-bond in an N-glycoside-
linked
3 0 sugar chain. Examples include a Lens culinaris lectin LCA (lentil
agglutinin derived
from Lens culinaris), a pea lectin PSA (pea lectin derived from Pisum
sativum), a broad
bean lectin VFA (agglutinin derived from Vicia faba), an Aleuria aurantia
lectin AAL
(lectin derived from Aleuria aurantia) and the like.
Specifically, the cell of the present invention can be selected by culturing
3 5 cells for 1 day to 2 weeks, preferably 3 days to 1 week, in a medium
comprising the
above-described lectin at a concentration of several ten pg/ml to several
mg/ml,
-27-
CA 02542121 2006-04-07
preferably 0.5 to 2.0 mg/ml, subculturing surviving cells or picking up a
colony and
transferring it into another culture vessel, and subsequently continuing the
culturing in
the lectin-containing medium.
(b) Preparation of the cell of the present invention by RDO method
The cell of the present invention can be prepared by an RDO method by
targeting a gene encoding the oc-1,6-fucose modifying enzyme, for example, as
follows.
A cDNA or a genomic DNA encoding the a-1,6-fucose modifying enzyme
is prepared.
The nucleotide sequence of the prepared cDNA or genomic DNA is
determined.
Based on the determined DNA sequence, an RDO construct of an
appropriate length comprising a part encoding the a,-1,6-fucose modifying
enzyme, a
part of an untranslated region or a part of intron is designed and
synthesized.
The cell of the present invention can be obtained by introducing the
synthesized RDO into a host cell and then selecting a transformant in which a
mutation
is generated in the target enzyme, i.e., the oc-1,6-fucose modifying enzyme.
As the host cell, any cell such as yeast, an animal cell, an insect cell and a
plant cell can be used, so long as it has a gene encoding the target oc-1,6-
fucose
2 0 modifying enzyme. Examples include the host cells described in the
following item 2.
The method for introducing RDO into various host cells includes the
methods for introducing recombinant vectors suitable for various host cells,
described in
the following item 2.
The method for preparing cDNA encoding the a-1,6-fucose modifying
enzyme includes the "Preparation method of cDNA" described in the item 1(1)(a)
and
the like.
The method for preparing a genomic DNA encoding the oc-1,6-fucose
modifying enzyme includes the "Preparation method of genomic DNA" described in
the
item 1 ( 1 )(a) and the like.
3 0 The nucleotide sequence of the DNA can be determined by digesting it with
appropriate restriction enzymes, cloning the DNA fragments into a plasmid such
as
pBluescript SK(-) (manufactured by Stratagene), subjecting the clones to the
reaction
generally used as a method for analyzing a nucleotide sequence such as the
dideoxy
method of Sanger et al. [Proc. Natl. Acad Sci. USA, 74, 5463 (1977)] or the
like, and
then analyzing the clones by using an automatic nucleotide sequence analyzer
such as
A.L.F. DNA Sequencer (manufactured by Pharmacia) or the like.
-28-
CA 02542121 2006-04-07
The RDO can be prepared by a usual method or using a DNA synthesizer.
The method for selecting a cell in which a mutation occurred, by
introducing the RDO into the host cell, in the target enzyme, i.e., the gene
encoding the
a-1,6-fucose modifying enzyme, includes the methods for directly detecting
mutations
S in chromosomal genes described in Molecular Cloning, Second Edition, Current
Protocols in Molecular Biology and the like.
Furthermore, "Method for selecting transformant" described in the item
1(1)(a) based on the change of the activity of the a-1,6-fucose modifying
enzyme can
also be used.
The construct of the RDO can be designed in accordance with the methods
described in Science, 273, 1386 (1996); Nature Medicine, 4, 285 (1998);
Hepatology,
25, 1462 (1997); Gene Therapy, 5, 1960 (1999); J. Mol. Med., 75, 829 (1997);
Proc.
Natl. Acad Sci. USA, 96, 8774 (1999); Proc. Natl. Acad Sci. USA, 96, 8768
(1999);
Nuc. Acids. Res., 27, 1323 (1999); Invest. Dematol., 111, 1172 (1998); Nature
Biotech.,
16, 1343 (1998); Nature Biotech., 18, 43 (2000); Nature Biotech., 18, 555
(2000); and
the like.
(c) Preparation of the cell of the present invention by method using
transposon
The cell of the present invention can be prepared by using a transposon
system described in Nature Genet., 25, 35 (2000) or the like, and by selecting
a mutant
based on the activity of the a-1,6-fucose modifying enzyme, or the sugar chain
structure
of a produced antibody molecule or of a glycoprotein on the cell membrane.
The transposon system is a system in which a mutation is induced by
randomly inserting an exogenous gene into chromosome, wherein an exogenous
gene
2 S interposed between fransposoris is generally used as a vector for inducing
a mutation,
and a transposase expression vector for randomly inserting the gene into
chromosome is
introduced into the cell at the same time.
Any transposase can be used, so long as it is suitable for the sequence of the
transposon to be used.
3 0 As the exogenous gene, any gene can be used, so long as it can induce a
mutation in the DNA of a cell.
As the cell, any cell such as yeast, an animal cell, an insect cell or a plant
cell can be used, so long as it has a gene encoding the target a-1,6-fucose
modifying
enzyme. Examples include the host cells described in the following item 2.
3 5 For introducing a gene into the cell, the method for introducing
recombinant
vectors suitable for various host cells described in the following item 2 can
be used.
-29-
CA 02542121 2006-04-07
The method for selecting a mutant based on the activity of the a-1,6-fucose
modifying enzyme includes "Method for selecting transformant" described in the
above
item 1(1)(a) based on change of the activity of the oc-1,6-fucose modifying
enzyme.
(2) Method for introducing mutation into enzyme
The cell of the present invention can be prepared by introducing a mutation
into a gene encoding the a,-1,6-fucose modifying enzyme, and then by selecting
a clone
of interest in which the mutation is generated in the enzyme.
The oc-1,6-fucose modifying enzyme includes oc-1,6-fucosyltransferase, oc-
L-fucosidase and the like.
The method includes 1) a method in which a desired clone is selected from
mutants obtained by a mutation-inducing treatment of a parent cell line or
spontaneously generated mutants based on the change of the activity of the oc-
1,6-fucose
modifying enzyme, 2) a method in which a desired clone is selected from
mutants
obtained by a mutation-inducing treatment of a parent cell line or
spontaneously
generated mutants based on the sugar chain structure of a produced antibody
molecule
and 3) a method in which a desired clone is selected from mutants obtained by
a
mutation-inducing treatment of a parent cell line or spontaneously generated
mutants
based on the sugar chain structure of a glycoprotein on the cell membrane of
the cell.
2 0 As the mutation-inducing treatment, any treatment can be used, so long as
it
can induce a point mutation, a deletion or frame shift mutation in the DNA of
the parent
cell line. Examples include treatment with ethyl nitrosourea,
nitrosoguanidine,
benzopyrene or an acridine pigment and treatment with radiation. Also, various
alkylating agents and carcinogens can be used as mutagens. The method for
allowing
2 5 a mutagen to act upon cells includes the methods described in Tissue
Culture
Techniques, 3rd edition (Asakura Shoten), edited by Japanese Tissue Culture
Association (1996), Nature Genet., 24, 314 (2000) and the like.
The spontaneously generated mutant includes mutants which are
spontaneously formed by continuing subculture under general cell culture
conditions
3 0 without applying special mutation-inducing treatment.
The method for selecting a clone of interest based on the change of the
activity of the a-1,6-fucose modifying enzyme, the method for selecting a
clone of
interest based on the sugar chain structure of a prepared antibody molecule
and the
method for selecting a clone of interest based on the sugar chain structure of
a
3 5 glycoprotein on the cell membrane include "Method for selecting
transformant"
-30-
CA 02542121 2006-04-07
described in the above item 1(1)(a) based on change of the activity of the a-
1,6-fucose
modifying enzyme.
2. Process for producing glycoprotein based on antibody composition as an
example
A process for producing a glycoprotein using the cell of the present
invention is explained below based on production of an antibody composition as
a
specific example.
The antibody composition can be obtained by expressing it in a host cell to
which a gene encoding an antibody molecule is introduced, by using the methods
described in Molecular Cloning, Second Edition; Current Protocols in Molecular
Biology; Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, 1988
(hereinafter referred to as "Antibodies"); Monoclonal Antibodies: Principles
and
Practice, Third Edition, Acad. Press, 1993 (hereinafter referred to as
"Monoclonal
Antibodies"); and Antibody Engineering, A Practical Approach, IRL Press at
Oxford
University Press, 1996 (hereinafter referred to as "Antibody Engineering"),
for example,
as follows.
A cDNA of an antibody molecule is prepared.
Based on the prepared full length cDNA of an antibody molecule, an
appropriate length of a DNA fragment comprising a moiety encoding the protein
is
2 0 prepared, if necessary.
A recombinant vector is prepared by inserting the DNA fragment or the full
length cDNA into a site downstream of a promoter in an appropriate expression
vector.
A transformant which produces the antibody composition of the present
invention can be obtained by introducing the recombinant vector into a host
cell
2 5 suitable for the expression vector.
The cDNA can be prepared from a human or non-human animal tissue or
cell using, e.g., a probe primer specific for the antibody molecule of
interest, in
accordance with the methods described in "Preparation method of cDNA" in the
item
1 ( 1 )(a).
30 When yeast is used as the host cell, the expression vector includes YEP13
(ATCC 37115), YEp24 (ATCC 37051), YCp50 (ATCC 37419) and the like.
Any promoter can be used, so long as it can be expressed in yeast.
Examples include a promoter of a gene of the glycolytic pathway such as a
hexose
kinase gene, PHOS promoter, PGK promoter, GAP promoter, ADH promoter, gal 1
3 5 promoter, gal 10 promoter, heat shock protein promoter, MF a 1 promoter,
CUP 1
promoter and the like.
-31-
CA 02542121 2006-04-07
The host cell includes microorganisms belonging to the genus
Saccharomyces, the genus Schizosaccharomyces, the genus Kluyveromyces, the
genus
Trichosporon, the genus Schwanniomyces and the like, such as Saccharomyces
cerevisiae, Schizosaccharomyces pombe, Kluyveromyces lactis, Trichosporon
pullulans
and Schwanniomyces alluvius.
As the method for introducing the recombinant vector, any method can be
used, so long as it can introduce DNA into yeast. Examples include
electroporation
[Methods in Enrymology, 194, 182 ( 1990)], the spheroplast method [Proc. Natl.
Acad.
Sci. USA, 84, 1929 (1978)], the lithium acetate method [J. Bacteriol., 153,
163 (1983)],
the method described in Proc. Natl. Acad. Sci. USA, 75, 1929 (1978) and the
like.
When an animal cell is used as the host cell, the expression vector includes
pcDNAI, pcDMB (available from Funakoshi), pAGE107 [Japanese Published
Unexamined Patent Application No. 22979/91; Cytotechnology, 3, 133 (1990)],
pAS3-3
(Japanese Published Unexamined Patent Application No. 227075/90), pCDM8
[Nature,
329, 840 (1987)], pcDNAI/Amp (manufactured by Invitrogen), pREP4 (manufactured
by Invitrogen), pAGE103 [J. Biochemistry, 101, 1307 (1987)], pAGE210 and the
like.
Any promoter can be used, so long as it can be expressed in an animal cell.
Examples include a promoter of IE (immediate early) gene of cytomegalovirus
(CMV),
an early promoter of SV40, a promoter of retrovirus, a promoter of
metallothionein, a
2 0 heat shock promoter, an SRa promoter and the like. Also, an enhancer of
the IE gene
of human CMV may be used together with the promoter.
The host cell includes a human cell such as Namalwa cell, a monkey cell
such as COS cell, a Chinese hamster cell such as CHO cell or HBT5637 (Japanese
Published Unexamined Patent Application No. 299/88), a rat myeloma cell, a
mouse
2 5 myeloma cell, a cell derived from Syrian hamster kidney; an embryonic stem
cell, a
fertilized egg cell and the like.
As the method for introducing the recombinant vector, any method can be
used, so long as it can introduce DNA into an animal cell. Examples include
electroporation [Cytotechnology, 3, 133 (1990)], the calcium phosphate method
3 0 (Japanese Published Unexamined Patent Application No. 227075/90), the
lipofection
method [Proc. Natl. Acad Sci. USA, 84, 7413 (1987)], the injection method
[Manipulating the Mouse Embryo, A Laboratory Manual, Second Edition], a method
using particle gun (gene gun) (Japanese Patent No. 2606856, Japanese Patent
No.
2517813), the DEAF-dextran method [Biomanual Series 4-Gene Transfer and
3 5 Expression Analysis (Yodo-shay, edited by Takashi Yokota and Kenichi Arai
( 1994)],
the virus vector method (ManipulatingMouse Embryo, Second Edition) and the
like.
-32-
CA 02542121 2006-04-07
When an insect cell is used as the host, the protein can be expressed by the
method described in Current Protocols in Molecular Biology, Baculovirus
Expression
hectors, A Laboratory Manual, W.H. Freeman and Company, New York (1992),
BiolTechnology, 6, 47 ( 1988) or the like.
The protein can be expressed by co-infecting a recombinant gene
introducing vector and a baculovirus into an insect cell to obtain a
recombinant virus in
an insect cell culture supernatant and then infecting the insect cell with the
recombinant
virus.
The gene introducing vector used in the method includes pVL1392,
pVL1393, pBlueBacIII (all manufactured by Invitrogen) and the like.
The baculovirus includes Autographa californica nuclear polyhedrosis virus
which is infected by an insect of the family Barathra.
The insect cell includes Spodoptera frugiperda oocytes Sf~ and Sf21
[Current Protocols in Molecular Biology, Baculovirus Expression vectors, A
Laboratory Manual, W.H. Freeman and Company, New York (1992)], a Trichoplusia
ni oocyte High 5 (manufactured by Invitrogen) and the like.
The method for co-introducing the above recombinant gene-introducing
vector and the above baculovirus into an insect cell for preparing the
recombinant virus
includes the calcium phosphate method (Japanese Published Unexamined Patent
2 0 Application No. 227075/90), the lipofection method [Proc. Natl. Acad. Sci.
USA, 84,
7413 ( 1987)] and the like.
When a plant cell is used as the host cell, the expression vector includes Ti
plasmid, tobacco mosaic virus vector and the like.
As the promoter, any promoter can be used, so long as it can function in a
plant cell. Examples include cauliflower mosaic virus (CaMV) 35S promoter,
rice
actin 1 promoter and the like.
The host cell includes plant cells of tobacco, potato, tomato, carrot,
soybean,
rape, alfalfa, rice, wheat, barley and the like.
As the method for introducing the recombinant vector, any method can be
3 0 used, so long as it can introduce DNA into a plant cell. Examples include
a method
using Agrobacterium (Japanese Published Unexamined Patent Application No.
140885/84, Japanese Published Unexamined Patent Application No. 70080/85,
W094/00977), electroporation (Japanese Published Unexamined Patent Application
No.
251887/85), a method using a particle gun (gene gun) (Japanese Patent No.
2606856,
3 5 Japanese Patent No. 2517813) and the like.
-33-
CA 02542121 2006-04-07
As the method for expressing a gene, secretion production, expression of a
fusion protein of the Fc region with other protein and the like can be carried
out in
accordance with the method described in Molecular Cloning, Second Edition or
the like,
in addition to the direct expression.
When a gene is expressed by yeast, an animal cell, an insect cell, a plant
cell
or the like into which a gene relating to the synthesis of a sugar chain is
introduced, an
antibody molecule to which a sugar or a sugar chain is added by the introduced
gene can
be obtained.
An antibody composition can be obtained by culturing the obtained
transformant in a medium to form and accumulate the antibody molecule in the
culture
and then recovering it from the resulting culture. The method for culturing
the
transformant using a medium can be carried out in accordance with a general
method
which is used for the culturing of host cells.
As the medium for culturing the transformant obtained by using yeast as a
host, either a natural medium or a synthetic medium can be used, so long as it
comprises
carbon sources, nitrogen sources, inorganic salts and the like which can be
assimilated
by the organisms and culturing of the transformant can be carried out
efficiently.
As the carbon source, those which can be assimilated by the organism can
be used. Examples include carbohydrates such as glucose, fructose, sucrose,
molasses
2 0 containing them, starch and starch hydrolysate; organic acids such as
acetic acid and
propionic acid; alcohols such as ethanol and propanol; and the like.
The nitrogen source includes ammonia; ammonium salts of inorganic acid
or organic acid such as ammonium chloride, ammonium sulfate, ammonium acetate
and
ammonium phosphate; other nitrogen-containing compounds; peptone; meat
extract;
2 5 yeast eictract; corn steep liquor; casein hydrolysate; soybean meal;
soybean meal
hydrolysate; various fermented cells and hydrolysates thereof; and the like.
The inorganic material includes potassium dihydrogen phosphate,
dipotassium hydrogen phosphate, magnesium phosphate, magnesium sulfate, sodium
chloride, ferrous sulfate, manganese sulfate, copper sulfate, calcium
carbonate, and the
3 0 like.
The culturing is carried out generally under aerobic conditions such as
shaking culture or submerged-aeration stirring culture. The culturing
temperature is
preferably 15 to 40°C, and the culturing time is generally 16 hours to
7 days. During
the culturing, the pH is maintained at 3.0 to 9Ø The pH is adjusted using an
inorganic
35 or organic acid, an alkali solution, urea, calcium carbonate, ammonia or
the like.
-34-
CA 02542121 2006-04-07
If necessary, antibiotics such as ampicillin or tetracycline may be added to
the medium during the culturing.
When a microorganism transformed with a recombinant vector obtained by
using an inducible promoter as the promoter is cultured, an inducer may be
added to the
medium, if necessary. For example, when a microorganism transformed with a
recombinant vector obtained by using lac promoter is cultured, isopropyl-(3-D-
thiogalactopyranoside or the like may be added to the medium, and when a
microorganism transformed with a recombinant vector obtained by using trp
promoter
is cultured, indoleacrylic acid may be added to the medium.
When a transformant obtained by using an animal cell as the host is cultured,
the medium includes generally used RPMI 1640 medium [The Journal of the
American
Medical Association, 199, 519 (1967)], Eagle's MEM medium [Science, 122, 501
(1952)], Dulbecco's modified MEM medium [Virology, 8, 396 (1959)], 199 medium
[Proceeding of the Society for the Biological Medicine, 73, 1 (1950)] and
Whitten's
medium [Developmental Engineering Experimentation Manual-Preparation of
Transgenic Mice (Kodan-shay, edited by M. Katsuki (1987)], the media to which
insulin,
an insulin-like growth factor, transferrin, albumin, etc. is added, and the
like.
The culturing is carried out generally at a pH of 6 to 8 and 30 to
40°C for 1
to 7 days in the presence of 5% CO2. The culturing can be carried out for 1
day to
2 0 several months by a culturing method such as fed-batch culture and hollow-
fiber culture.
If necessary, antibiotics such as kanamycin or penicillin may be added to the
medium during the culturing.
The medium for the culturing of a transformant obtained by using an insect
cell as the host includes generally used TNM-FH medium (manufactured by
2 5 Pharmingen), Sf 900 II SFM medium (manufactured by Life Technologies),
ExCeII 400
and ExCell 405 (both manufactured by JRH Biosciences), Grace's Insect Medium
[Nature, 195, 788 (1962)] and the like.
The culturing is carried out generally at a pH of 6 to 7 and 25 to
30°C for 1
to 5 days.
3 0 In addition, antibiotics such as gentamicin may be added to the medium
during the culturing, if necessary.
A transformant obtained by using a plant cell as the host can be cultured as a
cell or after differentiating it into a plant cell or organ. The medium for
culturing the
transformant includes generally used Murashige and Skoog (MS) medium and White
3 5 medium, the media to which a plant hormone such as auxin, cytokinin, etc.
is added,
and the like.
-35-
CA 02542121 2006-04-07
The culturing is carried out generally at a pH of 5 to 9 and 20 to
40°C for 3
to 60 days.
If necessary, antibiotics such as kanamycin or hygromycin may be added to
the medium during the culturing.
Accordingly, an antibody composition can be produced by culturing a
transformant derived from a yeast, an animal cell or a plant cell, which
comprises a
recombinant vector into which a DNA encoding an antibody molecule is inserted,
in
accordance with a general culturing method, to thereby form and accumulate the
antibody composition, and then recovering the antibody composition from the
culture.
The method for producing an antibody composition includes a method of
intracellular expression in a host cell, a method of extracellular secretion
from a host
cell, and a method of producing it on a host cell membrane outer envelope. The
method can be selected by changing the host cell used or the structure of the
antibody
composition produced.
When the antibody composition is produced in a host cell or on a host cell
membrane outer envelope, it can be positively secreted extracellularly in
accordance
with the method of Paulson et al. [.~ Biol. Chem., 264, 17619 (1989)], the
method of
Lowe et al. [Broc. Natl. Acad Sci. USA, 86, 8227 (1989), Genes Develop., 4,
1288
( 1990)], the methods described in Japanese Published Unexamined Patent
Application
No. 336963/93 and W094/23021 and the like.
That is, an antibody molecule of interest can be positively secreted
extracellularly from a host cell by inserting a DNA encoding the antibody
molecule and
a DNA encoding a signal peptide suitable for the expression of the antibody
molecule
into an expression vector using a gene recombination technique, introducing
the
2 5 expression vector into the host cell and then expressing the antibody
molecule.
Also, its production amount can be increased in accordance with the method
described in Japanese Published Unexamined Patent Application No. 227075190 by
using a gene amplification system using a dihydrofolate reductase gene and the
like.
In addition, the antibody composition can also be produced by using a gene
3 0 introduced animal individual (transgenic non-human animal) or a plant
individual
(transgenic plant) which is constructed by the redifferentiation of an animal
or plant cell
into which the gene is introduced.
When the transformant is an animal individual or a plant individual, the
antibody composition can be produced in accordance with a general method by
rearing
3 S or cultivating it to thereby form and accumulate the antibody composition
and then
recovering the antibody composition from the animal or plant individual.
-36-
CA 02542121 2006-04-07
The method for producing an antibody composition by using an animal
individual includes a method in which the antibody composition of interest is
produced
in an animal constructed by introducing a gene in accordance with a known
method
[American Journal of Clinical Nutrition, 63, 639S (1996); American Journal of
Clinical
Nutrition, 63, 627S (1996); BiolTechnology, 9, 830 (1991)].
In the case of an animal individual, an antibody composition can be
produced by rearing a transgenic non-human animal into which a DNA encoding an
antibody molecule is introduced to thereby form and accumulate the antibody
composition in the animal, and then recovering the antibody composition from
the
animal. The place in the animal where the composition is formed and
accumulated
includes milk (Japanese Published Unexamined Patent Application No.
309192/88),
eggs of the animal and the like. As the promoter used in this case, any
promoter can
be used, so long as it can function in an animal. Preferred examples include
mammary
gland cell-specific promoters such as a, casein promoter, (3 casein promoter,
(3
lactoglobulin promoter, whey acidic protein promoter and the like.
The method for producing an antibody composition by using a plant
individual includes a method in which an antibody composition is produced by
cultivating a transgenic plant into which a DNA encoding an antibody molecule
is
introduced by a known method [?'issue Culture, 20 (1994); Tissue Culture, 21
(1995);
Trends in Biotechnology, 15, 45 (1997)] to form and accumulate the antibody
composition in the plant, and then recovering the antibody composition from
the plant.
Regarding an antibody composition produced by a transformant into which
a gene encoding an antibody molecule is introduced, for example, when the
antibody
composition is intracellularly expressed in a dissolved state, the cells after
culturing are
2 5 recovered by centrifugation, suspended in an aqueous buffer and then
disrupted with
ultrasonic oscillator, French press, Manton Gaulin homogenizer, dynomill or
the like to
obtain a cell-free extract. A purified product of the antibody composition can
be
obtained from a supernatant obtained by centrifuging the cell-free extract, by
using a
general enzyme isolation purification techniques such as solvent extraction;
salting out
3 0 and desalting with ammonium sulfate, and the like; precipitation with an
organic
solvent; anion exchange chromatography using a resin such as diethylaminoethyl
(DEAF)-Sepharose or DIAION HPA-75 (manufactured by Mitsubishi Chemical);
cation exchange chromatography using a resin such as S-Sepharose FF
(manufactured
by Pharmacia); hydrophobic chromatography using a resin such as butyl-
Sepharose,
3 5 phenyl-Sepharose; gel filtration using a molecular sieve; affinity
chromatography;
-37-
CA 02542121 2006-04-07
chromatofocusing; electrophoresis such as isoelectric focusing; and the like
which may
be used alone or in combination.
Also, when the antibody composition is expressed intracellularly by forming
an insoluble body, the cells are recovered, disrupted and centrifuged in the
same manner,
and the insoluble body of the antibody composition is recovered as a
precipitation
fraction. The recovered insoluble body of the antibody composition is
solubilized
using a protein denaturing agent. The antibody composition is made into a
normal
three-dimensional structure by diluting or dialyzing the solubilized solution,
and then a
purified preparation of the antibody composition is obtained by the same
isolation
purification method as above.
When the antibody composition is secreted extracellularly, the antibody
composition can be recovered from the culture supernatant. That is, the
culture is
treated by a technique such as centrifugation as described above to obtain a
soluble
fraction, and a purified preparation of the antibody composition can be
obtained from
the soluble fraction by the same isolation purification method as above.
The thus obtained antibody composition includes an antibody, the fragment
of the antibody, a fusion protein comprising the Fc region of the antibody,
and the like.
As an example for obtaining the antibody composition, methods for
producing a humanized antibody composition and an Fc fusion protein
composition is
2 0 described below in detail, but glycoproteins of other antibody
compositions and the like
can also be obtained in a manner similar to the above-described method or the
method.
A. Preparation of humanized antibody composition
(1) Construction of vector for expression of humanized antibody
2 5 A vector for expression of humanized antibody is an expression vector for
animal cell into which genes encoding the heavy chain (H chain) C region and
light (L
chain) C region of a human antibody are inserted, which can be constructed by
cloning
each of genes encoding the H chain C region and L chain C region of a human
antibody
into an expression vector for animal cell.
3 0 The C regions of a human antibody may be the H chain C region and L
chain C region of any human antibody. Examples include the C region belonging
to
IgGI subclass in the H chain of a human antibody (hereinafter referred to as
"hCyl "),
the C region belonging to x class in the L chain of a human antibody
(hereinafter
referred to as "hCK"), and the like.
-38-
CA 02542121 2006-04-07
As the genes encoding the H chain C region and L chain C region of a
human antibody, a chromosomal DNA comprising an exon and an intron can be
used,
and a cDNA can also be used.
As the expression vector for animal cell, any vector can be used, so long as
a gene encoding the C region of a human antibody can be inserted thereinto and
expressed therein. Examples include pAGE107 [Cytotechnology, 3, 133 (1990)],
pAGE 103 (J. Biochem., 101, 1307 ( 1987)], pHSG274 [Gene, 27, 223 ( 1984)],
pKCR
[Proc. Natl. Acad. Sci. USA, 78, 1527 (1981), pSGI (3 d2-4 [Cytotechnology, 4,
173
( 1990)] and the like. The promoter and enhancer used in the expression vector
for
animal cell includes SV40 early promoter and enhancer [J. Biochem., 101, 1307
(1987)],
Moloney mouse leukemia virus LTR promoter [Biochem. Biophys. Res. Commun.,
149,
9ti0 (1987)], immunoglobulin H chain promoter [Cell, 41, 479 (1985)] and
enhancer
[Cell, 33, 717 (1983)] and the like.
The vector for expression of humanized antibody may be either of a type in
which genes encoding the H chain and L chain of an antibody exist on separate
vectors
or of a type in which both genes exist on the same vector (hereinafter
referred to as
"tandem type"). In respect of easiness of construction of a humanized antibody
expression vector, easiness of introduction into animal cells, and balance
between the
expression amounts of the H and L chains of an antibody in animal cells, a
tandem type
2 0 of the vector for expression of humanized antibody is more preferred [J.
Immunol.
Methods, 167, 271 (1994)].
The constructed vector for expression of humanized antibody can be used
for expression of a human chimeric antibody and a human CDR-grafted antibody
in
animal cells.
(2) Obtaining of cDNA encoding V region of non-human animal antibody
cDNAs encoding the H chain C region and L chain V region of a non-
human animal antibody, such as a mouse antibody, can be obtained in the
following
manner.
3 0 A cDNA is synthesized from mRNA extracted from a hybridoma cell which
produces the mouse antibody of interest. The synthesized cDNA is cloned into a
vector such as a phage or a plasmid to obtain a cDNA library. Each of a
recombinant
phage or recombinant plasmid comprising a cDNA encoding the H chain V region
and a
recombinant phage or recombinant plasmid comprising a cDNA encoding the L
chain V
region is isolated from the library by using a C region part or a V region
part of an
existing mouse antibody as the probe. Full nucleotide sequences of the H chain
V
-39-
CA 02542121 2006-04-07
region and L chain V region of the mouse antibody of interest on the
recombinant phage
or recombinant plasmid are determined, and full length amino acid sequences of
the H
chain V region and L chain V region are deduced from the nucleotide sequences.
As the non-human animal, any animal such as mouse, rat, hamster or rabbit
can be used so long as a hybridoma cell can be produced therefrom.
The method for preparing total RNA from a hybridoma cell includes the
guanidine thiocyanate-cesium trifluoroacetate method [Methods in Enzymology,
154, 3
(1987)] and the like, and the method for preparing mRNA from total RNA
includes an
oligo(dT)-immobilized cellulose column method [Molecular Cloning, A Laboratory
Manual, Cold Spring Harbor Lab. Press New York (1989)] and the like. In
addition,
examples of a kit for preparing mRNA from a hybridoma cell include Fast Track
mRNA Isolation Kit (manufactured by Invitrogen), Quick Prep mRNA Purification
Kit
(manufactured by Pharmacia) and the like.
The method for synthesizing cDNA and preparing a cDNA library includes
the usual methods [Molecular Cloning, A Laboratory Manual, Cold Spring Harbor
Lab.
Press New York (1989), Current Protocols in Molecular Biology, Supplement 1-
34],
methods using a commercially available kit such as SuperScriptTM, Plasmid
System for
cDNA Synthesis and Plasmid Cloning (manufactured by GIBCO BRL) or ZAP-cDNA
Synthesis Kit (manufactured by Stratagene) and the like.
2 0 In preparing the cDNA library, the vector into which a cDNA synthesized
by using mRNA extracted from a hybridoma cell as the template is inserted may
be any
vector so long as the cDNA can be inserted. Examples include ZAP Express
[Strategies, 5, 58 (1992)], pBluescript II SK(+) [Nucleic Acids Research, 17,
9494
( 1989)], ~,zapII (manufactured by Stratagene), ~,gt l 0 and ~,gt l l [DNA
Cloning; A
Practical Approach, I, 49 (1985)], Lambda BlueMid (manufactured by Clorltech),
~,ExCell, pT7T3 18U (manufactured by Pharmacia), pcD2 [Mol. Cell. Biol., 3,
280
(1983)], pUClB [Gene, 33, 103 (1985)] and the like.
As Escnerichia coli into which the cDNA library constructed from a phage
or plasmid vector is introduced, any Escherichia coli can be used, so long as
the cDNA
library can be introduced, expressed and maintained. Examples include XL1-Blue
MRF' [Strategies, S, 81 (1992)], C600 [Genetics, 39, 440 (1954)], Y1088 and
Y1090
[Science, 222, 778 (1983)], NM522 [J. Mol Biol., 166, 1 (1983)], K802 [J. Mol.
Biol.,
16, 118 (1966)], JM105 [Gene, 38, 275 (1985)] and the like.
As the method for selecting a cDNA clone encoding the H chain V region
3 5 and L chain V region of a non-human animal antibody from the cDNA library,
a colony
hybridization or a plaque hybridization using an isotope- or fluorescence-
labeled probe
-40-
CA 02542121 2006-04-07
can be used [Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Lab.
Press
New York(1989)].
The cDNA encoding the H chain V region and L chain V region can also be
prepared by preparing primers and carrying out polymerase chain reaction
[hereinafter
referred to as "PCR"; Molecular Cloning, A Laboratory Manual, Cold Spring
Harbor
Lab. Press New York (1989); Current Protocols in Molecular Biology, Supplement
1-
34] using a cDNA synthesized from mRNA or a cDNA library as the template.
The nucleotide sequences of the cDNAs can be determined by digesting the
selected cDNAs according to the above methods with appropriate restriction
enzymes,
cloning the DNA fragments into a plasmid such as pBluescript SK(-)
(manufactured by
Stratagene), carrying out the reaction of a generally used nucleotide sequence
analyzing
method such as the dideoxy method of Sanger et al. [Proc. Natl. Acad Sci. USA,
74,
5463 (1977)] or the like and then analyzing the clones using an automatic
nucleotide
sequence analyzer such as A.L.F. DNA Sequencer (manufactured by Pharmacia) or
the
like.
Whether or not the obtained cDNAs encode the full length amino acid
sequences of the H chain V region and L chain V region of the antibody
comprising a
secretory signal sequence can be confirmed by deducing the full length amino
acid
sequences of the H chain V regionand L chain V region from the determined
nucleotide
2 0 sequence and comparing them with the full length amino acid sequences of
the H chain
V region and L chain V region of known antibodies [Sequences of Proteins of
Immunologicallnterest, US Dept. Health and Human Services (1991)].
(3) Analysis of amino acid sequence of V region of non-human animal antibody
2 5 Regarding the full length amino acid sequences of the H chain V region and
L chain V region of the antibody comprising a secretory signal sequence, the
length of
the secretory signal sequence and the N-terminal amino acid sequences can be
deduced
and subgroups to which they belong can also be found, by comparing them with
the full
length amino acid sequences of the H chain V region and L chain V region of
known
3 0 antibodies [Sequences of Proteins of Immunological Interest, US Dept.
Health and
Human Services, ( 1991 )]. In addition, the amino acid sequences of each CDR
of the H
chain V region and L chain V region can also be found by comparing them with
the
amino acid sequences of the H chain V region and L chain V region of known
antibodies [Sequences of Proteins of Immunological Interest, US Dept. Health
and
35 Human Services, (1991)].
-41-
CA 02542121 2006-04-07
(4) Construction of human chimeric antibody expression vector
A human chimeric antibody expression vector can be constructed by cloning
cDNAs encoding the H chain V region and L chain V region of a non-human animal
antibody into a site upstream of genes encoding the H chain C region and L
chain C
region of a human antibody in the vector for expression of humanized antibody
described in the item 2.A.(1). For example, a human chimeric antibody
expression
vector can be constructed by linking each of cDNAs encoding the H chain V
region and
L chain V region of a non-human animal antibody to a synthetic DNA comprising
nucleotide sequences at the 3'-terminals of the H chain V region and L chain V
region
of a non-human animal antibody and nucleotide sequences at the 5'-terminals of
the H
chain C region and L chain C region of a human antibody and also having a
recognition
sequence of an appropriate restriction enzyme at both terminals, and by
appropriately
cloning them into a site upstream of genes encoding the H chain C region and L
chain C
region of a human antibody contained in the vector for expression of humanized
antibody described in the item 2.A.(1).
(5) Construction of cDNA encoding V region of human CDR-grafted antibody
cDNAs encoding the H chain V region and L chain V region of a human
CDR-grafted antibody can be obtained as follows. First, amino acid sequences
of the
2 0 frameworks (hereinafter referred to as "FR") of the H chain V region and L
chain V
region of a human antibody for grafting CDR of the H chain V region and L
chain V
region of a non-human animal antibody of interest is selected. As the amino
acid
sequences of FRs of the H chain V region and L chain V region of a human
antibody,
any amino acid sequences can be used so long as they are derived from a human
2 5 antibody. Examples include amino acid sequences of FRs of the H chain V
region and
L chain V region of human antibodies registered at databases such as Protein
Data Bank,
amino acid sequences common in each subgroup of FRs of the H chain V region
and L
chain V region of human antibodies [Sequences of Proteins of Immunological
Interest,
US Dept. Health and Human Services (1991)] and the like. In order to prepare a
3 0 human CDR-grafted antibody having sufficient activities, it is preferred
to select an
amino acid sequence having a homology as high as possible (at least 60% or
more) with
amino acid sequences of FRs of the H chain V region and L chain V region of a
non-
human animal antibody of interest.
Next, the amino acid sequences of CDRs of the H chain V region and L
3 5 chain V region of the non-human animal antibody of interest are grafted to
the selected
amino acid sequences of FRs of the H chain V region and L chain V region of a
human
-42-
CA 02542121 2006-04-07
antibody to design amino acid sequences of the H chain V region and L chain V
region
of the human CDR-grafted antibody. The designed amino acid sequences are
converted into DNA sequences by considering the frequency of codon usage found
in
nucleotide sequences of antibody genes [Sequences of Proteins of Immunological
Interest, US Dept. Health and Human Services (1991)], and the DNA sequences
encoding the amino acid sequences of the H chain V region and L chain V region
of the
human CDR-grafted antibody are designed. Based on the designed DNA sequences,
several synthetic DNAs having a length of about 100 bases are synthesized, and
PCR is
carried out by using them. In this case, it is preferred in each of the H
chain and the L
chain that b synthetic DNAs are designed in view of the reaction efficiency of
PCR and
the Lengths of DNAs which can be synthesized.
Also, they can be easily cloned into the vector for expression of humanized
antibody described in the item 2.A.(1) by introducing recognition sequences of
an
appropriate restriction enzyme into the 5'-terminals of the synthetic DNA on
both
terminals. After the PCR, the amplified product is cloned into a plasmid such
as
pBluescript SK(-) (manufactured by Stratagene) and the nucleotide sequences
are
determined by the method in the item 2.A.(2) to thereby obtain a plasmid
having DNA
sequences encoding the amino acid sequences of the H chain V region and L
chain V
region of the desired human CDR-grafted antibody.
(6) Modification of amino acid sequence of V region of human CDR-grafted
antibody
It is known that a human CDR-grafted antibody in which CDRs in the H
chain V region and L chain V region of a non-human animal antibody of interest
are
simply grafted with FRs in the H chain V region and L chain V region of a
human
2 5 antibody -has lowered antigen-binding activity than the original non-human
animal
antibody [BIOlTECHNOLOGY, 9, 266 (1991)]. As the reason, it is considered that
several amino acid residues of FRs other than CDRs directly or indirectly
relate to
antigen-binding activity in the H chain V region and L chain V region of the
original
non-human animal antibody, and that they are changed to different amino acid
residues
3 0 of FRs in the H chain V region and L chain V region of a human antibody as
they are
grafted with CDRs. In order to solve the problem, in human CDR-grafted
antibodies,
among the amino acid sequences of FRs in H chain V region and L chain V region
of a
human antibody, an amino acid residue which directly relates to an antigen
binding, or
an amino acid residue which interacts with CDR, or an amino acid residue which
3 5 indirectly relates to an antigen binding by maintaining the three-
dimensional structure
of an antibody is identified and modif ed to an amino acid residue which is
found in the
- 43 -
CA 02542121 2006-04-07
original non-human animal antibody to thereby increase the antigen binding
activity
which has been decreased [BIOlTECHNOLOGY, 9, 266 (1991)].
In the production of a human CDR-grafted antibody, the most important
point is how to e~ciently identify the amino acid residues relating to the
antigen
binding activity in FR. Therefore, the three-dimensional structure of an
antibody is
constructed and analyzed by X-ray crystallography [J. Mol. Biol., 112, 535
(1977)],
computer-modeling [Protein Engineering, 7, 1501 (1994)] or the like. Although
the
information of the three-dimensional structure of antibodies has been useful
in the
production of a human CDR-grafted antibody, method for producing a human CDR-
l0 grafted antibody which can be applied to all antibodies has not been
established yet.
Therefore, various attempts must be made. Such attempts include producing
several
modified antibodies of each antibody and examining the relationship between
each of
the modified antibodies and its antigen binding activity.
The modification of the amino acid residue of FRs in H chain V region and
L chain V region of a human antibody can be accomplished using various
synthetic
DNA for modification according to PCR as described in the item 2.A.(5). With
regard
to the amplified product obtained by the PCR, the nucleotide sequence is
determined
according to the method as described in the item 2.A.(2) to thereby confirm
whether the
objective modification has been carried out.
(7) Construction of human CDR-grafted antibody expression vector
A human CDR-grafted antibody expression vector can be constructed by
cloning the cDNAs encoding the H chain V region and L chain V region of the
human
CDR-grafted antibody constructed in the items 2.A.(5) and (6) into a site
upstream of
2 5 the gene encoding the H chain C region and L chain C region of a human
antibody in
the vector for expression of humanized antibody described in the item 2.A. ( 1
). For
example, recognizing sequences of an appropriate restriction enzyme are
introduced
into the 5'-terminals of both terminals of a synthetic DNA fragment, among the
synthetic DNAs which are used in the items 2.A.(5) and (6) for constructing
the H chain
3 0 V region and L chain V region of the human CDR-grafted antibody, so that
they are
cloned into a site upstream of the genes encoding the H chain C region and L
chain C
region of a human antibody in the vector for expression of humanized antibody
described in the item 2.A.(1) in such a manner that they can be expressed in a
suitable
form, to thereby construct the human CDR-grafted antibody expression vector.
-44-
CA 02542121 2006-04-07
(8) Stable production of humanized antibody
A transformant capable of stably producing a human chimeric antibody and
a human CDR-grafted antibody (both hereinafter referred to as "humanized
antibody")
can be obtained by introducing the humanized antibody expression vector
described in
the items 2.A.(4) and (7) into an appropriate animal cell.
The method for introducing a humanized antibody expression vector into an
animal cell includes electroporation [Japanese Published Unexamined Patent
Application No. 257891/90, Cytotechnology, 3, 133 (1990)] and the like.
As the animal cell into which a humanized antibody expression vector is
introduced, any cell can be used so long as it is an animal cell capable of
producing the
humanized antibody.
Examples include mouse myeloma cells such as NSO cell and SP2/0 cell,
Chinese hamster ovary cells such as CHO/dhfr- cell and CHO/DG44 cell, rat
myeloma
such as YB210 cell and IR983F cell, BHK cell derived from a Syrian hamster
kidney, a
human myeloma cell such as Namalwa cell, and the like, and a Chinese hamster
ovary
cell CHO/DG44 cell, a rat myeloma YB2/0 cell and the cells described in the
item 1 and
the like are preferred.
After introduction of the humanized antibody expression vector, a
transformant capable of stably producing the humanized antibody can be
selected by
2 0 using a medium for animal cell culture comprising an agent such as 6418
sulfate
(hereinafter referred to as "G418"; manufactured by SIGMA) and the like in
accordance
with the method described in Japanese Published Unexamined Patent Application
No.
257891/90. The medium to culture animal cells includes RPMI 1640 medium
(manufactured by Nissui Pharmaceutical), GIT medium (manufactured by Nihon
2 5 Pharmaceutical), EX-CELL 302 medium (manufactured by JRH), IIVVIDM medium
(manufactured by GIBCO BRL), Hybridoma-SFM medium (manufactured by GIBCO
BRL), media obtained by adding various additives such as insulin, an insulin-
like
growth factor, transferrin and albumin to these media, and the like. The
humanized
antibody can be formed and accumulated in the culture supernatant by culturing
the
3 0 obtained transformant in a medium. The amount of production and antigen
binding
activity of the humanized antibody in the culture supernatant can be measured
by a
method such as enzyme-linked immunosorbent assay [hereinafter referred to as
"ELISA"; Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory,
Chapter
14 (1998), Monoclonal Antibodies: Principles and Practice, Academic Press
Limited
35 (1996)] or the like. Also, the amount of the humanized antibody produced by
the
transformant can be increased by using a DHFR gene amplification system in
-45-
CA 02542121 2006-04-07
accordance with the method described in Japanese Published Unexamined Patent
Application No. 257891/90.
The humanized antibody can be purified from a culture supernatant of the
transformant using a protein A column [Antibodies, A Laboratory Manual, Cold
Spring
Harbor Laboratory, Chapter 8 (1988), Monoclonal Antibodies: Principles and
Practice,
Academic Press Limited (1996)]. In addition, purification methods generally
used for
the purification of proteins can also be used. For example, the purification
can be
carried out through the combination of gel filtration, ion exchange
chromatography,
ultrafiltration and the like. The molecular weight of the H chain, L chain or
antibody
l0 molecule as a whole of the purified humanized antibody can be measured,
e.g., by
polyacrylamide gel electrophoresis [hereinafter referred to as "SDS-PAGE";
Nature,
227, 680 ( 1970)], Western blotting (Antibodies, A Laboratory Manual, Cold
Spring
Harbor Laboratory, Chapter 12, ( 1988), Monoclonal Antibodies: Principles and
Practice, Academic Press Limited (1996)] or the like.
B. Preparation of Fc fusion protein
(1) Construction of vector for expression of Fc fusion protein
A vector for expression Fc fusion protein is a vector for expression of
animal cell into which genes encoding the Fc region of a human antibody and a
protein
2 0 to be fused are inserted, which can be constructed by cloning each of
genes encoding
the Fc region of a human antibody and the protein to be fused into a vector
for
expression of animal cell.
The Fc region of a human antibody includes those comprising a part of a
hinge region and/or CH1 in addition to regions comprising CH2 and CH3 regions.
2 5 Also, it can be any Fc region so long as at least one amino acid of CH2 or
CH3 is
deleted, substituted, added or inserted, and substantially has the binding
activity to the
Fcy receptor.
As the genes encoding the Fc region of a human antibody and the protein to
be fused, a chromosomal DNA comprising an exon and an intron can be used, and
a
3 0 cDNA can also be used. The method for linking the genes and the Fc region
includes
PCR using each of the gene sequences as the template (Molecular Cloning,
Second
Edition; Current Protocols in Molecular Biology, Supplement 1-34).
As the vector for expression of animal cell, any vector can be used, so long
as a gene encoding the C region of a human antibody can be inserted thereinto
and
35 expressed therein. Examples include pAGE107 [Cytotechnology, 3, 133
(1990)],
pAGE103 [J. Biochem., 101, 1307 (1987)], pHSG274 [Gene, 27, 223 (1984)], pKCR
-46-
CA 02542121 2006-04-07
jProc. Natl. Acad. Sci. USA, 78, 1527 (1981), pSGI (3 d2-4 [Cytotechnology, 4,
173
(1990)] and the like. The promoter and enhancer in the vector for expression
of animal
cell include SV40 early promoter and enhancer [J. Biochem., 101, 1307 (1987)],
Moloney mouse leukemia virus LTR promoter [Biochem. Biophys. Res. Commun.,
149,
960 (1987)], immunoglobulin H chain promoter [Cell, 41, 479 (1985)] and
enhancer
[Cell, 33, 717 (1983)], and the like.
(2) Obtaining of DNA encoding Fc region of human antibody and protein to be
fused
A DNA encoding the Fc region of a human antibody and the protein to be
fused can be obtained in the following manner.
A cDNA is synthesized from mRNA extracted from a cell or tissue which
expresses the protein of interest to be fused with Fc. The synthesized cDNA is
cloned
into a vector such as a phage or a plasmid to obtain a cDNA library. A
recombinant
phage or recombinant plasmid comprising cDNA encoding the protein of interest
is
isolated from the library by using the gene sequence part of the protein of
interest as the
probe. A full nucleotide sequence of the protein of interest on the
recombinant phage
or recombinant plasmid is determined, and a full length amino acid sequence is
deduced
from the nucleotide sequence.
As the non-human animal, any animal such as mouse, rat, hamster or rabbit
2 0 can be used so long as a cell or tissue can be removed therefrom.
The method for preparing a total RNA from a cell or tissue includes the
guanidine thiocyanate-cesium trifluoroacetate method [Methods in Enrymology,
154, 3
(1987)] and the like, and the method for preparing mRNA from total RNA
includes an
oligo (dT)-immobilized cellulose column method (Molecular Cloning, Second
Edition)
2 5 and the like. In addition; a kit for preparing mRNA from a cell or tissue
includes Fast
Track mRNA Isolation Kit (manufactured by Invitrogen), Quick Prep mRNA
Purification Kit (manufactured by Pharmacia) and the like.
The method for synthesizing a cDNA and preparing a cDNA library
includes the usual methods (Molecular Cloning, Second Edition; Current
Protocols in
3 0 Molecular Biology, Supplement 1-34); methods using a commercially
available kit such
as SuperScriptTM, Plasmid System for cDNA Synthesis and Plasmid Cloning
(manufactured by GIBCO BR.L) or ZAP-cDNA Synthesis Kit (manufactured by
Stratagene); and the like.
In preparing the cDNA library, the vector into which a cDNA synthesized
3 5 by using mRNA extracted from a cell or tissue as the template is inserted
may be any
vector so long as the cDNA can be inserted. Examples include ZAP Express
-47-
CA 02542121 2006-04-07
[Strategies, 5, 58 (1992)], pBluescript II SK(+) [Nucleic Acids Research, 17,
9494
( 1989)], ~,zapII (manufactured by Stratagene), ~,gt 10 and ~.gt 11 [DNA
Cloning, A
Practical Approach, I, 49 (1985)], Lambda BlueMid (manufactured by Clontech),
7~ExCell, pT7T3 18U (manufactured by Pharmacia), pcD2 [Mol. Cell. Biol., 3,
280
(1983)], pUCl8 [Gene, 33, 103 (1985)] and the like.
As Escherichia coli into which the cDNA library constructed from a phage
or plasmid vector is introduced, any Escherichia coli can be used, so long as
the cDNA
library can be introduced, expressed and maintained. Examples include XL,1-
Blue
MRF' [Strategies, 5, 81 (1992)], C600 [Genetics, 39, 440 (1954)], Y1088 and
Y1090
[Science, 222, 778 (1983)], NM522 [.I. Mol Biol., 166, 1 (1983)], K802 [J. Mol
Biol.,
16, 118 (1966)), JM105 [Gene, 38, 275 (1985)] and the like.
As the method for selecting a cDNA clone encoding the protein of interest
from the cDNA library, a colony hybridization or a plaque hybridization using
an
isotope- or fluorescence-labeled probe can be used (Molecular Cloning, Second
Edition). The cDNA encoding the protein of interest can also be prepared by
preparing primers and using a cDNA synthesized from mRNA or a cDNA library as
the
template according to PCR.
The method for fusing the protein of interest with the Fc region of a human
antibody includes PCR. For example, synthesized oligo DNAs (primers) are
designed
2 0 at the 5'-terminal and 3'-terminal of the gene sequence encoding the
protein of interest,
and PCR is carried out using the primers to prepare a PCR product. In the same
manner, primers are designed for the gene sequence encoding the Fc region of a
human
antibody to be fused to prepare a PCR product. At this time, the primers are
designed
in such a manner that the same restriction enzyme site or the same gene
sequence is
2 5 present in the 3'-terminal of the P-CR product of the protein to be fused
and the 5'-
terminal of the PCR product of the Fc region. When it is necessary to modify
the
amino acids around the linked site, mutation is introduced by using the primer
into
which the mutation is introduced. PCR is further carried out by using the two
kinds of
the obtained PCR fragments to link the genes. Also, they can be linked by
carrying out
3 0 ligation after treatment with the same restriction enzyme.
The nucleotide sequence of the DNA can be determined by digesting the
gene sequence linked by the above method with appropriate restriction enzymes,
cloning the DNA fragments into a plasmid such as pBluescript SK(-)
(manufactured by
Stratagene), carrying out analysis by using a generally used nucleotide
sequence
35 analyzing method such as the dideoxy method of Sanger et al. [Proc. Natl.
Acad Sci.
-48-
CA 02542121 2006-04-07
USA, 74, 5463 (1977)] or a nucleotide sequence analyzer such as ABI PRISM 377
DNA
Sequencer (manufactured by PE Biosystems).
Whether or not the obtained cDNA encodes the full length amino acid
sequences of the Fc fusion protein comprising a secretory signal sequence can
be
confirmed by deducing the full length amino acid sequence of the Fc fusion
protein
from the determined nucleotide sequence and comparing it with the amino acid
sequence of interest.
(3) Stable production of Fc fusion protein
A transformant capable of stably producing an Fc fusion protein can be
obtained by introducing the Fc fusion protein expression vector described in
the item (1)
into an appropriate animal cell.
The method for introducing the Fc fusion protein expression vector into an
animal cell include electroporation [Japanese Published Unexamined Patent
Application
No. 257891190, Cytotechnology, 3, 133 (1990)] and the like.
As the animal cell into which the Fc fusion protein expression vector is
introduced, any cell can be used, so long as it is an animal cell which can
produce the Fc
fusion protein.
Examples include mouse myeloma cells such as NSO cell and SP2/0 cell,
2 0 Chinese hamster ovary cells such as CHOldhfr- cell and CHO/DG44 cell, rat
myeloma
such as YB2/0 cell and IR983F cell, BHK cell derived from a Syrian hamster
kidney, a
human myeloma cell such as Namalwa cell, and the like, and preferred are a
Chinese
hamster ovary cell CHO/DG44 cell, a rat myeloma YB2/0 cell, the host cells
used in the
method of the present invention described in the item l and the like.
2 5 After introduction of the Fc fusion protein expression vector, a
trarlsformant
capable of stably producing the Fc fusion protein can be selected by using a
medium for
animal cell culture comprising an agent such as 6418 in accordance with the
method
described in Japanese Published Unexamined Patent Application No. 257891/90.
The
medium to culture animal cells includes RPMI 1640 medium (manufactured by
Nissui
30 Pharmaceutical), GIT medium (manufactured by Nihon Pharmaceutical), EX-CELL
302
medium (manufactured by JRH), IIVVIDM medium (manufactured by GIBCO BRL),
Hybridoma-SFM medium (manufactured by GIBCO BRL), media obtained by adding
various additives such as insulin, an insulin-like growth factor, thransferrin
and albumin
to these media, and the like. The Fc fusion protein can be formed and
accumulated in
3 5 the culture supernatant by culturing the obtained transformant in a
medium. The
amount of production and antigen binding activity of the Fc fusion protein in
the culture
-49-
CA 02542121 2006-04-07
supernatant can be measured by a method such as ELISA. Also, the amount of the
Fc
fusion protein produced by the transformant can be increased by using a dhfr
gene
amplification system and the like in accordance with the method described in
Japanese
Published Unexamined Patent Application No. 257891/90.
The Fc fusion protein can be purified from a culture supernatant culturing
the transformant by using a protein A column or a protein G column
(Antibodies,
Chapter 8; Monoclonal Antibodies). In addition, purification methods generally
used
for the purification of proteins can also be used. For example, the
purification can be
carried out through the combination of a gel filtration, an ion exchange
chromatography,
an ultrafiltration and the like. The molecular weight as a whole of the
purified Fc
fusion protein molecule can be measured by SDS-PAGE [Nature, 227, 680 (1970)],
Western blotting (Antibodies, Chapter 12, Monoclonal Antibodies) or the like.
Thus, the processes for producing an antibody and Fc fusion protein
composition using an animal cell as the host have been described, but, as
described
above, the antibody and the Fc fusion protein composition can also be produced
by a
yeast, an insect cell, a plant cell, an animal individual or a plant
individual.
When a cell has the ability to express a glycoprotein such as an antibody
molecule innately, the antibody composition or glycoprotein composition of the
present
invention can be produced by preparing a glycoprotein producing cell using the
method
2 0 described in the item l, culturing the cell and then purifying the
antibody composition
or glycoprotein composition of interest from the resulting culture.
3. Method for producing the glycoprotein composition of the present invention
by
serum-free culturing
2 5 It is necessary to further naturalize the cell of the present invention in
a
serum-free medium. A glycoprotein composition in a serum-free or protein-free
medium can be produced by producing a glycoprotein using the cell of the
present
invention.
The naturalization method in a serum-free medium in the present invention
3 0 includes a method wherein a cell in which a genomic gene encoding the oc-
1,6-fucose
modifying enzyme is knocked out is sub-cultured in a medium containing serum
and
then directly naturalized or continuously naturalized in a commercially
available serum-
free medium or the like (Cell & Tissue Culture: Laboratory Procedures, JOHN
WILEY
& SONS 2C:1) and the like. Specific examples are described below.
3 5 During the serum-free naturalization, there is a case in which the
survival
rate of the cell temporarily decreases, causing death of the cell. Thus, in
order to
- 50 -
CA 02542121 2006-04-07
restore the survival rate of the cell or keep it at a high level, it is
preferable to inoculate
the cell to give a cell density of 1 x 105 to l Ox 105 cells/ml, preferably 4x
105 to 6x 105
cells/ml, at the time when the cell is inoculated into a serum-free
naturalization medium.
For example, in the case of a direct naturalization method, the cell is
inoculated into a
medium and cultured at 37°C in a 5% COz incubator using a conventional
animal cell
culture method such as batch culture, and when the cell density reaches l Ox
105 to
40x 105 cellslml, the cells are inoculated into a serum-free medium and
cultured under
similar conditions.
The cell in which a genomic gene encoding the a-1,6-fucose modifying
enzyme is knocked out is inoculated into a serum-free medium to give a density
of
1 x 105 to l Ox 105 cells/ml, preferably 4x 105 to 6x 105 cells/ml, and 4 to 7
days after
culturing according to a conventional animal cell culture method, the cells
which reach
a cell density of l Ox 105 to 40x 105 cells/ml are selected as cells to be
naturalized in a
serum-free medium.
Subculture of the cells naturalized in the serum-free medium can be carried
out by inoculating them into a medium to be used in the batch culture, which
is
described later, to give a density of 10x105 to 30x105 cells/ml, and culturing
them for 3
to 5 days under the culture conditions to be used in the batch culture, which
is described
later. In this connection, it is preferable to keep the survival rate of the
cells
2 0 naturalized in the serum-free medium at 90% or more during the sub-
culturing. In
addition, regarding the cell in which a genomic gene encoding the a-1,6-fucose
modifying enzyme is knocked out, such as a cell in which the genomic gene of a-
1,6-
fucosyltransferase was knocked out or a transformed cell of the cell, albumin
may be
added to the serum-free medium preferably in an amount of 0.1 to 10 g/l, more
2 5 preferably 0.5 to 3 g/1, for the purpose of keeping productivity of a
desired glycoprotein
by the cells naturalized in the serum-free medium.
After the naturalization of the cell using the method of the present invention
for its naturalization in a serum-free medium, a cloned (single cell) cell
line can be
prepared by using a limiting dilution method by a 96-well plate, a colony
forming
3 0 method or the like.
A method for preparing a cloned cell line by limiting dilution method is
described below.
A cell suspension is diluted, inoculated into a plate at such a density that
the
cells are dispensed at a frequency of one or less cell per well, and cultured
at 30 to 40°C
35 for several weeks in a 5% C02 incubator using commercially available serum-
free
medium and the like. After completion of the culturing, the concentration of a
desired
-51-
CA 02542121 2006-04-07
glycoprotein in cell culture supernatants where cell growth is observed is
examined, and
a cell having high productivity of said glycoprotein is selected.
The cloning method using a colony forming method is as follows.
In the case of adherent cells, cells are inoculated into a plate by diluting a
cell suspension and cultured, and then formation of colonies is confirmed. The
colonies are separated using a ring such as a penicillin cap, the cells are
separated using
an enzyme such as trypsin and transferred to appropriate culture devices, and
then
productivity of the desired glycoprotein is examined to select a cell having
high
productivity of the glycoprotein_
In the case of suspension cells, a cell suspension is diluted, cells thereof
are
inoculated into a soft agar and cultured, and the formed colonies are picked
up under a
microscope and returned to a static culturing, and then productivity of the
desired
glycoprotein is examined to select a cell having high productivity.
By repeatedly carrying out the above-described method, a clone in which a
genomic gene encoding the a-1,6-fucose modifying enzyme is knocked out,
wherein it
has characteristics of interest and is naturalized in the serum-free medium,
can be
selected.
By the above-described method, a clone in which a genomic gene of an a-
1,6-fucose modifying enzyme is knocked out, wherein it is naturalized in the
serum-free
2 0 medium, can be obtained.
The above-described clone in which a genomic gene encoding the a-1,6-
fucose modifying enzyme is knocked out, wherein it is naturalized in the serum-
free
medium, can be sub-cultured by a method in which the above-described cell
naturalized
in the serum-free medium is sub-cultured. The cell in which a genomic gene
encoding
the a-1,6-fucose modifying enzyme is knocked out, wherein it is naturalized in
the
serum-free medium, using the naturalization method to a serum-free medium in
the
present invention includes cells prepared by naturalizing WK704-2B8P (FERM BP-
8337), WK704-2871 (FERM BP-8336) and WK704-2760 (FERM BP-8335) in a serum-
free medium, and the like.
3 0 In this connection, the naturalization method of a cell in a protein-free
medium in the present invention can also be carried out a method similar to
the above-
described naturalization method of a cell in a serum-free medium.
As the culturing method of a cell in the present invention, any one of the
generally used animal cell culturing methods can be used, so long as it is a
method
which can efficiently produce a desired glycoprotein composition. Examples
include
batch culture, repeat batch culture, fed-batch culture, perfusion culture and
the like, and
-52-
CA 02542121 2006-04-07
fed-batch culture and perfusion culture are preferable for the purpose of
increasing
productivity of the desired glycoprotein.
( 1 ) Batch culture
As the serum-free medium used in the culturing method of a cell in the
present invention, those in which various physiologically active substances
and nutrient
factors are added, instead of serum, to a basal medium which is used in the
general
animal cell culturing, and is also supplemented with carbon sources, nitrogen
sources
and the like which can be assimilated by animal cells.
Examples include RPMI 1640 medium [The Journal of the American
Medical Association, 199, 519 (1967)], Eagle's MEM medium [Science, 122, 501
(1952)], Dulbecco's modified MEM medium [Virology, 8, 396 (1959)), 199 medium
[Proceeding of the Society far the Biological Medicine, 73, 1 ( 1950)), F 12
medium
[Proc. Natl. Acad. Sci. SSA, 53, 288 (1965)], >MDM medium [J Experimental
Medicine, 147, 923 (1978)] and the like, and DMEM medium, F12 medium, IMDM
medium and the like are preferably used.
If necessary, a nutrient factor, a physiologically active substance and the
like which are necessary for the growth of animal cells are added to the serum-
free
medium. These additives are contained in the medium in advance before the
culturing.
2 0 The nutrient factor includes glucose, an amino acid, a vitamin and the
like.
The amino acid includes L-alanine, L-arginine, L-asparagine, L-aspartic
acid, L-cystine, L-glutamic acid, L-glutamine, glycine, L-histidine, L-
isoleucine,
L-leucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-
threonine,
L-tryptophan, L-tyrosine, L-valine and the like, which are used alone or in
combination
2 5 of two or more.
The vitamin includes d-biotin, D-pantothenic acid, choline, folic acid, myo-
inositol, niacinamide, pyridoxal, riboflavin, thiamin, cyanocobalamin, DL-a.-
tocopherol
and the like, which are used alone or in combination of two or more.
The physiologically active substance includes insulin, an insulin-like growth
3 0 factor, transferrin, albumin and the like.
As the concentrations of the nutrient factors, the concentration of glucose is
200 to 6000 mg/1, preferably 3000 to 5000 mg/1.
As the concentrations of the amino acids, for example, 1 to 160 mg/1
(preferably 3 to 120 mg/1) of L-alanine, 10 to 1000 mg/1 (preferably 30 to 800
mg/1) of
3 5 L-arginine monohydrochloride, 10 to 200 mg/1 (preferably 20 to 150 mg/1)
of
L-asparagine monohydrate, 5 to 100 mg/1 (preferably from 10 to 75 mg/1) of L-
aspartic
-53-
CA 02542121 2006-04-07
acid, 10 to 200 mg/1 (preferably 20 to 150 mg/1) of L-cystine dihydrochloride,
5 to 200
mg/1 (preferably 10 to 150 mg/1) of L-glutamic acid, 50 to 2000 mg/I
(preferably 100 to
1500 mgll) of L-glutamine, 2 to 100 mg/1 (preferably 5 to 75 mg/1) of glycine,
5 to 200
mg/1 (preferably 10 to 150 mg/1) of L-histidine monohydrochloride dihydrate, 2
to 300
mg/1 (preferably 4 to 200 mg/1) of L-isoleucine, 5 to 300 mgll (preferably 10
to 200
mg/1) of L-leucine, 10 to 300 mgll (preferably 20 to 250 mgll) of L-lysine
monohydrochloride, 5 to 100 mgll (preferably 10 to 75 mg/I) of L-methionine, 5
to 200
mg/1 (preferably 10 to 150 mg/1) of L-phenylalanine, 5 to 200 mg/1 (preferably
10 to 150
mg/I) of L-proline, 5 to 200 mg/1 (preferably 10 to 150 mg/1) of L-serine, 5
to 200 mg/1
(preferably 10 to 150 mg/I) of L-threonine, 1 to 40 mgll (preferably 2 to 30
mg/I) of L-
tryptophan, 2 to 300 mg/1 (preferably 4 to 200 mg/1) of L-tyrosine disodium
dihydrate
and S to 300 mg/1 (preferably 10 to 200 mg/1) of L-valine are cited.
As the concentrations of the vitamins, for example, 0.001 to 0.4 mg/1
(preferably 0.002 to 0.3 mg/1) of d-biotin, 0.001 to 10.0 mg/1 (preferably
0.002 to 7.5
mgll) of calcium D-pantothenate, 0.1 to 20.0 mg/1 (preferably 0.2 to 15.0
mg/1) of
choline chloride, 0.005 to 20.0 mgll (preferably 0.01 to 15.0 mg/1) of folic
acid, 0.01 to
300 mg/1 (preferably 0.05 to 200 mg/1) of myo-inositol, 0.01 to 20.0 mg/1
(preferably
0.02 to 15.0 mg/1) of niacinamide, 0.01 to 15.0 mg/1 (preferably 0.02 to 10.0
mg/1) of
pyridoxal monohydrochloride, 0.005 to 2.0 mg/1 (preferably 0.01 to 1.5 mg/1)
of
2 0 riboflavin, 0.005 to 20.0 mg/I (preferably 0.01 to 15.0 mg/1) of thiamin
monohydrochloride and 0.001 to 5.0 mg/1 (preferably 0.002 to 3.0 mg/1) of
cyanocobalamin are cited.
As the concentrations of the physiologically active substances, for example,
10 to 500 mg/1, preferably 50 to 340 mgll, of insulin; 10 to 500 mgll,
preferably 50 to
2 5 300 mgJl, of an insulin-like growth factor; 10 to 500 mg/l, preferably SO
to 300 mg/l, of
transferrin; and 200 to 6000 mg/l, preferably 700 to 4000 mg/l, of albumin are
cited.
The batch culture is carried out generally under conditions of, for example,
pH 6 to 8 and 30 to 40°C, for 3 to 12 days. In addition, if necessary,
antibiotics such
as streptomycin and penicillin may be added to the medium during the
culturing. In
3 0 this connection, dissolved oxygen concentration control, pH control,
temperature
control, agitation and the like can be carried out in accordance with the
methods
generally used in the culturing of animal cells.
(2) Fed-batch culture
3 5 As the serum-free medium to be used in the culturing method of a cell in
the
present invention, those in which various physiologically active substances
and nutrient
-54-
CA 02542121 2006-04-07
factors are added, instead of serum, to a basal medium which is used in the
general
animal cell culturing, and is also supplemented with carbon sources, nitrogen
sources
and the like which can be assimilated by animal cells. Examples include RPMI
1640
medium [The Journal of the American Medical Association, 199, 519 (1967)],
Eagle's
MEM medium [Science, 122, 501 ( 1952)], Dulbecco's modified MEM medium
[Virology, 8, 396 (1959)], 199 medium [Proceeding of the Society for the
Biological
Medicine, 73, 1 ( 1950)], F 12 medium [Proc. Natl. Acad. Sci. USA, 53, 288 (
1965)],
IIVVIDM medium [J Experimental Medicine, 147, 923 (1978)] and the like, and
DMEM
medium, F12 medium, IMDM medium and the like are preferably used. In addition
to
the media described in the above, the serum-free medium described in the batch
culture
may also be used.
If necessary, a physiologically active substance, a nutrient factor and the
like which are necessary for the growth of animal cells are added to the serum-
free
medium. These additives are contained in the medium in advance before the
culturing,
1 S or if necessary, added optionally to the culture liquid during the
culturing.
The nutrient factor includes glucose, an amino acid, a vitamin and the like.
The amino acid includes L-alanine, L-arginine, L-asparagine, L-aspartic
acid, L-cystine, L-glutamic acid, L-glutamine, glycine, L-histidine, L-
isoleucine,
L-leucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-
threonine,
2 0 L-tryptophan, L-tyrosine, L-valine and the like, which are used alone or
in combination
of two or more.
The vitamin includes d-biotin, D-pantothenic acid, choline, folic acid, myo-
inositol, niacinamide, pyridoxal, riboflavin, thiamin, cyanocobalamin, DL-a,-
tocopherol
and the like, which are used alone or in combination of two or more.
2 5 As the physiologically active substances, insulin, insulin-like growth
factor,
transferrin, albumin and the like can be exemplified.
As the final concentrations of the nutrient factors to be added to the medium
or culture liquid, the concentration of glucose is 200 to 6000 mgll,
preferably 1000 to
5000 mg/l.
3 0 As the amino acids, for example, 1 to 960 mgJl (preferably 1 to 640 mgll)
of
L-alanine, 10 to 6000 mg/1 (preferably 11 to 4000 mg/1) of L-arginine
monohydrochloride, 10 to 1200 mg/1 (preferably 11 to 800 mgll) of L-asparagine
monohydrate, 5 to 600 mg/1 (preferably S to 400 mg/1) of L-aspartic acid, 10
to 1200
mgll (preferably 11 to 800 mg/1) of L-cystine dihydrochloride, 5 to 1200 mg/1
3 5 (preferably 5 to 800 mg/1) of L-glutamic acid, 53 to 12000 mg/I
(preferably 55 to 8000
mgll) of L-glutamine, 2 to 600 mgll (preferably 2 to 400 mgll) of glycine, 5
to 1200
-SS-
CA 02542121 2006-04-07
mgll (preferably 5 to 800 mgJl) of L-histidine monohydrochloride dehydrate, 4
to 1800
mgll (preferably 4 to 1200 mg/1) of L-isoleucine, 3 to 1800 mg/1 (preferably
14 to 1200
mg/1) of L-leucine, 10 to 1800 mg/1 (preferably 11 to 1200 mg/1) of L-lysine
monohydrochloride, 4 to 600 mg/1 (preferably 5 to 400 mg/1) of L-methionine, 5
to
1200 mg/1 (preferably 5 to 800 mgil) of L-phenylalanine, 5 to 1200 mg/1
(preferably 5 to
800 mg/1) of L-proline, 5 to 1200 mg/1 (preferably 5 to 800 mg/1) of L-serene,
S to 1200
mg/1 (preferably 5 to 800 mg/1) of L-threonine, 1 to 240 mg/1 (preferably 1 to
160 mg/1)
of L-tryptophan, 8 to 1800 mg/1 (preferably 8 to 1200 mgll) of L-tyrosine
disodium
dehydrate, and 12 to 1800 mg/1 (preferably 12 to 1200 mg/I) of L-valine are
cited.
As the vitamin, for example, 0.001 to 2.4 mg/1 (preferably 0.001 to 1.6 mg/I)
of d-biotin, 0.011 to 60 mg/1 (preferably 0.011 to 40 mg/1) of calcium D-
pantothenate,
0.11 to 90 mgll (preferably 0.11 to 60 mg/1) of choline chloride, 0.01 to 120
mg/1
(preferably 0.01 to 80 mg/1) of folic acid, 0.05 to 1800 mg/1 (preferably 0.05
to 1200
mg/1) of myo-inositol, 0.02 to 120 mg/1 (preferably 0.03 to 80 mg/1) of
niacinamide,
0.02 to 90 mg/1 (preferably 0.03 to 60 mg/1) of pyridoxal monohydrochloride,
0.01 to 12
mg/1 (preferably 0.01 to 98 mg/1) of riboflavin, 0.01 to 120 mg/1 (preferably
0.01 to 80
mg/1) of thiamin monohydrochloride and 0.001 to 30 mg/1 (preferably 0.001 to
20 mg/1)
of cyanocobalamin are cited.
As the final amounts of the physiologically active substances to be added to
2 0 the medium or culture liquid, for example, 10 to 3000 mg/l, preferably 11
to 2000 mg/1
of insulin; 10 to 3000 mg/l, preferably 11 to 2000 mg/1 of an insulin-like
growth factor;
10 to 3000 mg/l, preferably 11 to 2000 mg/1 of transfernn; and 200 to 36000
mg/l,
preferably 220 to 24000 mg/1 of albumin are cited.
According to the culturing method of a cell in the present invention, the
2 5 "final amounts of substances to be added" is calculated after final
completion of the
addition of the concentrated culture liquid to be added during the fed-batch
culturing
and expressed as a value obtained by dividing the sum total of the weight of
said
substance contained in the medium and the weight of said substance added to
the culture
liquid by the sum total of the amount of the medium and the amount of the
added
3 0 concentrated culture liquid.
In carrying out the fed-batch culturing, it is preferable to add each of the
physiologically active substances, nutrient factors and the like at a
concentration higher
than the generally used concentration. For example, 1/30 to 1/3, preferably
1/20 to 1/5,
of the culture liquid volume is added as a portion of the feeding. When added
to the
3 5 culture liquid, it is preferable to supplementarily add it during the
period of culturing
continuously or separately for several times to 10 and several times.
According to the
-56-
CA 02542121 2006-04-07
fed-batch culture method described in the above in which the physiologically
active
substances, nutrient factors and the like are added continuously or
intermittently in
small portions, it has high metabolic efficiency of cells, decrease of
achieving cell
density of the cultured cells due to accumulation of waste matter in the
culture liquid
can be prevented, and concentration of the glycoprotein of interest in the
recovered
culture liquid is high in comparison with the batch culture method, so that
separation
and purification of the glycoprotein becomes easy, and production of the
glycoprotein
per medium can be increased in comparison with the batch culture.
The fed-batch culture is carried out generally at pH 6 to 8 and 30 to
40°C
for 3 to 12 days. In addition, if necessary, antibiotics such as streptomycin
and
penicillin may be added to the medium during the culturing. In this
connection,
dissolved oxygen concentration control, pH control, temperature control,
agitation and
the like can be carried out in accordance with the methods generally used in
the
culturing of animal cells.
(3) Perfusion culture
As the serum-free medium to be used in the culturing method of a cell in the
present invention, those in which various physiologically active substances
and nutrient
factors are added, instead of serum, to a basal medium which is used in the
general
2 0 animal cell culturing, and is also supplemented with carbon sources,
nitrogen sources
and the like which can be assimilated by animal cells in general. Examples
include
RPMI 1640 medium [The Journal of the American Medical Association, 199, 519
(1967)], Eagle's MEM medium [Science, 122, 501 (1952)], Dulbecco's modified
MEM
medium [l~irology, 8, 396 (1959)], 199 medium [Proceeding of the. Society for
the
2 5 Biological Medicine, 73, 1 (1950)], F 12 medium [Proc. Natl. Acad. Sci:
US'A, 53, 288
( 1965)], IMDM medium [J. Experimental Medicine, 147, 923 ( 1978)] and the
like, and
DMEM medium, F12 medium, IMDM medium and the like are preferably used. In
addition to the media described above, the serum-free medium described in the
batch
culture may also be used.
3 0 If necessary, a physiologically active substance, a nutrient factor and
the
like which are necessary for the growth of animal cells are added to the serum-
free
medium. These additives may be contained in the medium before the culturing or
in
the medium to be fed into the culture liquid.
The nutrient factor includes glucose, an amino acid, a vitamin and the like.
3 5 The amino acid includes L-alanine, L-arginine, L-asparagine, L-aspartic
acid, L-cystine, L-glutamic acid, L-glutamine, glycine, L-histidine, L-
isoleucine,
- 57 -
CA 02542121 2006-04-07
L-leucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-
threonine,
L-tryptophan, L-tyrosine, L-valine and the like, which are used alone or in
combination
of two or more.
The vitamin includes d-biotin, D-pantothenic acid, choline, folic acid, myo-
inositol, niacinamide, pyridoxal, riboflavin, thiamin, cyanocobalamin, DL-a,-
tocopherol
and the like, which are used alone or in combination of two or more.
The physiologically active substance includes insulin, insulin-like growth
factor, transferrin, albumin and the like.
As the concentrations of the nutrient factors, the concentration of glucose is
controlled to 500 to 6000 mg/l, preferably 1000 to 2000 mg/1.
The nutrient factors include an amino acid, a vitamin and the like. As the
amounts of other physiologically active substances or nutrient factors to be
added, for
example, 4 to 560 mglml, preferably from 20 to 360 mg/ml, of insulin; 4 to 560
mg/ml,
preferably 20 to 360 mg/ml, of an insulin-like growth factor; 4 to 560 mg/ml,
preferably
20 to 360 mg/ml, of transferrin; and 80 to 6500 mg/ml, preferably 280 to 4500
mg/ml of
albumin are cited.
The amino acid includes L-alanine, L-arginine, L-asparagine, L-aspartic
acid, L-cystine, L-glutamic acid, L-glutamine, glycine, L-histidine, L-
isoleucine, L-
leucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-
threonine, L-
2 0 tryptophan, L-tyrosine, L-valine and the like, which are used alone or in
combination of
two or more. As the concentrations of the amino acids, for example, 1 to 200
mgll
(preferably 2 to 160 mg/1) of L-alanine, 10 to 1140 mg/1 (preferably 30 to 940
mg/1) of
L-arginine monohydrochloride, 10 to 250 mg/1 (preferably 20 to 200 mg/1) of L-
asparagine monohydrate, 5 to 148 mg/1 (preferably 10 to 120 mg/1) of L-
aspartic acid,
10 to 350 mg/1 (preferably Z0 to 300 mg/1) of L=cystine dihydrochloride, 5 to
320 ing/1
(preferably 10 to 270 mg/1) of L-glutamic acid, 50 to 3300 mg/1 (preferably
100 to 1800
mgJl) of L-glutamine, 2 to 148 mg/1 (preferably 5 to 123 mg/1) of glycine, 5
to 270 mg/1
(preferably 10 to 220 mg/1) of L-histidine monohydrochloride dihydrate, 4 to
470 mgll
(preferably 4 to 370 mgll) of L-isoleucine, 10 to 470 mg/1 (preferably 13 to
370 mg/1) of
3 0 L-leucine, 10 to 530 mgll (preferably 20 to 480 mgll) of L-lysine
monohydrochloride, 4
to 150 mg/1 (preferably 4 to 120 mg/1) of L-methionine, 4 to 310 mg/1
(preferably 4 to
260 mgll) of L-phenylalanine, 5 to 270 mg/1 (preferably 10 to 210 mgll) of L-
proline, 5
to 270 mg/1 (preferably 10 to 220 mg/1) of L-serine, 5 to 350 mg/1 (preferably
10 to 300
mgll) of L-threonine, 1 to 65 mg/1 (preferably 2 to SS mgll) of L-tryptophan,
4 to 470
mg/1 (preferably 8 to 370 mg/1) of L-tyrosine disodium dihydrate, and 10 to
450 mgll
(preferably 11 to 350 mg/1) ofL-valine are cited.
-58-
CA 02542121 2006-04-07
The vitamin includes d-biotin, D-pantothenic acid, choline, folic acid, myo-
inositol, niacinamide, pyridoxal, riboflavin, thiamin, cyanocobalamin, DL-a-
tocopherol
and the like, which are used alone or in combination of two or more. As the
final
amounts of the vitamins to be added, for example, 0.001 to 0.44 mgll
(preferably 0.02 to
0.34 mg/1) of d-biotin, 0.01 to 16 mg/1 (preferably 0.02 to 14 mg/1) of
calcium D-
pantothenate, 0. I to 21 mgll (preferably 30.2 to 16 mg/1) of choline
chloride, 0.01 to 26
mg/I (preferably 0.01 to 21 mg/1) of folic acid, 0.05 to 310 mgll (preferably
0.05 to 211
mg/1) of myo-inositol, 0.02 to 26 mg/1 (preferably 0.02 to 21 mg/1) of
niacinamide, 0.02
to 21 mg/I (preferably 0.02 to 16 mgll) of pyridoxal monohydrochloride, 0.01
to 2.6
mg/1 (preferably 0.01 to 2.6 mg/1) of riboflavin, 0.01 to 26 mg/1 (preferably
0.01 to 21
mgll) of thiamin monohydrochloride, and 0.001 to 5 mg/1 (preferably 0.002 to 3
mg/1)
of cyanocobalamin are cited.
In the culturing method of a cell in the present invention, the culture is
efficiently separated by a generally used device for separating a culture and
cells, the
concentrated cell suspension is returned to the original culture vessel, and
the fresh
medium corresponding to the reduced volume is newly supplemented. By this, the
proper culturing environment is constantly maintained.
In the case of the cell of the present invention, apart from the medium
exchange ratio with fresh medium, productivity of the glycoprotein of interest
can be
2 0 increased by stabilizing the culturing system through discharge of the
growing cells into
outside of the culturing system in response to the growth rate of the cells.
For example,
a culturing having high productivity becomes possible when 2l5 to 3/5 of the
total cells
present in the culture vessel are discharged outside of the system at the
doubling time of
the cells, by adjusting the rate of discharging the cells outside of the
system to the cell
2 5 growth rate iri such a manner that the intended cell-density can be
maintained:
According to the present invention, the culturing is carried out generally
under conditions of, for example, pH 6 to 8 and 30 to 40°C, for 10 to
40 days. In
addition, if necessary, antibiotics such as streptomycin and penicillin may be
added to
the medium during the culturing. In this connection, dissolved oxygen
concentration
30 control, pH control, temperature control, agitation and the like can be
carried out in
accordance with the methods generally used in the culturing of animal cells.
As described above, the glycoprotein of interest can be produced by
culturing the cell of the present invention in which a genomic gene encoding
the a-1,6-
fucose modifying enzyme is knocked out to thereby form and accumulate the
desired
3 5 glycoprotein, and recovering the glycoprotein from the culture.
- 59 -
CA 02542121 2006-04-07
When the cell is grown by the culturing method of a cell in the present
invention, it is desirable to carry out the culturing by keeping the insulin
concentration
in the culture liquid at 10 mgll or more, preferably 20 mg/1 or more. On the
other hand,
when the glycoprotein of interest is produced, it is desirable to carry out
the culturing,
for example, by keeping the insulin concentration in the culture liquid at 10
mgll or less,
preferably 5 mgll or less. In this connection, when insulin is contained in
the
preculture medium, insulin may not be added thereto for the purpose of
increasing
productivity of the antibody, but it is desirable in general to keep the
insulin
concentration in the medium at a level of 0.01 to 10 mg/l, preferably 0.01 to
5 mg/l.
The method for adjusting insulin concentration in the culture is suitably
used in culturing which can adjust the concentration of insulin, such as fed-
bath culture
or perfusion culture.
In this connection, the method for culturing a cell can also be carried out in
accordance with the above-described method by employing a method similar to
the
culturing method that uses a serum-free medium, using a medium which is free
from
proteins such as serum, insulin, insulin-like growth factor, transferrin and
albumin.
The glycoprotein composition of interest can be produced by the culturing
method.
4. Activity evaluation of glycoprotein composition
2 0 Methods for measuring a protein amount of the purified glycoprotein
composition, affinity to the receptor, half life in blood, distribution in
tissue after
administer into blood and change of protein interaction necessary for
expression of
pharmacological activity are measured by known methods described in Current
Protocols In Protein Science, John Wiley & Sons Inc., (1995); New Biochemical
2 5 Experimentation Series 19 Animal Experimental Test, Tokyo Kagaku Dojin,
edited by
Japanese Biochemical Society (1991); New Biochemical Experimentation Series 8-
Intracellular Information and Cell Response, Tokyo Kagaku Dojin, edited by
Japanese
Biochemical Society (1990); New Biochemical Experimentation Series 9 Hormone
I,
Peptide hormone, Tokyo Kagaku Dojin, edited by Japanese Biochemical Society
3 0 ( 1991 ); Experimental Biology Course 3-Isotope Experimental Test, Maruzen
( 1982);
Monoclonal Antibodies: Principles and Applications, Wiley-Liss, Inc., (1995);
Enzyme-
Linked Immuno Adsorbent Assay, 3rd Ed., Igaku Shoin (1987); Revised Enryme
Immunoassay, Gakusai Kikaku (1985); and the like.
Specific examples include a method in which a purified glycoprotein
35 composition is labeled with a compound such as a radioisotope and binding
activity to a
receptor of the labeled glycoprotein composition or an interacted protein is
-60-
CA 02542121 2006-04-07
quantitatively determined. Furthermore, interaction between the proteins can
be
measured by using various apparatus such as BIAcore Series manufactured by
Biacore
(J. Immnunol. Methods, 145, 229 ( 1991 ); Experimental Medicine Supplement,
Biomanual UP Series, Experimental Test of Intermolecular Interaction
Experimental
Test, Yodo-sha ( 1996)).
By administration of the labeled glycoprotein into the living body, the half
life in blood and the distribution of the glycoprotein in tissue after
administered into the
living body can be known. Detection of the labeled material is preferably
carried out
by a detection method in which a method for detecting a labeled substance is
combined
with an antigen-antibody reaction specific to the glycoprotein which is to be
detected.
5. Activity evaluation of antibody composition
When the glycoprotein composition is an antibody composition, known
methods described in Monoclonal Antibodies, Antibody Engineering and the like
can be
used as the methods for measuring the protein amount of the purified antibody
composition, the binding activity to an antigen and the ef~ector function.
For example, when the antibody composition is a humanized antibody, the
binding activity to an antigen and the binding activity to an antigen-positive
cultured
clone can be measured by methods such as ELISA and an immunofluorescent method
2 0 [Cancer Immunol. Immunother., 36, 373 (1993)]. The cytotoxic activity
against an
antigen-positive cultured clone can be evaluated by measuring CDC activity,
ADCC
activity [Cancer Immunol. Immunother., 36, 373 (1993)] and the like.
Also, safety and therapeutic effect of the antibody composition in human
can be evaluated by using an appropriate model of animal species relatively
close to
2 5 human, such as Macaca fascicularis.
6. Analysis of sugar chains in glycoprotein composition
The sugar chain structure in the glycoprotein composition expressed in
various cells can be analyzed in accordance with the general analysis of the
sugar chain
3 0 structure of a glycoprotein. For example, the sugar chain which is bound
to IgG
molecule in the antibody composition comprises a neutral sugar such as
galactose,
mannose or fucose, an amino sugar such as N-acetylglucosamine and an acidic
sugar
such as sialic acid, and can be analyzed by a method, such as a sugar chain
structure
analysis, using sugar composition analysis, two dimensional sugar chain
mapping or the
3 5 like.
-61-
CA 02542121 2006-04-07
(1) Analysis of neutral sugar and amino sugar compositions
The sugar chain composition in the glycoprotein composition can be
analyzed by carrying out acid hydrolysis of sugar chains with trifluoroacetic
acid or the
like to release a neutral sugar or an amino sugar and analyzing the
composition ratio.
Examples include a method using a sugar composition analyzer (BioLC)
manufactured by Dionex. The BioLC is an apparatus which analyzes a sugar
composition by HPAEC-PAD (high performance anion-exchange chromatography-
pulsed amperometric detection) [,l. Liq. Chromatogr., 6, 15?7 (1983)].
The composition ratio can also be analyzed by a fluorescence labeling
method using 2-aminopyridine. Specifically, the composition ratio can be
calculated
in accordance with a known method [Agric. Biol. Chem., 55 1 , 283-284 ( 1991
)], by
labeling an acid-hydrolyzed sample with a fluorescence with 2-
aminopyridylation and
then analyzing the composition by HI'LC.
(2) Analysis of sugar chain structure
The sugar chain structure of the glycoprotein composition can be analyzed
by the two dimensional sugar chain mapping method [Anal. Biochem., 171, 73
(1988),
Biochemical Experimentation Methods 23 -Methods for Studying Glycoprotein
Sugar
Chains (Japan Scientific Societies Press) edited by Reiko Takahashi (1989)].
The two
2 0 dimensional sugar chain mapping method is a method for deducing a sugar
chain
structure by, e.g., plotting the retention time or elution position of a sugar
chain by
reverse phase chromatography as the X axis and the retention time or elution
position of
the sugar chain by normal phase chromatography as the Y axis, respectively,
and
comparing them with those of known sugar chains.
2 5 Specifically, sugar chains are released from a glycoprotein composition by
hydrazinolysis, and the released sugar chain is subjected to fluorescence
labeling with
2-aminopyridine (hereinafter referred to as "PA") [J. Biochem., 95, 197
(1984)], and
then the sugar chains are separated from an excess PA-treating reagent and the
like by
gel filtration, and subjected to reverse phase chromatography. Thereafter,
each peak of
3 0 the separated sugar chains are subjected to normal phase chromatography.
The sugar
chain structure can be deduced by plotting the results on a two dimensional
sugar chain
map and comparing them with the spots of a sugar chain standard (manufactured
by
Takara Shuzo Co., Ltd.) or a literature [Anal. Biochem., 171, 73 (1988)].
The structure deduced by the two dimensional sugar chain mapping method
3 5 can be confirmed by further carrying out mass spectrometry such as MALDI-
TOF-MS
of each sugar chain.
-62-
CA 02542121 2006-04-07
7. Application of the glycoprotein composition
Since the glycoprotein composition produced by the present invention has a
sugar chain structure to which fucose is not bound, for example, effects, such
as
improvement of affinity with a receptor, improvement of serum half life,
improvement
of tissue distribution after administration into blood and improvement of its
interaction
with a protein necessary for pharmacological activity, can be expected and
high
physiological activity can be obtained. Particularly, when it is an antibody
composition, it has high effector function, namely ADCC activity. The above
glycoprotein composition having high physiological activity, particularly the
antibody
composition having high ADCC activity, is useful for preventing and treating
various
diseases including cancers, inflammatory diseases, immune diseases such as
autoimmune diseases, allergies and the like, cardiovascular diseases and
various
diseases which are caused by viral and bacterial infections.
In the case of cancers, namely malignant tumors, cancer cells grow.
General anti-tumor agents inhibit the growth of cancer cells. In contrast, an
antibody
having high ADCC activity can treat cancers by injuring cancer cells through
its cell
killing effect, and therefore, it is more effective as a therapeutic agent
than the general
anti-tumor agents. At present, in the therapeutic agent for cancers, an anti-
tumor effect
of an antibody medicament alone is not suffcient, so that combination therapy
with
chemotherapy has been carried out [Science, 280, 1197 (1998)]. Since the
antibody
composition produced by the present invention having high anti-tumor effect,
the
dependency on chemotherapy is decreased and side effects is reduced.
In immune diseases such as inflammatory diseases, autoimmune diseases
2 5 and allergies, in vivo reactions of the diseases are induced by the
release of a mediator
molecule by immunocytes. For example, the allergy reaction can be suppressed
by
eliminating immunocytes using an antibody having high ADCC activity.
The cardiovascular diseases include arteriosclerosis and the like. The
arteriosclerosis is treated using balloon catheter at present, but
cardiovascular diseases
3 0 can be prevented and treated by inhibiting growth of arterial cells in
restricture after
balloon catheter treatment using an antibody having high ADCC activity.
Various diseases including viral and bacterial infections can be prevented
and treated by inhibiting proliferation of cells infected with a virus or
bacterium using
an antibody having high ADCC activity.
3 5 An antibody which recognizes a tumor-related antigen, an antibody which
recognizes an allergy- or inflammation-related antigen, an antibody which
recognizes
- 63 -
CA 02542121 2006-04-07
cardiovascular disease-related antigen, an antibody which recognizes
autoimmune
disease-related antigen and an antibody which recognizes a viral or bacterial
infection-
related antigen are exemplified below.
The antibody which recognizes a tumor-related antigen includes anti-GD2
antibody [Anticancer Res., 13, 331 (1993)], anti-GD3 antibody [Cancer Immunol.
Immunother., 36, 260 (1993)], anti-GM2 antibody [Cancer Res., 54, 1511
(1994)], anti
HER2 antibody [Proc. Natl. Acad Sci. USA, 89, 4285 (1992)], anti-CD52 antibody
[Nature, 332, 323 (1998)], anti-MAGE antibody [British J. Cancer, 83, 493
(2000)),
anti-HM1.24 antibody [Molecular Immunol., 36, 387 (1999)], anti-parathyroid
hormone-related protein (PTHrP) antibody [Cancer, 88, 2909 (2000)], anti-FGF8
antibody [Proc. Natl. Acad. Sci. USA, 86, 9911 ( 1989)], anti-basic fibroblast
growth
factor antibody, anti-FGF8 receptor antibody [J Biol. Chem., 265, 16455
(1990)], anti-
basic fibroblast growth factor receptor antibody, anti-insulin-like growth
factor antibody
[J Neurosci. Res., 40, 647 (1995)], anti-insulin-like growth factor receptor
antibody [J
Neurosci. Res., 40, 647 (1995)], anti-PMSA antibody [J Urology, 160, 2396
(1998)],
anti-vascular endothelial cell growth factor antibody [Cancer Res., 57, 4593
(1997)],
anti-vascular endothelial cell growth factor receptor antibody [Oncogene, 19,
2138
(2000)], anti-CA125 antibody, anti-17-lA antibody, anti-integrin av~3
antibody, anti-
CD33 antibody, anti-CD22 antibody, anti-HLA antibody, anti-HLA-DR antibody,
anti-
2 0 CD20 antibody, anti-CD 19 antibody, anti-EGF receptor antibody [Immunology
Today,
21, 403 (2000)], anti-CD10 antibody [American Journal of Clinical Pathology,
113, 374
(2000)] and the like.
The antibody which recognizes an allergy- or inflammation-related antigen
includes anti-interleukin 6 antibody [Immunol. Rev., 127, 5 (1992)], anti-
interleukin 6
receptor antibody [Molecular Immurrol., 31, 371--(1994)], anti-inferleukin 5
antibody
[Immunol. Rev., 127, 5 (1992)], anti-interleukin 5 receptor antibody and anti-
interleukin
4 antibody [Cytokine, 3, 562 (1991)], anti-interleukin 4 receptor antibody [J.
Immunol
Meth., 217, 41 (1998)], anti-tumor necrosis factor antibody [Hybridoma, 13,
183
(1994)], anti-tumor necrosis factor receptor antibody [Molecular Pharmacol.,
58, 237
(2000)], anti-CCR4 antibody [Nature, 400, 776 (1999)], anti-chemokine antibody
[J
Immuno. Meth., 174, 249 (1994)], anti-chemokine receptor antibody [J Exp.
Med., 186,
1373 (1997)], anti-IgE antibody, anti-CD23 antibody, anti-CDlla antibody
[Immunology Today, 21, 403 (2000)], anti-CRTH2 antibody [J Immunol., 162, 1278
(1999)], anti-CCR8 antibody (W099/25734), anti-CCR3 antibody (US6207155) and
the
3 5 like.
-64-
CA 02542121 2006-04-07
The antibody which recognizes a cardiovascular disease-related antigen
includes anti-GpIIb/IIIa antibody [J. Immunol., 152, 2968 (1994)], anti-
platelet-derived
growth factor antibody [Science, 253, 1129 (1991)], anti-platelet-derived
growth factor
receptor antibody [J. Biol. Chem., 272, 17400 (1997)], anti-blood coagulation
factor
antibody (Circulation, 101, 1158 (2000)] and the like.
The antibody which recognizes an antigen relating to autoimmune diseases
(for example, psoriasis, rheumarthritis, Crohn's diseases, colitis ulcerosa,
systemic
erythematodes, disseminated sclerosis and the like) includes an anti-auto-DNA
antibody
(Immunol. Letters, 72, 61 (2000)], anti-CDlla antibody, anti-ICAM3 antibody,
anti-
CD80 antibody, anti-CD2 antibody, anti-CD3 antibody, anti-CD4 antibody, anti-
integrin a4(37 antibody, anti-CD40L antibody, anti-IL-2 receptor antibody
[Immunology
Today, 21, 403 (2000)], and the like.
The antibody which recognizes a viral or bacterial infection-related antigen
includes anti-gp120 antibody [Structure, 8, 385 (2000)], anti-CD4 antibody [J.
Rheumatology, 25, 2065 (1998)], anti-CCR4 antibody, anti-Vero toxin antibody
(J. Clin.
Microbiol., 37, 396 (1999)], and the like.
These antibodies can be obtained from public organizations such as ATCC
(The American Type Culture Collection), RIKEN Gene Bank at The Institute of
Physical and Chemical Research, and National Institute of Bioscience and Human
2 0 Technology, Agency of Industrial Science and Technology, or private
reagent sales
companies such as Dainippon Pharmaceutical, R & D SYSTEMS, PharMingen, Cosmo
Bio and Funakoshi.
The medicament comprising the glycoprotein composition in the present
invention can be administered as a therapeutic agent alone, but generally, it
is preferred
2 5 to provide it as a pharmaceutical formulation prepared by an arbitrary
method well
known in the technical field of pharmaceuticals, by mixing it with one or more
pharmaceutically acceptable carriers.
It is desirable to select a route of administration which is most effective
for
treatment. Examples include oral administration and parenteral administration,
such as
3 0 buccal, tracheal, rectal, subcutaneous, intramuscular or intravenous. In
the case of a
glycoprotein antibody preparation, intravenous administration is preferred.
The dosage form includes sprays, capsules, tablets, granules, syrups,
emulsions, suppositories, injections, ointments, tapes and the like.
The pharmaceutical preparation suitable for oral administration includes
3 5 emulsions, syrups, capsules, tablets, powders, granules and the like.
-65-
CA 02542121 2006-04-07
Liquid preparations, such as emulsions and syrups, can be produced using,
as additives, water; sugars such as sucrose, sorbitol and fructose; glycols
such as
polyethylene glycol and propylene glycol; oils such as sesame oil, olive oil
and soybean
oil; antiseptics such as p-hydroxybenzoic acid esters; flavors such as
strawberry flavor
and peppermint; and the like.
Capsules, tablets, powders, granules and the like can be produced using, as
additive, excipients such as lactose, glucose, sucrose and mannitol;
disintegrating agents
such as starch and sodium alginate; lubricants such as magnesium stearate and
talc;
binders such as polyvinyl alcohol, hydroxypropylcellulose and gelatin;
surfactants such
as fatty acid ester; plasticizers such as glycerine; and the like.
The pharmaceutical preparation suitable for parenteral administration
includes injections, suppositories, sprays and the like.
Injections can be prepared using a carrier, such as a salt solution, a glucose
solution, a mixture of both thereof or the like. Also, powdered injections can
be
prepared by freeze-drying the glycorprotein composition in the usual way and
adding
sodium chloride thereto.
Suppositories can be prepared using a carrier such as cacao butter,
hydrogenated fat, carboxylic acid or the like.
Sprays can be prepared using the compound as such or using the
2 0 glycorprotein composition together with a carrier which does not stimulate
the buccal or
airway mucous membrane of the patient and can facilitate absorption of the
glycorprotein composition by dispersing it as fine particles.
The carrier includes lactose, glycerol and the like. Depending on the
properties of the glycorprotein composition and the carrier used, it is
possible to
2 5 produce pharmaceutical -preparations such as aerosols, dry powders and the
like. In
addition, the components exemplified as additives for oral preparations can
also be
added to the parenteral preparations.
Although the clinical dose or the frequency of administration varies
depending on the objective therapeutic effect, administration method, treating
period,
3 0 age, body weight and the like, it is usually I O p,g/kg to 20 mgikg per
day and per adult.
Also, as the method for examining antitumor effect of the antibody
composition against various tumor cells, in vitro tests include CDC activity
measuring
method, ADCC activity measuring method and the like, and in viva tests include
antitumor experiments using a tumor system in an experimental animal such as a
mouse,
3 5 and the like.
-66-
CA 02542121 2006-04-07
CDC activity and ADCC activity and antitumor experiments can be carried
out in accordance with the methods described in Cancer Immunology
Immunotherapy,
36, 373 (1993); Cancer Research, 54, 1511 (1994) and the like.
Brief Description of the Drawings
Fig. 1 shows construction of a plasmid pKOFUTBNeo.
Fig. 2 shows construction of a plasmid pBs-2B8L.
Fig. 3 shows construction of a plasmid pBs-2B8H and a plasmid pBs-
2B 8Hm.
Fig. 4 shows construction of a plasmid pKANTEX2B8P.
Fig. 5 shows ADCC activities of an anti-CD20 chimeric antibody purified
from a FUT8 gene double knockout clone derived from CHO/DG44 cell to human B
lymphocyte cultured cell line Raji cell. The ordinate and the abscissa show
the
cytotoxic activity and the antibody concentration, respectively.
Fig. 6 shows changes of viable cell density and survival rate when a cell
naturalized in a protein-free medium is cultured in the protein-free medium.
Fig. 7 shows changes of viable cell density and survival rate in fed-batch
culturing of a cell naturalized in a protein-free medium.
Fig. 8 shows changes of viable cell density (A), cell survival rate (B),
2 0 cumulative viable cell density (C) and antibody density (D) in suspension
agitation
reactor serum-free fed-batch using clone Ms704/CD20 naturalized in the serum-
free
medium. The abscissa of each graph shows cultured days after commencement of
the
culturing.
Fig. 9 shows ADCC activities of two kinds of purified-anti-CD20 human
2 5 chimeric antibodies upon B cell in human peripheral blood. The ordinate
shoves the
ratio of CD2-negative and CD 19-positive human B cell in the lymphocyte
fraction, and
the abscissa shows the antibody concentration. Open circles show activity of
an anti-
CD20 human chimeric antibody (Ms704/CD20 antibody) produced by a suspension
agitation reactor serum-free fed-batch culturing method using clone Ms704/CD20
3 0 naturalized in the serum-free medium, and closed circles show activity of
an anti-CD20
human chimeric antibody (DG44/CD20 antibody) produced using the parent cell
line
CHO/DG44 cell.
Fig. 10 shows in vitro ADCC activities of two kinds of purified anti-CD20
human chimeric antibodies upon WIL2-S cell. The ordinate shows the cytotoxic
35 activity, and the abscissa shows the antibody concentration. Open circles
show
-67-
CA 02542121 2006-04-07
activity of Ms704/CD20 antibody, and closed circles show that of DG44/CD20
antibody, respectively.
Fig. 11 shows in vitro ADCC activity of an anti-CD20 human chimeric
antibody composition prepared by adding 0 to 300 ng/ml of DG44/CD20 antibody
to
3.7 ng/ml of Ms704/CD20 antibody, upon WIL,2-S cell. The ordinate shows the
cytotoxic activity, and the abscissa shows the antibody concentration of added
DG44/CD20 antibody. The symbol * in the drawing shows an antibody composition
having 20% or more of the ratio of antibody having a sugar chain to which
fucose is not
bound.
Fig. 12 shows in vitro ADCC activities of an antibody composition
consisting of Ms704/CD20 alone and an antibody composition prepared by mixing
Ms704/CD20 antibody with 9-fold amount of DG44/CD20 antibody, upon WIL2-S
cell.
The ordinate shows the cytotoxic activity. The numerical values shown on the
abscissa represent concentration of the Ms704/CD20 antibody, concentration of
the
added DG44/CD20 antibody, and total antibody concentration from the upper
side.
Open squares show the activity of the antibody composition consisting of
Ms704/CD20
alone, and closed squares show that of the antibody composition prepared by
mixing
Ms704/CD20 antibody with 9-fold amount of DG44/CD20 antibody.
2 0 Best Mode for Carrying Out the Invention
The present invention will be described below in detail based on Examples;
however, Examples are only simple illustrations, and the scope of the present
invention
is not limited thereto.
2 5 Example 1
Construction of CHO/DG44 cell in which both alleles of a-1,6-
fucosyltransferase
(FUTB) gene on the genome have been disrupted
The cell line CHO/DG44 comprising the deletion of a genome region for
both alleles of a-1,6-fucosyltransferase (hereinafter referred to as "FUT8")
including
3 0 the translation initiation codons was constructed according to the
following steps.
1. Construction of Chinese hamster FUT8 gene targeting vector plasmid
pKOFUTBNeo
comprising exon 2
A plasmid pKOFUTBNeo was constructed in the following manner using
3 5 targeting vector plasmid pKOFUT8Puro of exon 2 of Chinese hamster FUT8
gene
-68-
CA 02542121 2006-04-07
constructed by the method described in Example 13-1 of W002/31140, and a
plasmid
pKOSelectNeo (manufactured by Lexicon).
Using 16 units of a restriction enzyme AscI (New England Biolabs), 1.0 pg
of plasmid pKOSelectDT (manufactured by Lexicon) was allowed to react at
37°C for 2
hours. The reacting solution was subjected to agarose gel electrophoresis, and
approximately 1.6 Kb AscI fragment comprising the neomycin resistance gene
expression unit was recovered using QIAquick Gel Extraction Kit (manufactured
by
QIAGEN).
Next, 1.0 p.g of plasmid pKOFUTBPuro was allowed to react at 37°C
for 2
hours by using 16 units of a restriction enzyme AscI (manufactured by New
England
Biolabs). After the digestion reaction, the end of the DNA fragment was
dephosphorylated with alkaline phosphatase derived from Escherichia coli C 15
(manufactured by Takara Shuzo Co., Ltd.) according to the attached
instructions.
After the reaction, the DNA fragment was recovered by phenol/chloroform
extraction
and ethanol precipitation.
To 0.1 pg of the plasmid pKOSelectNeo-derived AscI fragment
(approximately 1.6 Kb) and 0.1 p,g of the plasmid pKOFUT8Puro-derived AscI
fragment (approximately 10.1 Kb) obtained above, sterlized water was added to
give a
total volume of 5 pL and 5 p,L, of Ligation High (manufactured by Toyobo Co.,
Ltd.)
2 0 was further added to react at 16°C for 30 minutes. Escherichia coli
DHSa.
(manufactured by Toyobo Co., Ltd.) was transformed by using the resulting
recombinant plasmid DNA. Each plasmid DNA was prepared from each transformant
and each nucleotide sequence was analyzed by using BigDye Terminator Cycle
Sequencing Ready Reaction Kit v2.0 (manufactured by Applied Biosystems)
according
2 5 to the attached instructions and DNA Sequencer ABI PRISM 377. The plasmid
pKOFUTBNeo having the objective nucleotide sequence shown in Fig. 1 was
obtained,
and was used as a targeting vector for the preparation of FUT8 gene-knockout
cell of
CHO cell.
3 0 2. Preparation of CHO cell in which one copy of the FUT8 gene on the
genome has
been disrupted
( 1 ) Obtaining of clone in which the targeting vector pKOFUTBNeo has been
introduced
The Chinese hamster FUT8 genome region targeting vector pKOFUTBNeo
constructed in Example 1-1 was introduced into Chinese hamster ovary-derived
3 5 CHO/DG44 cells deficient in the dihydrofolate reductase gene (dhfr)
[Somataic Cell
andMolecular Genetics, 12, 555 (1986)] in the following manner.
-69-
CA 02542121 2006-04-07
After 280 pg of plasmid pKOFUTBNeo was allowed to react at 37°C
for 5
hours by adding 400 units of a restriction enzyme SaII (manufactured by New
England
Biolabs) for linearization, 4 pg of the linearized pKOFUTBNeo was introduced
into
1.6 x 106 cells by electroporation [Cytotechnolo~, 3, 133 (1990)]. The
resulting cells
were suspended in INIDM-dFBS (10)-HT(1) [INIDM medium (manufactured by
Invitrogen) containing 10% dialysis FBS (Invitrogen) and 1-fold concentration
HT
supplement (manufactured by Invitrogen)] and then inoculated into a 10-cm dish
for
adherent cell culture (manufactured by Falcon). After culturing in a 5% C02
incubator
at 37°C for 24 hours, the medium was replaced with 10 ml of INIDM-
dFBS(10) (Il~M
medium containing 10% dialysis FBS) containing 600 gg/ml 6418 (manufactured by
Nacalai Tesque, Inc.). Culturing was carried out for 15 days while the above
medium
replacement was repeated every 3 to 4 days to obtain 6418-resistant clones.
(2) Confirmation of homologous recombination by genomic PCR
Confirmation of the homologous recombination in the 6418-resistant clones
obtained in the above (1) was carried out by genomic PCR in the following
manner.
The 6418-resistant clones on a 96-well plate were subjected to
trypsinization, and a 2-fold volume of a frozen medium (20% DMSO, 40% fetal
calf
serum and 40% IMDM) was added in each well. One half of the cell suspension in
2 0 each well was inoculated into a flat-bottomed 96-well plate for adherent
cells
(manufactured by Asahi Techno Glass) to prepare a replica plate, while the
other half
was stored by cryopreservation as a master plate.
The neomycin-resistant clones on the replica plate were cultured using
IIVVIDM-dFBS(10) containing 600 ~tg/ml 6418 for one week, followed by recovery
of
cells. The geriomic--DNA of each clone was prepared from the recovered cells
according to a known method [Analytical Biochemistry, 201, 331 (1992)] and
then
dissolved overnight in 30 pl of TE-RNase buffer (pH 8.0) [10 mmol/1 Tris-HCI,
1
mmol/1 EDTA, 200 p,g/ml RNase A].
Primers used in the genomic PCR were designed as follows. Primers
3 0 which bind to the sequence of a part exceeding a targeting vector
homologous region
(SEQ B7 NO:10 or 11) and primers which bind to the sequence within the vector
(SEQ
ID N0:12 or 13) in the FUT8 genome region obtained by the method described in
Example 12 of W003/31140 (SEQ ID N0:9) were prepared. The following
polymerase chain reaction (PCR) was carried out by using them. Specifically, a
3 5 reaction mixture [25 p,l; DNA polymerase ExTaq (manufactured by Takara
Shuzo Co.,
Ltd.), ExTaq buffer (manufactured by Takara Shuzo Co., Ltd.), 0.2 mmol/1
dNTPs, 0.5
-70-
CA 02542121 2006-04-07
~mol/1 of the above gene-specific primers (forward primer: SEQ >D NO:10 or 11;
reverse primer: SEQ m N0:12 or 13)] containing 10 ~l of each genomic DNA
solution
prepared above was prepared, and PCR was carried out, after heating at
94°C for 3
minutes, by cycles, one cycle consisting of reaction at 94°C for one
minute, reaction at
60°C for one minute and reaction at 72°C for 2 minutes.
After the PCR, the reaction mixture was subjected to 0.8% (w/v) agarose gel
electrophoresis, and clones with which a specific amplification (approximately
1.7 Kb)
containing a boundary part of the CHO cell genomic region and the target
vector
homologous region was observed were determined to be positive clones.
(3) Confirmation of homologous recombination by genomic Southern blotting
Confirmation of the homologous recombination in the positive clones
obtained in the above (2) was carried out by genomic Southern blotting in the
following
manner.
Among the master plates stored by cryopreservation in the above (2), a 96-
well plate containing the positive clones found in (2) was selected. After the
plate was
allowed to stand at 5% COZ and 37°C for 10 minutes, the cells in the
wells
corresponding to the positive clones were inoculated into a flat-bottomed 24-
well plate
for adherent cells (manufactured by Greiner). After culturing using IIVIDM-
dFBS(10)
2 0 containing at a concentration of 600 ~g/ml for one week, the cells were
inoculated into
a flat-bottomed 6-well plate for adherent cells (Greiner). The genomic DNA of
each
clone was prepared from the recovered cells in the plate according to a known
method
[Nucleic Acids Research, 3, 2303 (1976)] and then dissolved overnight in 150-
N,1 of TE-
RNase buffer (pH 8.0) [ 10 mmol/1 Tris-HCI, 1 mmol/1 EDTA, 200 p,g/ml RNase
A].
2 5 The genomic DNA prepared above (12 pg) was digested with 25 units of a
restriction enzyme BamHI (manufactured by New England Biolabs) at 37°C
overnight.
A DNA fragment was recovered by ethanol precipitation from the reaction
mixture.
The recovered fragment was dissolved in 20 ~,l of TE bufFer (pH 8.0) ( 10
mmol/1 Tris-
HCI, 1 mmol/1 EDTA) and then subjected to 0.6% (w/v) agarose gel
electrophoresis.
3 0 After the electrophoresis, the genomic DNA was transferred to a nylon
membrane
according to a known method [Proc. Natl Acad. Sci. USA, 76, 3683 (1979)],
followed
by heat treatment of the nylon membrane at 80°C for 2 hours.
Separately, a probe used in the Southern blotting was prepared in the
following manner. Firstly, PCR was carried out as follows by using primers
which
3 5 bind to the sequence of a part exceeding the targeting vector homologous
region (SEQ
B7 NOs: l4 and 15) in the FUT8 genome region (SEQ m N0:9) obtained by the
method
-71-
CA 02542121 2006-04-07
described in Example 12 of W002/31140. That is, 20 p,l of a reaction mixture
[DNA
polymerise ExTaq (manufactured by Takara Shuzo Co., Ltd.), ExTaq buffer
(manufactured by Takara Shuzo Co., Ltd.), 0.2 mmol/1 dNTPs, 0.5 pmol/1 each of
the
above gene-specific primers (SEQ ~ NOs:l4 and 15)] containing 4.0 ng of
plasmid
pFUT8fgE2-2 described in Example 12 of W002/31140 was prepared, and PCR was
carried out, after heating at 94°C for one minute, by 25 cycles, one
cycle consisting of
reaction at 94°C for 30 seconds, reaction at 55°C for 30 seconds
and reaction at 74°C
for one minute. After the PCR, the reaction mixture was subjected to 1.75%
(w/v)
agarose gel electrophoresis, and approximately 230 by probe DNA fragment was
purified. Then, 5 ~l of the obtained probe DNA solution was subjected to
radiolabeling using [a-32P] dCTP 1.75 MBq and Megaprime DNA Labelling system,
dCTP (manufactured by Amersham Pharmacia Biotech).
Hybridization was carried out in the following manner. The above nylon
membrane was put into a roller bottle and 15 ml of a hybridization solution [5
x SSPE,
50 x Denhaldt's solution, 0.5% (w/v) SDS, 100 ~g/ml salmon sperm DNA] was
added
thereto. Prehybridization was carried out at 65°C for 3 hours. Then,
the 32P-labeled
probe DNA was heat-denatured and put into the bottle, followed by heating at
65°C
overnight.
After the hybridization, the nylon membrane was immersed in 50 ml of
2 0 2 x SSC-0.1% (w/v) SDS and heated at 65°C for 15 minutes. After a
washing step
was repeated twice, the nylon membrane was immersed in 50 ml of 0.2 x SSC-0.1%
(w/v) SDS and heated at 65°C for 15 minutes. After washing, the nylon
membrane
was exposed to an X-ray film at -80°C for development.
The genomic DNAs of the parent cell line CHOlDG44 and the 50-10-104
2 5 clone, which is the positive clone obtained in the above (2) were analyzed
according to
the present method. In the cell line CHO/DG44, only approximately 25.5 Kb
fragment
derived from the wild-type FUT8 allele was detected. On the other hand, in the
positive clone, i.e., clone 50-10-104, approximately 20.0 Kb fragment specific
to the
allele which underwent homologous recombination was detected in addition to
3 0 approximately 25.5 Kb fragment derived from the wild-type FUT8 allele. The
quantitative ratio of these two kinds of fragments was 1:1, whereby it was
confirmed
that the clone 50-10-104 was a hemi-knockout clone wherein one copy of the
FUTB
allele was disrupted.
-72-
CA 02542121 2006-04-07
3. Preparation of CHOIDG44 cell in which the FUTB gene on the genome has been
double-knocked out
(1) Obtaining of clone in which targeting vector pKOFUTBPuro has been
introduced
To the FUT8 hemi-knockout clone 50-10-104 obtained in Example 1-2(2),
the Chinese hamster FUT8 gene exon 2 targeting vector plasmid pKOFUTBPuro
constructed by the method described in Example 13-1 of W002/31140 was
introduced
in the following manner.
After 440 pg of plasmid pKOFUTBPuro was allowed to react at 37°C
for 5
hours by adding 800 units of a restriction enzyme SaII (manufactured by New
England
Biolabs) for linearization, 4 ~g of the linearized pKOFUTBPuro was introduced
into
1.6 x 106 cells of the FUT8 gene-hemi-knockout clone by electroporation
[Cytotechnology, 3, 133 (1990)]. The resulting cells were suspended in IMDM-
dFBS(10)-HT(1) and then inoculated into a 10-cm dish for adherent cell culture
(manufactured by Falcon). After culturing in a 5% COZ incubator at 3?°C
for 24 hours,
the medium was replaced with 10 ml of IMDM-dFBS(10)-HT(1) containing 15 p,g/ml
puromycin (manufactured by SIGMA).
Culturing was carried out for 15 days while the above medium replacement
was repeated every 7 days to obtain drug-resistant clones.
2 0 (2) Confirmation of homologous recombination by genomic Southern blotting
Confirmation of the homologous recombination in the drug-resistant clones
obtained in the above (1) was carried out by genomic Southern blotting in the
following
manner.
A culture supernatant was removed from a 10-cm dish in which the
2 5 puromycin-resistant clones were expressed, 7 ml of a phosphate buffer was
poured, and
the dish was moved under a stereoscopic microscope. Next, colonies were ripped
off
and sucked by using PIPETMAN (manufactured by GILSON) and were collected in a
round-bottomed 96-well plate (manufactured by Falcon). After trypsinizaton,
each
clone was inoculated into a flat-bottomed 96-well plate for adherent cells
(manufactured
30 by Asahi Techno Glass), followed by culturing using IMDM-dFBS(10)-HT(1)
containing 15 p.g/ml puromycin (manufactured by SIGMA) for one week.
After the culturing, each clone on the above plate was subjected to
trypsinization and the resulting cells were inoculated into a flat-bottomed 24-
well plate
for adherent cells (manufactured by Greiner). After culturing using INIDM-
dFBS(10)-
3 5 HT( 1 ) containing 15 p.g/ml puromycin (manufactured by SIGMA) for one
week, the
cells were inoculated into a flat-bottomed 6-well plate for adherent cells
(manufactured
-73-
CA 02542121 2006-04-07
by Greiner). The genomic DNA of each clone was prepared from the plate
according
to a known method [Nucleic Acids Research, 3, 2303 (1976)] and then dissolved
overnight in 150 ~l of TE-RNase buffer (pH 8.0).
The genomic DNA prepared above (12 fig) was digested with 25 units of a
restriction enzyme BamHI (manufactured by New England Biolabs) at 37°C
overnight
for digestion reaction, and a DNA fragment recovered by ethanol precipitation
was
dissolved in 20 ~1 of TE buffer (pH 8.0) and then subjected to 0.6% (w/v)
agarose gel
electrophoresis. After the electrophoresis, the genomic DNA was transferred to
a
nylon membrane according to a known method [Proc. Natl. Acad. Sci. USA, 76,
3683
(1979)], followed by heat treatment of the nylon membrane at 80°C for 2
hours.
Separately, a probe used in the Southern blotting was prepared in the
following manner. First, the following PCR was carried out by using primers
which
bind to the sequence of a part exceeding the targeting vector homologous
region in the
FUT8 genomic region (SEQ m NOs:16 and 17). That is, 20 ~,l of a reaction
mixture
[DNA polymerase ExTaq (manufactured by Takara Shuzo Co., Ltd.), ExTaq buffer
(manufactured by Takara Shuzo Co., Ltd.), 0.2 mmol/I dNTPs, 0.5 umol/1 each of
the
above gene-specific primers (SEQ B7 NOs: l6 and 17)] containing 4.0 ng of the
plasmid
pFUT8fgE2-2 constructed by the method described in Example 12 of W002131140
was
prepared, and PCR was carried out, after heating at 94°C for one
minute, by 25 cycles,
2 0 one cycle consisting of reaction at 94°C for 30 seconds, reaction
at 55°C for 30 seconds
and reaction at 74°C for one minute. After the PCR, the reaction
mixture was
subjected to 1.75% (w/v) agarose gel electrophoresis, and approximately 230 by
probe
DNA fragment was purified. Then, 5 ~.1 of the obtained probe DNA solution was
subjected to radiolabeling using [oc-32P] dCTP 1.75 MBq and Megaprime DNA
2 5 Labelling system, dCTP (manufactured by Amer~ham Pharmacia Biotech):
Hybridization was carried out in the following manner. The above nylon
membrane was put into a roller bottle and 15 ml of a hybridization solution [5
x SSPE,
50 x Denhaldt's solution, 0.5% (w/v) SDS, 100 ~g/ml salmon sperm DNA] was
added
thereto. Prehybridization was carried out at 65°C for 3 hours. Then,
the 32P-labeled
3 0 probe DNA was heat-denatured and put into the bottle, followed by heating
at 65°C
overnight.
After the hybridization, the nylon membrane was immersed in 50 ml of
2 x SSC-0.1% (w/v) SDS and heated at 65°C for 15 minutes. After this
washing step
was repeated twice, the nylon membrane was immersed in 50 ml of 0.2 x SSC-0.1%
35 (w/v) SDS and heated at 65°C for 15 minutes. After washing, the
nylon membrane
was exposed to an X-ray film at -80°C for development.
-74-
CA 02542121 2006-04-07
The genomic DNA of the clone WK704, which is one of the puromycin-
resistant clones obtained from the clone 50-10-104 according to the method
described in
the above (1), was analyzed according to the present method. In the clone
WK704,
approximately 25.5 Kb fragment derived from the wild-type FUTB allele was
eliminated
and only approximately 20.0 Kb fragment specific to the allele which underwent
homologous recombination was detected. From this result, it was confirmed that
the
clone WK704 was a clone wherein both FUT8 alleles were disrupted.
4. Removal of the drug resistance genes from FUT8 gene-double-knockout cells
( 1 ) Introduction of Cre recombinase expression vector
Into WK704 of FUTB-double-knockout clone obtained in the item 3 of
Example 1, the Cre recombinase expression vector pBs185 (manufactured by Life
Technologies) was introduced in the following manner.
After 4 ~tg of plasmid pBs185 was introduced into 1.6 x 106 cells by
electroporation [Cytotechnolo~, 3, 133 (1990)), the resulting cells were
suspended in
10 ml of IMDM-dFBS(10)-HT(1) and the suspension was diluted 20000-fold with
the
same medium. The diluted suspension was inoculated into seven 10-cm dishes for
adherent cell culture (manufactured by Falcon), followed by culturing in S%
COZ at
37°C for 10 days to form colonies.
(2) Obtaining of clone in which the Cre recombinase expression vector has been
introduced
Arbitrary clones were collected from colonies obtained by gene introduction
into WK704_ in the following manner. First, a culture supernatant was removed
from a
2 5 10-cm dish, 7 ml of a phosphate buffer was poured, and the dish was moved
under a
stereoscopic microscope. Next, colonies were ripped off and sucked using
PIPETMAN (manufactured by GILSON) and were collected in a round-bottomed 96-
well plate (manufactured by Falcon). After trypsinization, each clone was
inoculated
into a flat-bottomed 96-well plate for adherent cells (manufactured by Iwaki
Glass),
3 0 followed by culturing using IIVVIDM-dFBS( 10)-HT(1 ) for one week.
After the culturing, each clone on the above plate was subjected to
trypsinization, and a 2-fold volume of a frozen medium (20% DMSO, 40% fetal
calf
serum and 40% IMDN17 was mixed therewith. One half thereof was inoculated into
a
flat-bottomed 96-well plate for adherent cells (manufactured by Iwaki Glass)
to prepare
3 5 a replica plate, while the other half was stored by cryopreservation as a
master plate.
-75-
CA 02542121 2006-04-07
The replica plate was cultured using INIDM-dFBS(10)-HT(1) containing
600 p,g/ml 6418 and 15 ~g/ml puromycin for 7 days. Positive clones in which
the
drug resistance genes on both alleles between IoxP sequences has been removed
by the
expression of Cre recombinase die in the presence of 6418 and puromycin. The
positive clones were selected according to this negative selection method.
(3) Confirmation of removal of the drug resistance genes by genomic Southern
blotting
Confirmation of the removal of the drug resistance genes in the positive
clones collected in the above (2) was carried out by genomic Southern blotting
in the
following manner.
Among the master plates stored by cryopreservation in the item (2), a 96-
well plate containing the above positive clones was selected. After the plate
was
allowed to stand at 5% COZ and 37°C for 10 minutes, the cells in the
wells
corresponding to the above clones were inoculated into a flat-bottomed 24-well
plate for
adherent cells (manufactured by Greiner). After culturing using IIVVIDM medium
(manufactured by Invitrogen) to which 10% fetal bovine serum (manufactured by
Invitrogen) and 1 x concentration HT supplement (manufactured by Invitrogen)
had
been added for one week, the cells were inoculated into a flat-bottomed 6-well
plate for
adherent cells (manufactured by Greiner). The genomic DNA of each clone was
2 0 prepared from the plate according to a known method [Nucleic Acids
Research, 3, 2303
(1976)] and then dissolved overnight in 150 p,l of TE-RNase buffer (pH 8.0).
The genomic DNA prepared above (12 fig) was digested with 20 units of a
restriction enzyme NheI (manufactured by New England Biolabs) at 37°C
overnight.
A DNA fragment recovered from the reaction mixture by ethanol precipitation
was
dissolved in 20 p,l ofTE buffer (pH 8.0) and then subjected to 0.6% (w/v)
agarose gel
electrophoresis. After the electrophoresis, the genomic DNA was transferred to
a
nylon membrane according to a known method [Proc. Natl. Acad. Sci. USA, 76,
3683
(1979)], followed by heat treatment of the nylon membrane at 80°C for 2
hours for
immobilization.
3 0 Separately, a probe used in the Southern blotting was prepared in the
following manner. First, the following PCR was carried out by using primers
which
bind to the sequence of a part exceeding the targeting vector homologous
region in the
FUT8 genomic region (SEQ ID NOs:l6 and 17). That is, a reaction mixture [20
p.l;
DNA polymerase ExTaq (manufactured by Takara Shuzo Co., Ltd.), ExTaq buffer
(manufactured by Takara Shuzo Co., Ltd.), 0.2 mmol/1 dNTPs, 0.5 p.mol/1 each
of the
above gene-specific primers (SEQ 1D NOs: l6 and 17)] containing 4.0 ng of the
plasmid
-76-
CA 02542121 2006-04-07
pFUT8fgE2-2 obtaiend in item 1(2) of Example 1 was prepared, and PCR was
carried
out, after heating at 94°C for one minute, by 25 cycles, one cycle
consisting of reaction
at 94°C for 30 seconds, reaction at 55°C for 30 seconds and
reaction at 74°C for one
minute. After the PCR, the reaction mixture was subjected to 1.75% (w/v)
agarose gel
electrophoresis, and approximately 230 by probe DNA fragment was purified.
Then, 5
pl of the obtained probe DNA solution was subjected to radiolabeling using [a-
32P]
dCTP 1.75 MBq and Megaprime DNA Labelling system, dCTP (manufactured by
Amersham Pharmacia Biotech).
Hybridization was carried out in the following manner. The above nylon
membrane was put into a roller bottle and 15 ml of a hybridization solution [5
x SSPE,
50 x Denhaldt's solution, 0.5% (w/v) SDS, 100 p.g/ml salmon sperm DNA] was
added
thereto. Prehybridization was carried out at 65°C for 3 hours. Then,
the 32P-labeled
probe DNA was heat-denatured and put into the bottle, followed by heating at
65°C
overnight.
After the hybridization, the nylon membrane was immersed in 50 ml of
2 x SSC-0.1% (w/v) SDS and heated at 65°C for 15 minutes. After this
washing step
was repeated twice, the nylon membrane was immersed in 50 ml of 0.2 x SSC-0.1%
(w/v) SDS and heated at 65°C for 15 minutes. After washing, the nylon
membrane
was exposed to an X-ray film at -80°C for development.
2 0 By the above-described treatment with the restriction enzyme NheI,
approximately 8.0 Kb DNA fragment was derived from the wild-type FUT8 allele.
Also, by the similar treatment with the restriction enzyme, approximately 9.5
Kb DNA
fragment was obtained from the allele which underwent homologous recombination
with the targeting vector. Furthermore, by the similar treatment,
approximately 8.0 Kb
DNA fragment vvas derived when the neomycin resistance gene (approximately 1.6
Kb)
and the puromycin resistance gene (approximately 1.5 Kb) were removed from the
allele which underwent homologous recombination.
The genomic DNAs of the parent cell line CHOlDG44, the clone 50-10-104
described in the above item 2, the clone WK704 described in the above item 3,
and the
3 0 clone 4-5-C3, which is one of the drug-sensitive clones obtained from the
clone WK704
by the method described in the above (2), were analyzed according to the
present
method. In the cell line CH01DG44, only approximately 8.0 Kb DNA fragment
derived from the wild-type FUT8 allele was detected. In the clone 50-10-104
and the
clone WK704, approximately 9.5 Kb DNA fragment derived from the allele which
3 5 underwent homologous recombination was observed. On the other hand, in the
4-5-C3
clone, only approximately 8.0 Kb DNA fragment resulting from the removal of
the
_77_
CA 02542121 2006-04-07
neomycin resistance gene (approximately 1.6 Kb) and the puromycin resistance
gene
(approximately 1.5 Kb) from the allele which underwent homologous
recombination
was detected. From the above results, it was confirmed that the drug
resistance genes
had been removed by Cre recombinase in the clone 4-5-C3.
Besides the clone 4-5-C3, plural FUT8 gene-double-knockout clones in
which the drug-resistance gene had been removed (hereinafter referred to as
FUT8
gene-double-knockout cells) were obtained.
Example 2
Expression of antibody molecule in CHOlDG44 cell in which FUT8 allele was
double
knocked out:
1. Preparation of anti-CD20 chimeric antibody expression vector
( 1 ) Construction of cDNA encoding VL of anti-CD20 mouse monoclonal antibody
The cDNA (SEQ n7 N0:18) encoding the amino acid sequence of VL in
anti-CD20 mouse monoclonal antibody 2B8 described in W094i11026 was
constructed
using PCR as follows.
First, the binding nucleotide sequence (including a restriction enzyme
recognizing sequence for cloning to a vector for expression of humanized
antibody) of
the amplification primer for PCR was added to the 5'-terminal and 3'-terminal
of the
2 0 nucleotide sequence of VL described in W094/11026. The designed nucleotide
sequence was divided into total of 6 nucleotide sequences from the 5'-terminal
side with
about 100 bases each (the adjacent nucleotide sequences were adjusted in such
a manner
that their ends have a common sequence of about 20 bases at their termini) and
6
synthetic DNA_of SEQ 1D NOs:20, 21, 22, 23, 24 and 25 were prepared
(consignment
2 5 to GENSET company) iri alternate order of a sense chain and an antisense
chain.
Each oligonucleotide was added to 50 p,L of a reaction solution [KOD DNA
Polymerise affixture PCR Buffer # 1 (manufactured by Toyobo), 0.2 mM dNTPs, 1
mM
magnesium chloride, 0.5 EtM M13 primer M4 (manufactured by Takara Shuzo Co.,
Ltd.), O.SN.M M13 primer RV (manufactured by Takara Shuzo Co., Ltd.)] to give
a final
3 0 concentration of 0.1 pM. Using a DNA thermal cycler GeneAmp PCR System
9600
(manufactured by Perkin Elmer), the reaction solution was heated at
94°C for 3 minutes,
and the reaction was carried out by 25 cycles, one cycle consisting of
reaction at 94°C
for 30 seconds, reaction at 55°C for 30 seconds and reaction at
74°C for 1 minute after
2.5 units of KOD DNA Polymerise (manufactured by Toyobo) were added, and
further
35 heated at 72°C for 10 minutes. Then, 25 p,L of the reaction solution
was subjected to
_78_
CA 02542121 2006-04-07
agarose gel electrophoresis and a PCR product of about 0.44 kb of VL was
collected by
using a QIAquick Gel Extraction Kit (manufactured by QIAGEN).
Then, 0.1 ~g of DNA obtained from plasmid pBluescriptII SK(-)
(manufactured by Stratagene) by a restriction enzyme SmaI (manufactured by
Takara
Shuzo Co., Ltd.) and about 0.1 pg of the PCR product obtained above were added
to
sterilized water to give a total volume of 7.5 pL, and 7.5 pL of solution I of
a TAKARA
ligation kit ver. 2 (manufactured by Takara Shuzo Co., Ltd.) and 0.3 pL of a
restriction
enzyme SmaI (manufactured by Takara Shuzo Co., Ltd.) were added thereto,
followed
by reaction at 22°C for 2 hours. Using the thus obtained recombinant
plasmid DNA
solution, E. coli DHSa, strain (manufactured by Toyobo) was transformed. From
the
clones of the transformant, each plasmid DNA was prepared and was allowed to
react
by using a BigDye Terminator Cycle Sequencing Ready Reaction Kit v2.0
(manufactured by Applied Biosystems) according to the attached manufacture's
instruction, and then the nucleotide sequence was analyzed by a DNA sequencer
ABI
PRISM 377 of the same company. Thus, a plasmid pBs-2B8L having the nucleotide
sequence of interest shown in Fig. 2 was obtained.
(2) Construction of cDNA encoding VH of anti-CD20 mouse monoclonal antibody
cDNA (SEQ ID N0:19) encoding the amino acid sequence of VH of anti-
2 0 CD20 mouse monoclonal antibody 2B8 described in W094/11026 was constructed
using PCR as follows.
First, the binding nucleotide sequence (including a restriction enzyme
recognition sequence for cloning to a vector for expression of humanized
antibody) of
the amplification primer for PCR was added to the 5'-terminal and 3'-terminal
of the
2 5 nucleotide sequence of VH described in W094/11026. The designed nucleotide
sequence was divided into total of 6 nucleotide sequences from the 5'-terminal
side with
about 100 bases each (the adjacent nucleotide sequences were adjusted in such
a manner
that their ends have a common sequence of about 20 bases at their termini) and
6
synthetic DNA of SEQ ID NOs: 26, 27, 28, 29, 30 and 31 were prepared
(consignment
3 0 to GENSET company) in alternate order of a sense chain and an antisense
chain.
Each oligonucleotide was added to 50 pL of the reaction solution [KOD
DNA Polymerase affixture PCR Buffer #1 (manufactured by Toyobo), 0.2 mM dNTPs,
1 mM magnesium chloride, 0.5 pM M13 primer M4 (manufactured by Takara Shuzo
Co., Ltd.), 0.5 p,M M13 primer RV (manufactured by Takara Shuzo Co., Ltd.)] to
give a
3 5 final concentration of 0.1 pM, and, using a DNA thermal cycler GeneAmp PCR
System
9600 (manufactured by Perkin Elmer), the reaction solution was heated at
94°C for 3
- 79 -
CA 02542121 2006-04-07
minutes, and the reaction was carried out by 25 cycles, one cycle consisting
of reaction
at 94°C for 30 seconds, reaction at SS°C for 30 seconds and
reaction at 74°C for I
minute after 2.5 units of KOD DNA Polymerase (manufactured by Toyobo) was
added
thereto, and further heated at 72°C for 10 minutes. After 25 pL of the
reaction
solution was subjected to agarose gel electrophoresis, and a PCR product of
about 0.49
kb of VH was collected by using a QIAquick Gel Extraction Kit (manufactured by
QIAGEN).
Then, 0.1 pg of the DNA obtained from the plasmid pBluescriptII SK(-)
(manufactured by Stratagene) by a restriction enzyme SmaI (manufactured by
Takara
Shuzo Co., Ltd.) and about 0.1 pg of the PCR product obtained as described
above were
added to sterilized water to give a total volume of 7.5 pL, and 7.5 p.L
solution I of a
TAKARA ligation kit ver. 2 (manufactured by Takara Shuzo Co) and 0.3 pL of a
restriction enzyme SmaI (manufactured by Takara Shuzo Co., Ltd.) were added
thereto,
followed by reaction overnight at 22°C.
Using the thus obtained recombinant plasmid DNA solution, E. coli DHSoc
strain (manufactured by Toyobo) was transformed. Each plasmid DNA from the
clones of the transformant was prepared and was allowed to react by using a
BigDye
Terminator Cycle Sequencing Ready Reaction Kit v2.0 (manufactured by Applied
Biosystems) according to the attached manufacture's instruction, and then the
nucleotide
2 0 sequence was analyzed by a DNA sequencer ABI PRISM 377 of the same
company.
Thus, a plasmid pBs-2B8H having the nucleotide sequence of interest shown in
Fig. 3
was obtained.
Then, the synthetic DNA represented by SEQ ID N0:32 was designed in
order to substitute the amino acid residue at position 14 from Ala to Pro, and
the
2 5 substitution was carried out as follows by PCR using a LA PCR in vitro
Mutagenesis
Primer Set for pBluescriptII (manufactured by Takara Shuzo Co., Ltd.). After
50 gL
of a reaction solution [LA PCR Buffer II (manufactured by Takara Shuzo Co.,
Ltd.), 2.5
units of TAKARA LA Taq, 0.4 mM dNTPs, 2.5 mM magnesium chloride, 50 nM T3
BcaBEST Sequencing primer (manufactured by Takara Shuzo Co., Ltd.), 50 nM of
the
3 0 above-described primer for introducing mutation (5EQ 117 N0:32, produced
by
GENSET)] containing 1 ng of the above-described plasmid pBs-2B8H was prepared
and, using a DNA thermal cycler GeneAmp PCR System 9600 (manufactured by
Perkin
Elmer), the reaction solution was allowed to react by 25 cycles, one cycle
consisting of
reaction at 94°C for 30 seconds, reaction at 55°C for 2 minutes
and reaction at 72°C for
35 one and a half minute. Then, 30 pL of the reaction solution was subjected
to agarose
gel electrophoresis, and a PCR product of about 0.44 kb was collected using a
QIAquick
-80-
CA 02542121 2006-04-07
Gel Extraction Kit (manufactured by QIAGEN) and made to a 30 pL aqueous
solution.
Furthermore, PCR was carried out in the same manner using 50 pL of a reaction
solution [LA PCR Buffer II (manufactured by Takara Shuzo Co., Ltd.), 2.5 units
of
TAKARA LA Taq, 0.4 mM dNTPs, 2.5 mM magnesium chloride, 50 nM T7 BcaBEST
Sequencing primer (manufactured by Takara Shuzo Co., Ltd.), 50 nM MLTT B 1
primer
(manufactured by Takara Shuzo Co., Ltd.)] containing 1 ng of the above-
described
plasmid pBs-2B8H. Then, 30 pL of the reaction solution was subjected to
agarose gel
electrophoresis, and a PCR product of about 0.63 kb was collected using a
QIAquick
Gel Extraction Kit (manufactured by QIAGEN) and made to a 30 pL aqueous
solution.
Subsequently, 0.5 pL of the above obtained PCR product of about 0.44 kb and
the PCR
product of about 0.63 kb, respectively, were added to 47.5 ~L of a reaction
solution [LA
PCR Buffer II (manufactured by Takara Shuzo Co., Ltd.), 0.4 mM dNTPs, 2.5 mM
magnesium chloride] and, using a DNA thermal cycler GeneAmp PCR System 9600
(manufactured by Perkin Elmer), the reaction solution was allowed to react by
heating
at 90°C for 10 minutes, subsequent cooling to 37°C over 60
minutes, and then
maintaining the temperature at 37°C for 15 minutes to thereby carry out
annealing of
DNA. After 2.5 units of TAKARA LA Taq (manufactured by Takara Shuzo Co., Ltd.)
were added and allowed to react at 72°C for 3 minutes, 10 pmol of T3
BcaBEST
Sequencing primer (manufactured by Takara Shuzo Co., Ltd.) and T7 BcaBEST
2 0 Sequencing primer (manufactured by Takara Shuzo Co., Ltd.), respectively,
were added,
and the reaction solution was made to 50 pL and allowed to react by 10 cycles,
one
cycle consisting of reaction at 94°C for 30 seconds, reaction at
55°C for 2 minutes and
reaction at 72°C for one and a half minute as one cycle. Then, 25 pL of
the reaction
solution was purified with QIA quick PCR purification kit (manufactured by
QIAGEN)
2 5 and half the amount was allowed to react at 37°C for 1 hour using
10 units of a
restriction enzyme KpnI (manufactured by Takara 5huzo Co., Ltd.) and 10 units
of a
restriction enzyme Sacl (manufactured by Takara Shuzo Co., Ltd.). The reaction
solution was fractionated by agarose gel electrophoresis and a KpnI-SacI
fragment of
about 0.59 kb was collected.
3 0 Next, 1 pg of pBluescriptII SK(-) (manufactured by Stratagene) was reacted
at 37°C for 1 hour using 10 units of a restriction enzyme KpnI
(manufactured by Takara
Shuzo Co., Ltd.) and 10 units of SacI (manufactured by Takara Shuzo Co.,
Ltd.), and
then, the reaction solution was fractionated by agarose gel electrophoresis to
collect a
KpnI-SacI fragment of about 2.9 kb.
3 5 The KpnI-SacI fragment derived from the PCR product obtained as
described above and the KpnI-SacI fragment derived from the plasmid
pBluescriptII
-81-
CA 02542121 2006-04-07
SK(-) were ligated by using solution I of DNA Ligation Kit Ver.2 (manufactured
by
Takara Shuzo Co., Ltd.) according to the attached manufacture's instruction.
Using the
thus obtained recombinant plasmid DNA solution, E coli DHSa strain
(manufactured
by Toyobo) were transformed. Each plasmid DNA was prepared from the clones of
the transformant and allowed to react by using a BigDye Terminator Cycle
Sequencing
Ready Reaction Kit v2.0 (manufactured by Applied Biosystems) according to the
attached manufacture's instruction, and then, the nucleotide sequence was
analyzed with
a DNA sequencer ABI PRISM 377 of the same company.
Thus, a plasmid pBs-2B8Hm having the nucleotide sequence of interest
shown in Fig. 3 was obtained.
(3) Construction of anti-CD20 human chimeric antibody expression vector
Using vector pKANTEX93 for humanized antibody expression [Mol.
Immunol., 37, 1035 (2000)] and plasmid pBs-2B8L and pBs-2B8Hm obtained in the
items (1) and (2), the expression vector pKANTEX2B8P of the anti-CD20 human
chimeric antibody (hereinafter referred to as "anti-CD20 chimeric antibody")
was
constructed as follows.
After 2 pg of the plasmid pBs-2B8L obtained in the item (1) was allowed to
react at 55°C for 1 hour using 10 units of a restriction enzyme BsiWI
(manufactured
by New England Biolabs), further reaction was carried out at 37°C for 1
hour using 10
units of a restriction enzyme EcoRI (manufactured by Takara Shuzo Co., Ltd.).
The
reaction solution was fractionated by agarose gel electrophoresis to collect a
BsiWI-
EcoRI fragment of about 0.41 kb.
Then, 2 pg of the vector pKANTEX93 for humanized antibody expression
was allowed to react at 55°C for 1 hour using 10 units of a restriction
enzyme BsiWI
(manufactured by New England Biolabs), and then further reaction was carried
out at
37°C for 1 hour using 10 units of a restriction enzyme EcoRI
(manufactured by Takara
Shuzo Co., Ltd.). The reaction solution was fractionated by agarose gel
electrophoresis to collect a BsiWI-EcoRI fragment of about 12.75 kb.
3 0 Next, the above obtained BsiWI-EcoRI fragment derived from plasmid pBs-
2B8L and the BsiWI-EcoRI fragment derived from the plasmid pKANTEX93 were
ligated by using solution I of DNA Ligation Kit Ver.2 (manufactured by Takara
Shuzo
Co., Ltd.) according to the attached manufacture's instruction. Using the thus
obtained
recombinant plasmid DNA solution, E. coli DHSa strain (manufactured by Toyobo)
3 5 was transformed to obtain a plasmid pKANTEX2B8-L shown in Fig. 4.
- 82 -
CA 02542121 2006-04-07
Then, 2 pg of the plasmid pBs-2B8Hm obtained in the item (2) was allowed
to react at 37°C for 1 hour by using 10 units of a restriction enzyme
ApaI (manufactured
by Takara Shuzo Co., Ltd.), and then, further reaction was carried out at
37°C for 1 hour
by using 10 units of a restriction enzyme NotI (manufactured by Takara Shuzo
Co.,
Ltd.). The reaction solution was fractionated by agarose gel electrophoresis
to collect
an ApaI-NotI fragment of about 0.45 kb.
Next, 3 pg of the plasmid pKANTEX2B8-L obtained above was allowed to
react at 37°C for 1 hour by using 10 units of a restriction enzyme ApaI
(manufactured
by Takara Shuzo Co., Ltd.), and then further reaction was carried out at
37°C for 1 hour
l0 by using 10 units of a restriction enzyme NotI (manufactured by Takara
Shuzo Co.,
Ltd.). The reaction solution was fractionated by agarose gel electrophoresis
to collect
an ApaI-NotI fragment of about 13.16 kb.
Then, the above obtained ApaI-NotI fragment derived from plasmid pBs-
2B8Hm and the ApaI-NotI fragment derived from plasmid pKANTEX2B8-L were
ligated by using solution I of DNA Ligation Kit Ver.2 (manufactured by Takara
Shuzo
Co., Ltd.) according to the attached manufacture's instruction. Using the
recombinant
plasmid DNA solution obtained in this manner, E. coli DHSa, strain
(manufactured by
Toyobo) was transformed and each plasmid DNA was prepared from the clone of
the
transformant.
2 0 Using the obtained plasmid, the nucleotide sequence was analyzed by using
a BigDye Terminator Cycle Sequencing Ready Reaction Kit v2.0 (manufactured by
Applied Biosystems) with DNA sequencer 377 of the same company. As a result,
it
was confirmed that a plasmid pKANTEX2B8P cloned with the DNA of interest shown
in Fig. 4 was obtained.
2. Expression of anti-CD20 chimeric antibody
The expression vector pKANTEX2B8P of the anti-CD20 antibody obtained
in the item 1 of this Example was introduced into the FUT8 gene double
knockout clone
WK704 prepared in the item 5(2) of Example 1.
3 0 The gene introduction into WK704 of the plasmid pKANTEX2B8P was
carried out by electroporation [Cytotechnology, 3, 133 (1990)] by the
procedure as
follows. First, 10 ~.g of the plasmid pKANTEX2B8P was dissolved in 100 ~l of
NEBuffer 4 (manufactured by New England Biolabs), and 40 units of a
restriction
enzyme AatII (manufactured by New England Biolabs) were added thereto, then
the
linearization was carried out by digestion at 37°C for 2 hours. The
reaction solution
was extracted with phenol/chloroform extraction, followed by ethanol
precipitation, and
-83-
CA 02542121 2006-04-07
the recovered linear plasmid was made into a 1 pg/pl aqueous solution.
Separately,
WK704 was suspended into K-PBS buffer (137 mmol/1 KCI, 2.7 mmol/1 NaCI, 8.1
mmol/1 Na2HP04, 1.5 mmol/1 KHZPOa, 4.0 mmol/1 MgClz) to give a density of
8X10'
cells/ml. After 200 ~l of the cell suspension (1.6X106 cells) were combined
with 4 pl
(4 pg) of the above-described linearized plasmid, the total cell-DNA mixture
was
transferred to Gene Pulser Cuvette (electrode distance: 2 mm) (manufactured by
BIO-
RAD) and the gene introduction was carried out by using Gene Pulser cell
fusion device
(manufactured by BIO-RAD) at a pulse voltage of 350 V and a capacity of 250
pF.
After the gene introduction, the cell suspension was suspended in INIDM medium
(manufactured by Invitrogen) supplemented with 10% fetal bovine serum
(manufactured by Invitrogen) and 1 X concentration HT supplement (manufactured
by
Invitrogen), and inoculated onto T75 flasks for adhesion cell culture
(manufactured by
Greiner). After culturing at 5 % COZ and 37°C for 24 hours, the culture
supernatant
was removed and 10 ml IMDM medium (manufactured by Invitrogen) supplemented
with 10% fetal bovine dialysis serum (manufactured by Invitrogen) were filled
therein.
The culturing was carried out for 15 days while the medium exchange process
was
repeated every 3 to 4 days, and a transformant WK704-2B8P was obtained.
Furthermore, the clone WK704-2B8P, as a name of WK704-2B8P, has been deposited
on March 20, 2003, as FERM BP-8337 in International Patent Organism
Depositary,
2 0 National Institute of Advanced Industrial Science and Technology (Tsukuba
Central 6,
1-1, Higashi 1-Chome Tsukuba-shi, Ibaraki-ken, Japan).
3. Expression of anti-ganglioside GD3 chimeric antibody
The vector plasmid pKANTEX641 for expression of the anti-ganglioside
2 5 GD3 chimeric antibody was introduced into tlie- FUT8 gene double knockout
clone
WK704 prepared in the item 5(2) of Example 1 and a stable expression clone of
anti
GD3 chimeric antibody was prepared. The pKANTEX641 is a derivative comprising
the vector plasmid pChi641LHGM4 for expression of the anti-GD3 chimeric
antibody
described in W000/61739 and the vector pKANTEX93 for humanized antibody
expression [Mol. Immunol., 37, 1035 (2000)] in which an EcoRI-HindIII fragment
containing a tandem type antibody expression unit obtained from pChi641LHGM4
is
ligated with an EcoRI-HindIII fragment containing the origin of replication
obtained
from pKANTEX93.
The gene introduction into WK704 of the plasmid pKANTEX641 was
carried out by electroporation [Cytotechnology, 3, 133 (1990)] by the
procedure as
follows. First, 10 pg of the plasmid pKANTEX641 was dissolved in 100 pl of
- 84 -
CA 02542121 2006-04-07
NEBuffer 4 (manufactured by New England Biolabs), and 40 units of a
restriction
enzyme AatII (manufactured by New England Biolabs) were added thereto, and
then the
linearization was carried out by digestion at 37°C for 2 hours. The
reaction solution
was extracted with phenol/chloroform extraction, followed by ethanol
precipitation, and
the recovered linear plasmid was made into a 1 ~g/p,l aqueous solution.
Separately,
WK704 was suspended into K-PBS buffer (137 mmoUl KCI, 2.7 mmol/1 NaCI, 8.1
mmol/1 Na2HP04, 1.5 mmol/1 KHzP04, 4.0 mmol/I MgCl2) to give a density of 8X
107
cells/ml. After 200 pl of the cell suspension (1.6X106 cells) was mixed with 4
gl (4
ug) of the above-described linearized plasmid, the whole cell-DNA mixture was
transferred to Gene Pulser Cuvette (electrode distance: 2 mm) (manufactured by
BIO-
RAD) and the gene introduction was carried out by using Gene Pulser cell
fusion device
(manufactured by BIO-RAD) at a pulse voltage of 3 50 V and a capacity of 250
pF.
After the gene introduction, the cell suspension was suspended in IIVVIDM
medium
(manufactured by Invitrogen) supplemented with 10 % fetal bovine serum
(manufactured by Invitrogen) and 1 X concentration HT supplement (manufactured
by
Invitrogen), and inoculated onto T75 flasks for adhesion cell culture
(manufactured by
Greiner). After culturing at 5 % COz and 37°C for 24 hours, the culture
supernatant
was removed and 10 ml of IMDM medium (manufactured by Invitrogen) supplemented
with 10% fetal bovine dialysis serum (manufactured by Invitrogen) were filled
therein.
2 0 The culturing was carried out for 15 days while the medium exchange
process was
repeated every 3 to 4 days, and a transformant WK704-2871 was obtained.
Furthermore, the clone WK704-2871, as a name of WK704-2871, has been deposited
on March 20, 2003, as FERM BP-8336 in International Patent Organism
Depositary,
National Institute of Advanced Industrial Science and Technology (Tsukuba
Central 6,
1-1, Higashi 1-Chome Tsukuba-shi, Ibaraki-ken 305-8566 Japan).
4. Expression of the anti-CCR4 chimeric antibody
The vector pKANTEX2160 for expression of anti-CCR4 chimeric antibody
described in W001/64754 was introduced into the FUT8 gene double knockout
clone
3 0 WK704 prepared in the item 5(2) of Example 1 and a stable expression clone
of the anti
CCR4 chimeric antibody was prepared.
The gene introduction into the WK704 of the plasmid pKANTEX2B8P was
carried out in a similar manner to the electroporation technique
[Cytotechnology, 3, 133
(1990)] according to the procedure as follows. First, 15 pg of the plasmid
3 5 pKANTEX2160 were dissolved in 100 pl of NEBufI'er 4 (manufactured by New
England Biolabs), 40 units of a restriction enzyme AatII (manufactured by New
-85-
CA 02542121 2006-04-07
England Biolabs) were added thereto, and then the linearization was carried
out by
digestion at 37°C for 2 hours. The reaction solution was extracted with
phenol/chloroform extraction, followed by ethanol precipitation, and the
recovered
linear plasmid was made into a 1 ~g/~.l aqueous solution. Separately, WK704
was
suspended in K-PBS buffer (137 mmolll KCI, 2.7 mmol/1 NaCI, 8.1 mmol/1
Na2HP04,
1.5 mmolJl KHzP04, 4.0 mmol/1 MgCl2) to give a density of 8 X 10' cells/ml.
After 200
pl of the cell suspension (1.6X l06 cells) was combined with 4 pl (4 pg) of
the above-
described linearized plasmid, the whole cell-DNA mixture was transferred to
Gene
Pulser Cuvette (electrode distance: 2 mm) (manufactured by BIO-RAD) and the
gene
introduction was carried out by using Gene Pulser cell fusion device
(manufactured by
BIO-RAD) at a pulse voltage of 350 V and a capacity of 250 p,F. After the gene
introduction, the cell suspension was suspended in IIvLDM medium (manufactured
by
Invitrogen) supplemented with 10% fetal bovine serum (manufactured by
Invitrogen)
and 1 X concentration HT supplement (manufactured by Invitrogen), and
inoculated
onto T75 flasks for adhesion cell culture (manufactured by Greiner). After
culturing at
5 % COz and 37°C for 24 hours, the culture supernatant was removed and
l0 ml IMDM
medium (manufactured by Invitrogen) supplemented with 10 % fetal bovine
dialysis
serum (manufactured by Invitrogen) were filled therein. The culturing was
carried out
for 15 days while this medium exchange process was repeated every 3 to 4 days,
and a
2 0 transformant WK704-2760 was obtained. Furthermore, the clone WK704-2760,
as a
name of WK704-2760, has been deposited on March 20, 2003, as FERM BP-8335 in
International Patent Organism Depositary, National Institute of Advanced
Industrial
Science and Technology (Tsukuba Central 6, 1-1, Higashi I-Chome Tsukuba-shi,
Ibaraki-ken, Japan).
5. Measurement of human IgG antibody concentration in culture supernatant
(ELISA)
A goat anti-human IgG (H & L) antibody (manufactured by American
Qualex) was diluted with phosphate buffered saline (hereinafter referred to as
PBS) to
give a concentration of 1 ~g/ml, dispensed at 50 p,l/well into a 96-well ELISA
plate
(manufactured by Greiner) and then allowed to stand at 4°C overnight
for adsorption.
After washing with PBS, PBS containing BSA at a concentration of 1%
(hereinafter
referred to as I% BSA-PBS) (manufactured by Wako Pure Chemical Industries) was
added at 100 p,l/well and allowed to react at room temperature for 1 hour to
thereby
block the remaining active groups. The 1% BSA-PBS was discarded, and culture
3 5 supernatant of a transformant or variously diluted solution of antibody
purified from the
culture supernatant was added at 50 ~1/well and allowed to react at room
temperature
-86-
CA 02542121 2006-04-07
for 1 hour. After the reaction, each well was washed with PBS containing Tween
20 at
a concentration of 0.05% (hereinafter referred to as Tween-PBS) (manufactured
by
Wako Pure Chemical Industries), and then a peroxidase-labeled goat anti-human
IgG (H
& L) antibody solution (manufactured by American Qualex), diluted 2000-fold
with 1%
S BSA-PBS, was added as a secondary antibody solution at 50 plJwell and
allowed to
react at room temperature for 1 hour. After the reaction and subsequent
washing with
Tween-PBS, an ABTS substrate solution [a solution prepared by dissolving 0.55
g of
2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)ammonium (manufactured
by
Wako Pure Chemical Industries) in 1 liter of 0.1 M citrate buffer (pH 4.2),
and adding
hydrogen peroxide (manufactured by Wako Pure Chemical Industries) to give a
concentration of 1 ~llml just before use) was added at 50 ~,l/well to develop
color, and
the ahsorbance at 415 nm (hereinafter referred to as OD415) was measured.
6. Purification of antibody molecule
The clone WK704-2B8P for expression of anti-CD20 antibody obtained in
the item 2 of this Example was suspended in INff~M medium (manufactured by
Invitrogen) supplemented with 10% fetal bovine dialysis serum (manufactured by
Invitrogen) to give a density of 3X105 cellsiml and a total volume of 300 ml
was
inoculated into 10 bottles of T 182 flasks for adhesion cell culture
(manufactured by
2 0 Greiner). The clone WK704-2871 for expression of anti-GD3 antibody
obtained in the
item 3 of this Example and the clone WK704-2760 for expression of anti-CCR4
antibody obtained in the item 4 of this Example were inoculated in the same
manner.
After culturing for 3 days, all culture supernatants of each clone were
removed and
exchanged to EXCELL301 medium (manufactured by JRH Biosciences). They were
2 5 cultured for 7 days at 37°C in a 5% C02 incubator, and then each
cell suspension was
collected. Each of all collected cell suspensions was centrifuged for 10
minutes at
3000 rpm and 4°C to recover a supernatant, and then the supernatant was
filtered with a
PES membrane having a pore size of 0.22 um and a volume of 500 ml
(manufactured
by Asahi Technoglass).
3 0 In a column having a diameter of 0.8 cm, 0.5 ml of Mab Select
(manufactured by Amersham Pharmacia Biotech) was packed and then 3.0 ml
purified
water and 3.0 ml of 0.2 mo111 boric acid - 0.15 mol/1 NaCI buffer (pH 7.5)
were filled
into the tube successively. Furthermore, the carrier was equilibrated by
successive
cleaning with 2.0 ml of 0.1 mol/1 citrate buffer (pH 3.5) and 1.5 ml of 0.2
mol/1 boric
3 5 acid - 0.15 mol/1 NaCI buffer (pH 7.5). Then, after 300 ml of the above-
described
culture supernatant was packed into the column, it was washed with 3.0 ml of
0.2 mol/1
_ 87 -
CA 02542121 2006-04-07
boric acid - 0.15 molll NaCI buffer (pH 7.5). After the washing, the antibody
absorbed on the carrier was eluted by using 1.25 ml of 0.1 mol/1 citrate
buffer (pH 3.5).
After 250 pl of the first eluted fraction was disposed, 1 ml of the next
eluted fraction
was recovered and naturalized by mixing with 200 ~l of 2 mol/1 Tris-HCl (pH
8.5).
The obtained eluted solution was dialyzed overnight at 4°C by using 10
mol/1 citric acid
- 0.15 mol/1 NaCI buffer (pH 6.0). After the dialysis, the antibody solution
was
recovered and was sterilized and filtered by using Millex GV having a pore
size of 0.22
pm (manufactured by MIL,LIPORE).
Example 3
In vitro cytotoxic activity (ADCC activity) of antibody composition produced
by
CHO/DG44 cell in which FUT8 gene was double knocked out:
In order to evaluate the in vitro cytotoxic activity of the anti-CD20 antibody
purified in Example 2-6, the ADCC activity was measured as follows.
( 1 ) Preparation of target cell suspension
A human B lymphocyte cultured cell line Raji cell (3CRB9012) cultured in
RPMI1640-FCS(10) medium [PRMI1640 medium (manufactured by GIBCO BRL)
supplemented with 10% FCS] was washed with RPMI1640-FCS(5) medium
2 0 [PRMI1640 medium (manufactured by GlBCO BRL) supplemented with 5 % FCS] by
centrifuge separation and suspension. Then, the suspension was prepared with
RPMI1640-FCS(5) medium to give a density of 2X 105 cells/ml as the target cell
suspension.
2 5 (2) Preparation of effector cell suspension
After 50 ml of venous blood of a healthy person was collected, 0.5 ml of
heparin sodium (manufactured by Shimizu Seiyaku) was added thereto, followed
by
mixing gently. The mixture was centrifuged (800 g, 20 minutes) with Lymphoprep
(manufactured by AXIS SHIELD) according to the manufacture's instruction to
separate
3 0 a mononuclear cell phase. The cells were washed 3 times with RPMI1640-
FCS(5)
medium by centrifugal separation and re-suspended to give a density of 4X 106
cells/ml
by using the same medium, and the resulting suspension was used as effector
cell
suspension.
_88_
CA 02542121 2006-04-07
(3) Measurement of the ADCC activity
To each well of a 96-well U-shape bottom plate (manufactured by Falcon),
50 ~l (1 X 104 cells/well) of the target cell suspension prepared in the above
(1) was
dispensed. Then, 50 p.l (2x 105 cells/well, the ratio of the effector cells
and target cells
becomes 20 : 1) of the effector cell suspension prepared in the above (2) was
added.
Moreover, various anti CD20 chimeric antibodies were added to give a final
concentration of 0.3 to 3000 ng/ml and a total volume of 150 ul, and the
reaction was
carried out at 37°C for 4 hours. After the reaction, the plates were
centrifuged and the
lactate dehydrogenase (LDH) activity in the supernatant was measured by
CytoTox96
Non-Radioactive Cytotoxicity Assay (manufactured by Promega). The
spontaneously
released LDH amount of the target cells was calculated by carrying out the
same
procedure as described above, except for using only medium instead of the
effector cell
suspension and measuring the LDH activity in the supernatant. The absorbance
data of
the spontaneous release of the effector cells was obtained by carrying out the
same
procedure as described above, except for using the medium instead of the
ef~'ector cell
suspension and the antibody solution. The total free LDH amount involved in
all
targeted cytoclasis was calculated by the measurement of the LDH activity in
the
supernatant, conducting the same procedure as described above, except for
using only
medium instead of the effector cell suspension and the antibody solution, and
adding 15
2 0 pl of 9% Triton X-100 solution 45 minutes before the end of the reaction.
The ADCC
activity was calculated according to the following formula (II) by using these
values.
LDH amount in spontaneously released
(sample supernatant ) - ~ LDH amount
ADCC activity (%) = X 100 (II)
total released ~ - spontaneously released
LDH amount LDH amount
2 5 The ADCC activity of each anti-CD20 antibody is shown in Fig. 5. The
antibodies obtained from FUT8 gene double knockout clone WK704-2B8P showed a
higher ADCC activity than commercially available Rituxan~ in all antibody
concentrations and the maximum cytotoxic activity value was also higher.
Rituxan~
is an anti-CD20 chimeric antibody produced by using CHO cell, as the host
cell, in
3 0 which the FUT8 gene was not disrupted. Furthermore, as a result of the
measurement
of the ADCC activity of each of the antibodies obtained from the FUTS gene
double
knockout clone WK704-2871 and the clone WK704-2760, it was shown that a higher
cytotoxic activity than an antibody produced by a usual CHO cell line in which
FUT8
gene was not disrupted was obtained in the same manner as in the case of the
anti-CD20
_89_
CA 02542121 2006-04-07
antibody. Based on the above results, it was found that an antibody having a
higher
cytotoxic activity can be prepared by using a host cell in which the FUT8
allele was
disrupted, in comparison with the case of using host cells in which FUT8 gene
was not
disrupted.
Example 4
Analysis of monosaccharide composition of antibody composition produced by
CHO/DG44 cell in which FUT8 allele was double knocked out:
Analysis of the neutral sugar and amino sugar composition of the anti-
CD20-antibody, the anti-GD3 antibody and the anti-CCR4 antibody produced by
the
FUT8 gene double knock out clones in the item 6 of Example 2 was carried out
as
follows.
After the antibody was dried under reduced pressure using a centrifugal
concentrator, a 2.0 to 4.0 mol/1 trifluoroacetic acid solution was added
thereto and acid
hydrolysis was carried out at 100°C for 2 to 4 hours to release neutral
sugars and amino
sugars from the protein. The trifluoroacetic acid solution was removed with a
centrifugal concentrator, and the sugars were redissolved in deionized water
and
subjected to analysis using a carbohydrate analysis system (DX-500
manufactured by
Dionex). The analysis was carried out according to the elution program shown
in
2 0 Table 1 using CarboPac PA-1 column and CarboPac PA-1 guard column
(manufactured
by Dionex), a 10 to 20 mM solution of sodium hydroxide in deionized water as
an
eluting solution and a 500 mM solution of sodium hydroxide in deionized water
as a
washing solution.
2 5 Table 1
Elution program for neutral sugar and amino sugar composition analysis
Time (min.) 0 35 35.1 45 45.1 58
Eluting solution (%) 100 100 0 0 100 100
Washing solution (%) 0 0 100 100 0 0
From the obtained peak areas of neutral and amino sugar components, the
composition ratio of components (fucose, galactose and mannose) was
calculated,
3 0 regarding the value of N-acetylglucosamine as 4
The ratios of complex type sugar chains to which fucose is not bound
among the total complex type sugar chains were calculated based on the
monosaccharide composition of each antibody. As a result, it was shown that
fucose is
-90-
CA 02542121 2006-04-07
not bound to the complex type sugar chains of the anti-CD20 antibody, the anti-
GD3
antibody and the anti-CCR4 antibody produced by the FUT8 gene double knock out
clones.
Example 5
Naturalization of FUT8 gene double knock out CHO/DG44 cell in protein-free
medium
Naturalization of the clone 4-5-C3 prepared in Example 1 as an FUT8 gene
double knock out CHO/DG44 cell to a protein-free medium was carried out.
A serum-added medium comprising IMDM medium (manufactured by
Invitrogen) further supplemented with 1% (v/v) HT Supplement (manufactured by
Invitrogen) and 10% (v/v) fetal bovine serum (dFBS; manufactured by
Invitrogen)
(hereinafter referred to as "basal serum medium") was prepared. Using the
medium,
the clone 4-5-C3 was inoculated into a T flask at a cell density of 2 to 4x
105 cells/ml,
and static culturing was carried out at 37°C under a 5% COz
concentration by setting the
sub-culture period to 2 to 4 days. At the time of sub-culture, total volume
exchange
from the culture liquid to fresh medium was carried out by centrifugation.
Using the cells obtained by the sub-culturing described in the above, static
sub-culture of 6 passages and for 29 days was carried out using a protein-free
medium
comprising EX-CELL325PF (manufactured by JRH) further supplemented with 1%
2 0 (v/v) HT Supplement (manufactured by Invitrogen) and 6 mM glutamine
(manufactured
by Invitrogen) (hereinafter referred to as "basal protein-free medium"). The
culturing
was carried out in the same manner as the case of serum culturing, using a T
flask at
37°C and 5% COz concentration. Subsequently, suspension rotary
culturing was
carried out for 6 passages and for 20 days using the basal protein-free medium
in a
conical flask. The culturing temperature was set to 35°C, and the
rotation speed to 90
to 100 rpm, and at the time of sub-culture, the sub-culturing was carried out
after
substituting air in the conical flask through the blowing of 5% concentration
of COz to
the upper face of the medium, in an amount of 4 volumes or more of the culture
container.
3 0 By the sub-culturing using the basal protein-free medium described in the
above, the cells which did not proliferate due to cell aggregation in the
early culturing
stage were finally able to be converted into naturalized cells which can be
sub-cultured
using the basal protein-free medium.
Next, the thus prepared clone 4-5-C3 naturalized in the protein-free medium
3 5 was cloned by a limiting dilution method in the following manner.
-91-
CA 02542121 2006-04-07
The naturalized cells prepared using the basal protein-free medium were
diluted and then inoculated in 0.05 ml per well portions at 0.5 cell/well into
a 96-well
plate. Subsequently, a culture supernatant (conditioned medium) of the
naturalized
clone, which was sterilized using a sterilization filter was added thereto in
0.05 ml per
well portions. As a result of inoculating into a total of 768 wells and
culturing for 1 to
2 weeks, 49 clones in which single colony growth was confirmed were obtained.
The
thus obtained 49 clones were cultured in an expanded manner into a 24 well
plate and
then into a 6 well plate, and then, taking the proliferative ability of the
thus obtained
individual clones into consideration, 17 clones having good proliferative
ability were
selected. The thus obtained 17 clones were mixed and used as a cell
naturalized in a
protein-free medium.
Changes of viable cell density and survival rate by the thus obtained cell
naturalized in a protein-free medium during the sub-culture in the protein-
free medium
were shown. The results are shown in Fig. 6.
As shown in Fig. 6, an amount of cells naturalized in a protein-free medium
obtained by the method described in the above had grown 3 times during 2 to 3
days
after initiation of culturing in the medium at a low cell density. This shows
that,
different from the parent cell line, namely the cell line before
naturalization in the
protein-free medium, even when the cells are cultured in the basal protein-
free medium,
2 0 they can be converted in such a manner that sub-culturing can be stably
carried out.
Example 6
Serum-free fed-batch culture of FUT8 gene double knock out CHO/DG44 cell
naturalized in protein-free medium:
2 5 Fed-batch culture was carned out using the cell naturalised in a protein-
free
medium obtained in Example S.
Using the basal protein-free medium, the cell naturalized in a protein-free
medium was prepared into a cell density of 2x 105 cells/ml. Then, 15 ml of the
thus
prepared cell naturalized in a protein-free mediums was added to a 125 ml
capacity
3 0 conical flask and cultured at a culturing temperature of 35°C and
at a rotation speed of
100 rpm for 3 days. In this connection, at the time of the cell inoculation,
air in the
conical flask was substituted through the blowing of 500 ml or more of 5% in
concentration of COZ to the upper face of the medium. The cells obtained by
culturing
for 3 days were used as the seed cells and adjusted to a cell density of 3 x
105 cells/ml
35 using the basal protein-free medium, 30 ml of the suspension was inoculated
into a 125
ml capacity conical flask, and then the fed-batch culture was started at a
culturing
-92-
CA 02542121 2006-04-07
temperature of 35°C and at a rotation speed of 100 rpm. At the time the
cells were
inoculated, air in the flask was substituted through the blowing of 1 liter or
more of 5%
in concentration of COZ to the upper face of the medium. After commencement of
the
fed-batch culturing, a feed medium having the composition shown below was
added in
3.3 ml portions on the 3rd day and 6th day for the purpose of supplementing
consumed
amounts of amino acids and the like. In addition, 20% (w/v) glucose solution
was
added on the 3rd day of the culturing to make the final glucose concentration
to 5000
mgil. The results are shown in Fig. 7. The cells grew after commencement of
the
culturing until day 3, and the cell density was maintained for the most part
until day 3 to
day 6. Viable cell density on the 6th day of the culturing reached 2x106
cellslml.
The survival rate rapidly decreased when 6 days had passed from the
commencement of
culturing, and the cell survival rate became less that 50% on the 9th day, and
the fed-
bath culturing was completed.
In this connection, the feed medium used in the fed-hatch culturing was a
medium prepared by supplementing a general medium with amino acids (0.177 g/I
L-
alanine, 0.593 g/1 L-arginine monohydrochloride, 0.177 g/1 L-asparagine
monohydrate,
0.212 g/1 L-aspartic acid, 0.646 g/1 L-cystine dihydrochloride, 0.530 g/1 L-
glutamic acid,
5.84 g/1 L-glutamine, 0.212 g/1 glycine, 0.297 g/1 L-histidine
monohydrochloride
dihydrate 0.742 g/l, L-isoleucine, 0.742 g/1 L-leucine, 1.031 g/1 L-lysine
2 0 monohydrochloride, 0.212 gll L-methionine, 0.466 g/1 L-phenylalanine,
0.283 g/1
L-proline, 0.297 g/1 L-serine, 0.671 g/1 L-threonine, 0.113 g/1 L-tryptophan,
0.735 g/1
L-tyrosine disodium dihydrate, and 0.664 g/1 L-valine), vitamins (0.0918 mg/1
d-biotin,
0.0283 g/1 calcium D-pantothenate, 0.0283 g/1 choline chloride, 0.0283 g/1
folic acid,
0.0509 gll myo-inositol, 0.0283 gll niacinamide, 0.0283 gll pyridoxal
hydrochloride,
2 5 0.00283 g/I riboflavin, 0.0283 g/1 thiamin hydrochloride, and 0.0918 mg71
cyanocobalamin) and 0.314 gll insulin.
Example 7
Production of anti-CD20 human chimeric antibody by FUT8 gene double knock out
3 0 CHO/DG44 cell naturalized in protein-free medium, and biological activity
of the same:
Using the FUT8 gene double knock out cell naturalized in the protein-free
medium as described in Example 6, a stably producing cell of an anti-CD20
human
chimeric antibody was established, and productivity of the anti-CD20 human
chimeric
antibody and biological activity of the produced antibody were evaluated. In
this case,
3 5 in order to show superiority of the high ADCC activity antibody production
by the
FUT8 gene double knock out cell naturalized in the protein-free medium, anti-
CD20
-93-
CA 02542121 2006-04-07
human chimeric antibody producing clones were also established from CHO/DG44
cell
which is the parent cell line of the FUT8 gene double knock out cell, the GDP-
mannose-
4,6-dehydratase mutant cell line of CHO cell, Lec 13 cell, established by
Stanley, et al.
(Somat. Cell Mol Genet., 12, 51 (1986)) and the rat-rat hybridoma YB2/0
(American
Type Culture Collection CRL-1662), and their comparison was carried out. In
the case
of the Lec 13 and YB2/0 cells, they were used as comparative controls because
it has
been reported that it is possible to eiTect expression of a high ADCC activity
antibody
having high ratio of sugar chains in which fucose is not bound (J. Biol.
Chem., 277, 30,
26733 (2002); WO 02/31140).
1. Construction of clone stably producing anti-CD20 human chimeric antibody
In accordance with the method described in the item 2 of Example 2, an
anti-CD20 human chimeric antibody expression vector pKANTEX2B8P was introduced
into the FUTB gene double knock out cell naturalized in the protein-free
medium as
described in Example 6, the CHO/DG44 cell and the Lecl3 cell, and the cells
were
respectively inoculated into a 96-well culture plate (manufactured by Greiner)
and
cultured at 37°C for 1 to 2 weeks in a 5% COz incubator. Regarding the
transformants
of wells where their growth was observed in the IIVVIDM-dFBS(10) medium, they
were
further cultured for 1 to 2 weeks by changing the medium to IMDM-dFBS(10)
medium
2 0 containing 50 nmol/1 of MTX (manufactured by Sigma), in order to increase
the
antibody production by using a dhfr gene amplification system. Regarding the
transformants showing resistance to SO nmol/1 of MTX, their culturing was
continued
by further increasing the MTX concentration. By measuring expression of the
anti-
CD20 human chimeric antibody in the culture supernatants by the ELISA method
2 5 described iri the item 5 of Exafriple 2, transformarits capable of growing
in the IIVIDM
dFBS(10) medium containing 200, 500 or 1000 nmol/1 in concentration of MTX and
of
highly producing anti-CD20 human chimeric antibody were finally selected.
Regarding the YB2/0 cell, transformants capable of highly producing anti-CD20
human
chimeric antibody were selected in accordance with the method described in WO
3 0 03/055993.
Next, the transformants capable of highly producing anti-CD20 human
chimeric antibody obtained in this manner were naturalized in a serum-free
medium in
accordance with the method described in Example 5. EX-CELL 302 medium
(manufactured by 3RH) containing 200, 500 or 1000 nmol/1 of MTX and 6 mM L-
3 5 glutamine (manufactured by Invitrogen) (hereinafter referred to as "serum-
free
medium") was used in the serum-free medium naturalization of respective
transformants
-94-
CA 02542121 2006-04-07
established from the FUT8 gene double knock out cell naturalized in the
protein-free
medium, the CHOlDG44 cell and the Lecl3 cell. CD-Hybridoma medium
(manufactured by Invitrogen) (hereinafter referred to as "serum-free medium")
was used
for the naturalization of transformants established from the YB2/0 cell to the
serum-free
medium. The transformant established from the FUT8 gene double knock out cell
naturalized in the protein-free medium in this manner was named as clone
Ms704/CD20,
the transformant established from the CHO/DG44 cell was named as clone
DG44/CD20,
the transformant established from the Lecl3 cell was named as clone
Lecl3/CD20, and
the transformant established from the YB2/0 cell was named as clone YB/CD20.
In
this connection, the clone Ms704/CD20 has been deposited on August 13, 2004,
as
FERM BP-10092 in International Patent Organism Depositary, National Institute
of
Advanced Industrial Science and Technology (Tsukuba Central 6, 1-1, Higashi I-
Chome Tsukuba-she, Ibaraki-ken, 3apan).
2. Production of anti-CD20 human chimeric antibody by conical Mask serum-free
fed-
batch culture
Using the clone Ms704/CD20, clone DG44/CD20, clone Lecl3/CD20 and
clone YB/CD20 established in the item 1 of this Example, serum-free fed-batch
culture
using a conical flask was carried out, and production of anti-CD20 human
chimeric
2 0 antibody by each clone was carried out.
(1) Serum-free fed-batch culture using conical flask
A medium prepared by further adding 20% (w/v) glucose solution to the
serum-free medium of the previous item to a final concentration of 5000 mg/1
2 5 (hereinafter referred to as "seruiri-free fed-batch culture medium") was
used as the basal
medium of the fed-batch culture. A medium containing various amino acids
(0.177 g/1
L-alanine, 0.593 g/1 L-arginine monohydrochloride, 0.177 g/1 L-asparagine
monohydrate, 0.212 g/I L-aspartic acid, 0.646 g/1 L-cystine dihydrochloride,
0.530 g/1
L-glutamic acid, 5.84 g/1 L-glutamine, 0.212 gel glycine, 0.297 g/I L-
histidine
3 0 monohydrochloride dehydrate, 0.742 g/I L-isoleucine, 0.742 g/1 L-leucine,
1.031 g/1
L-lysine monohydrochloride, 0.212 g/1 L-methionine, 0.466 g/1 L-phenylalanine,
0.283
g/I L-proline, 0.297 g/I L-serene, 0.671 g/1 L-threonine, 0.113 g/1 L-
tryptophan, 0.735 g/1
L-tyrosine disodium dehydrate, and 0.664 g/1 L-valine), various vitamins
(0.0918 mg/1
d-biotin, 0.0283 g/1 calcium D-pantothenate, 0.0283 g/I choline chloride,
0.0283 gel
3 5 folic acid, 0.0509 g/1 myo-inositol, 0.0283 g/1 niacinamide, 0.0283 g/1
pyridoxal
-95-
CA 02542121 2006-04-07
hydrochloride, 0.00283 g/1 riboflavin, 0.0283 gil thiamin hydrochloride, and
0.0918
mg/1 cyanocobalamin) and 0.314 gll insulin was used as the feed medium.
Each of the clone Ms704/CD20, clone DG44/CD20, clone Lecl3/CD20 and
clone YB/CD20 was suspended in the serum-free fed-batch culture medium at a
density
of 3 x 105 cells/ml, and 40 ml of said cell suspension was inoculated into a
250 ml
capacity conical flask (manufactured by Corning Glassworks). After
substituting air in
the flask through the blowing of 5% COZ gas in an amount of 4 volumes or more
of the
culture container, the container was sealed to carry out the culturing at
35°C while
stirring at a revolution speed of 90 to 100 rpm. On the 3rd day, 6th day, 9th
day and
11th day after commencement of the culturing, 3.3 ml of the above-described
feed
medium was added for the purpose of supplementing consumption of amino acids
and
the like, and 20% (w/v) glucose solution was added to a final concentration of
5000
mg/1 for the purpose of controlling glucose concentration. Also, on the 0th
day, 3rd
day, 6th day, 9th day, l lth day and 13th day, about 2 ml of the culture
liquid was
collected, and viable cell density and cell survival rate were measured by the
trypan
blue staining method, and the concentration of anti-CD20 human chimeric
antibody
contained in each culture supernatant was measured by the ELISA method
described in
the item 2 of Example 3, respectively.
The fed-batch culturing was completed when the cell survival rate of each
2 0 clone became 60% or less. Viable cell density and cell survival ratio of
the clone
Ms704iCD20 at each period after commencement of the culturing were identical
to or
larger than those of the clone DG44/CD20. On the other hand, the clone
Lecl3/CD20
was slow in the growing ability and also low in the maximum cell reach
density. Also,
the cell survival ratio of the clone YB/CD20 rapidly lowered after reaching
the
2 5 maximum cell reach density, so that it was difficult to carry out the fed-
batch culturing
for a prolonged period of time. In addition, regarding the antibody
production,
accumulated amount of the antibody increased in proportion to the cumulative
viable
cell density in all of the clones, and reached maximum production level at the
time of
the completion of culturing. Accordingly, it was revealed that, even in the
cell clone in
3 0 which the FUT8 gene was disrupted, difference in the surviving ability due
to cell
growth property and culturing stress was not found in comparison with the
parent clone,
and it shows good culturing behavior in comparison with other clones capable
of
expressing high ADCC activity antibody having high ratio of sugar chains to
which
fucose is not bound.
-96-
CA 02542121 2006-04-07
(2) Analysis of biological activities of antibody compositions produced by
serum-free
fed-batch culture
Using the culture liquids periodically collected from the clone Ms704/CD20,
clone DG44/CD20, clone Lecl3/CD20 and clone YBJCD20 during their serum-free
fed-
batch culturing of the above-described (1), the ratio of sugar chains, in
which fucose is
not bound, in the anti-CD20 human chimeric antibody composition contained in
each of
the cultured mediums, was analyzed. The ratio of sugar chains in which fucose
is not
bound was measured by the ELISA method using the binding activity for soluble
human
FcyRIIIa (hereinafter referred to as "shFcyRIIIa") as the index, based on the
conventionally known method described in Biotechnology and Bioengineering, 87,
618,
(2004). As the standard antibodies having already known ratio of sugar chains
in
which fucose is not bound, the KM2760-1 (ratio of sugar chains in which fucose
is not
bound: 90%) and KM3060 (ratio of sugar chains in which fucose is not bound:
10%)
described in the item 5 of Example 4 of WO 03/085119 were used. The cultured
mediums collected from the respective clones in the above-described (1) and
the
standard antibodies were prepared into antibody solutions of S pg/ml by
diluting with
1% BSA-PBS and used as the evaluation samples.
As a result of the measurement, the binding activity for shFcyRIIIa was
hardly found in samples of the clone DG44iCD20, so that it was revealed that
an
2 0 antibody composition having a sugar structure to which fucose is bound is
contained
therein. In the case of the samples of clone Lecl3/CD20 and YBlCD20, it was
revealed that they contain an antibody composition having high ratio of sugar
chains in
which fucose is not bound, in the early stage of the culturing, but the ratio
of antibody
composition having a sugar structure in which fucose is bound is increased as
the
culturing period prolongs. The ratio of sugar chains in which fucose is not
bound was
60% or less in the anti-CD20 human chimeric antibody contained in the sample
at the
time of completion of the fed-batch culturing of clone Lecl3/CD20. On the
other hand,
samples of the clone Ms704/CD20 showed strong binding activity against
shFcyRIIIa
stably throughout the culturing period. When the ratio of the sugar chain in
which
3 0 fucose is not bound in the anti-CD20 human chimeric antibody contained in
the samples
of clone Ms704/CD20 was calculated based on the absorbance of ELISA on the
standard antibodies, it was estimated that this is kept at 100% throughout the
culturing
period.
Based on the above results, it was revealed that the FUT8 gene double
3 5 knock out cell naturalized in the serum-free medium can stably produce the
antibody
composition having a fucose free sugar chain of N-acetylglucosamine in the
reducing
-97-
CA 02542121 2006-04-07
end in the complex type N-glycoside-linked sugar chain, by the serum-free fed-
batch
culture using a conical flask.
3. Production of anti-CD20 human chimeric antibody having a sugar chain in
which
fucose is not bound, by suspension agitation reactor serum-free fed-batch
culture
An examination was carried out on whether or not stable production of an
antibody having a sugar chain in which fucose is not bound can be made even by
the
suspension agitation reactor serum-free fed-batch culture which is used for
the
commercial production of antibody medicines.
(1) Expansion culturing of seed cells
EX-CELL 302 medium containing 500 nM of MTX and 1.75 g/1 of L-
glutamine (hereinafter referred to as "medium for expansion culturing") was
used as the
medium for carrying out expansion culturing until reaching the reactor
culturing.
About from 10 to 30% volume of the medium for expansion culturing was put into
a
125 ml, 250 ml or 1000 ml capacity conical flask (manufactured by Corning
Glassworks), and a cell suspension was inoculated to a density of 3 x 105
cells/ml and
cultured at 37°C for 4 days. Sub-culturing was repeated several times
until the number
of cells necessary for the inoculation of the reactor culturing was obtained.
(2) Reactor culturing
A medium prepared by further adding 500 nM of MTX and 1.75 g/1 of L-
glutamine to the medium for expansion culturing of ( 1 ) (hereinafter referred
to as
"medium for reactor culturing") was used as the basal medium of the reactor
culturing.
2 5 When the number of necessary cells was obtained by the above-described
expansion culturing, the cells were inoculated into a 1 liter capacity
bioreactor
(manufactured by ABLE) filled with 700 ml of the medium for reactor culturing,
to a
density of 3x105 cells/ml, and cultured for 17 days under a condition of
35°C, pH 7.1
and DO 50%. A medium consisting of amino acids (0.14 g/1 L-alanine, 0.47 g/1 L-
3 0 arginine monohydrochloride, 0.16 g/1 L-asparagine monohydrate, 0.17 g/1 L-
aspartic
acid, 0.51 g/1 L-cystine dihydrochloride, 0.42 g/1 L-glutamic acid, 7.3 g/1 L-
glutamine,
0.17 g/1 glycine, 0.24 g/1 L-histidine monohydrochloride dehydrate, 0.59 g/1 L-
isoleucine,
0.59 g/1 L-leucine, 0.82 g/1 L-lysine monohydrochloride, 0.17 g/1 L-
methionine, 0.37 g/1
L-phenylalanine, 0.22 g/1 L-proline, 0.24 g/1 L-serene, 0.53 g/1 L-threonine,
0.09 gll
3 5 L-tryptophan, 0.58 g/1 L-tyrosine disodium dehydrate, and 0.3 g/1 L-
valine), vitamins
(0.073 mg/1 d-biotin, 0.022 gel calcium D-pantothenate, 0.022 g/1 choline
chloride,
-98-
CA 02542121 2006-04-07
0.022 g/1 folic acid, 0.040 g/1 myo-inositol, 0.022 g/1 niacinamide, 0.022 gll
pyridoxal
hydrochloride, 0.0022 g/1 riboflavin, 0.022 g/1 thiamin hydrochloride, and
0.073 mgil
cyanocobalamin), 0.31 g/1 recombinant human insulin (manufactured by 7RH),
0.025 g/1
ethanolamine (manufactured by Sigma-Aldrich), 0.0098 g/1 2-mercaptoethanol
(manufactured by Sigma-Aldrich), 8 g/1 soybean hydrolysate HY-SOY
(manufactured
by Quest International), 16.8 gg/1 sodium selenite (manufactured by Sigma-
Aldrich), 2
ml/1 cholesterol lipid concentrated solution (250 x aqueous solution,
manufactured by
Invitrogen) and 0.05 g/1 ferric ethylenediaminetetraacetate sodium salt
(manufactured
by Sigma-Aldrich) was used as the feed medium, and 8.3% of the initial medium
volume was added on the 3rd, 5th, 7th, 9th and 1 lth days of the culturing. In
addition,
500 g/1 glucose solution was optionally added in such a manner that glucose
concentration on and after the 3rd day of the culturing became about 4 gfl.
By collecting the culture liquid once a day from commencement of the
culturing until completion of the culturing, viable cell density (cellslml)
and cell
survival rate were measured by a dye-exclusion method using 0.4% trypan blue
solution
(manufactured by Invitrogen), and antibody concentration (mg/1) measured by
HPLC,
respectively.
Specific antibody production rate was calculated by the following formula.
In this connection, regarding the cumulative viable cell density (cellsiml x
day), the
2 0 product of viable cell density (cells/ml) and unit time (day) was
calculated at each
measuring time, and their total was used as the value. In this Example, the
viable cell
density was measured once a day, so that the viable cell density x day at each
time was
totaled and used as the cumulative viable cell density.
2 5 Specific antibody production rate (pg/cell/day)
= antibody concentration (mg/1)
cumulative viable cell density (cells/ml x day)
The results of carrying out serum-free fed-batch culture using a suspension
3 0 agitation reactor are shown in Fig. 8. The viable cell density reached the
maximum on
the 13th day of the culturing. The cell survival rate maintained a high value
of 90% or
more from the commencement of culturing until on the 13th day of the
culturing,
gradually decreased thereafter and became 12% on the 17th day of the
culturing. The
cumulative viable cell density was 5.6x 107 cells/ml x day in 17 days, the
antibody
3 5 concentration at the time of the completion of culturing reached 1.7 g/1,
and the specific
antibody production rate showed 30 pg/cell/day. This result exceeded the
standard
- 99 -
CA 02542121 2006-04-07
production titer of antibody medicines, 0.5 to 1.0 g/l. In addition,
asparagine binding
type sugar chain was released from the antibody samples purified from the
cultured
mediums collected on the 5th, 7th, 14th and 17th days after commencement of
the
culturing, using N-glycanase F. After deproteinization and subsequent
desalting by an
ion exchange resin, sugar chain structures were analyzed by a mass
spectrometer. At
each point of time of the 5th, 7th, 14th and 17th days after commencement of
the
culturing, sugar chains in which fucose is bound were less than the detectable
limit, and
the antibody having the complex type N-glycoside-linked sugar chain in which
fucose is
not bound was stably produced.
Based on the above results, it was confirmed that the FUT8 gene double
knock out cell naturalized in the serum-free medium can stably and highly
produce the
antibody composition having a sugar chain in which fucose is not bound to the
N-
acetylglucosamine in the reducing end of the complex type N-glycoside-linked
sugar
chain, also by the serum-free fed-batch culture using a suspension agitation
reactor
which is used in the commercial production of antibody medicines.
4. Biological activities of antibody composition which is produced by the
serum-free
fed-batch culturing and to which fucose is not bound
By measuring biological activities of the anti-CD20 human chimeric
2 0 antibody produced in the item 3 of this Example (hereinafter also referred
to as
"Ms704/CD20 antibody"), superiority of the antibody composition produced by
the
present production method was confirmed. As the comparative control, the anti-
CD20
human chimeric antibody described in the item 2 of this Example (hereinafter
referred
also to as "DG44/CD20 antibody") was used, which was produced using the
2 5 CHO/DG44 cell used in the production of commercially available antibodies.
(1) Antigen binding activity of anti-CD20 human chimeric antibody against CD20
antigen expressed clone
When the activity was measured in accordance with the fluorescent antibody
30 technique described in the item 1 of Example 2 of WO 03/055993, a
difference in the
antibody staining strength on Raji cell was not observed by the FACS analysis,
and a
difference in the antigen binding activity was not observed between the anti-
CD20
human chimeric antibody produced in the item 3 of this Example and the anti-
CD20
human chimeric antibody produced using the CHO/DG44 cell described in the item
2 of
3 5 this Example. Accordingly, it was confirmed that when the production is
carried out
using the FUT8 gene double knock out cell naturalized in the serum-free
medium, the
- 100 -
CA 02542121 2006-04-07
product has the antigen binding activity equivalent to that of the antibody
composition
produced by using the parent cell line CHOiDG44 cell.
(2) Ex vivo cytotoxic activity (ADCC activity) of anti-CD20 human chimeric
antibodies
ADCC activity, in human peripheral blood, of the anti-CD20 human
chimeric antibody produced in the item 3 of this Example and the anti-CD20
human
chimeric antibody produced using the CHO/DG44 cell described in the item 2 of
this
Example was measured in the following manner.
Each of the Ms704/CD20 antibody and DG44/CD20 antibody was diluted
with Dulbecco's PBS (manufactured by Invitrogen) and dispensed in 100 pl/well
portions into each well of a 24 well flat bottom plate (manufactured by
Greiner). Next,
a human peripheral blood sample collected from a healthy person was mixed with
heparin sodium (manufactured by Shimizu Pharmaceutical) and dispensed in 500
pl/well portions, followed by culturing at 37°C overnight in a 5% COZ
incubator.
After the reaction, 150 p,l of the reaction liquid was collected from each
well and
washed with 1% BSA-PBS, and then an FITC-labeled mouse anti-CD19 monoclonal
antibody (manufactured by Beckman Coulter) and a PE-labeled mouse anti-CD2
monoclonal antibody (manufactured by Pharmingen) were added thereto and
allowed to
react at room temperature for 30 minutes in the dark. Removal of erythrocyte
and cell
2 0 fixation treatment were carried out using FAGS Lysing Solution
(manufactured by
Becton Dickinson), and after washing with 1% BSA-PBS, the fixed cells were
suspended in 500 pl of 1% BSA-PBS and filtered through a cell strainer
(manufactured
by Falcon) to prepare as an analyzing sample. A fraction containing about
5,000
lymphocytes per sample was measured using a flow cytometer FACS Caliber
(manufactured by Becton Dickinson), and the ratio of CD2-negative and CD19-
positive
B cell against the total cells was calculated.
The results are shown in Fig. 9. Under the Ms704/CD20 antibody added
condition, the ratio of B cell was reduced compared to the DG44/CD20 antibody
added
condition, so that high ADCC activity of the Ms704/CD20 antibody upon B cells
was
3 0 shown. Based on this result, it was confirmed that the antibody
composition produced
by the FUT8 gene double knock out cell naturalized in the serum-free medium
has
higher cytotoxic activity upon human blood plasma than that of the antibody
composition produced by its parent cell line CHO/DG44 cell.
- 101 -
CA 02542121 2006-04-07
(3) In vitro cytotoxic activity (ADCC activity) of anti-CD20 human chimeric
antibodies
In vitro ADCC activity of the anti-CD20 human chimeric antibody
produced in the item 3 of this Example and the anti-CD20 human chimeric
antibody
produced by its parent cell line CHO/DG44 cell described in the item 2 of this
Example
was measured using a human B lymphocyte cell line WIL2-S cell (ATCC CRL-8885)
which expresses human CD20 antigen, as the target cell, in accordance with the
method
described in Example 3.
The results are shown in Fig. 10. At each of the antibody concentrations,
the Ms704/CD20 antibody showed higher ADCC activity upon WIL2-S cell than the
DG44/CD20 antibody added condition.
Next, an anti-CD20 human chimeric antibody composition in which ratio of
the antibody having a sugar chain in which fucose is not bound was changed by
adding
DG44/CD20 antibody to a fixed amount of Ms704/CD20 antibody was prepared, and
its
ADCC activity was measured. Specifically, an anti-CD20 human chimeric antibody
composition in which from 0 to 300 ng/ml of DG44/CD20 antibody was added to
3.7
ng/ml of Ms7041CD20 antibody was prepared.
The results are shown in Fig. 11. When Ms704/CD20 antibody was
further added to 3.7 ng/ml of Ms704/CD20 antibody, increase of ADCC activity
was
observed with the increase of the total antibody concentration, but ADCC
activity of the
2 0 prepared antibody composition was conversely decreased when DG44/CD20
antibody
was further added to 3.7 ng/ml of Ms704/CD20 antibody, in spite of the
increase in the
total antibody concentration. This fact shows that an antibody molecule having
a sugar
chain in which fucose is bound inhibits ADCC activity of an antibody molecule
having
a sugar chain in which fucose is not bound. In addition, also in the case of
antibody
compositions in which an antibody molecule having a sugar chain in which
fucose is
bound was mixed with an antibody molecule having a sugar chain in which fucose
is
not bound, the antibody composition having 20% or more of the ratio of the
antibody
having a sugar chain in which fucose is not bound showed considerably high
ADCC
activity in comparison with that of the antibody composition having less than
20% of
3 0 the said ratio.
Furthermore, ADCC activity of 1 ng/ml of an Ms704/CD20 antibody
sample and an antibody prepared by adding 9 volumes of 9 ng/ml of DG44/CD20
antibody to 1 ng/ml of Ms704/CD20 antibody was measured.
The results are shown in Fig. 12. ADCC activity of Ms704/CD20 antibody
3 5 was sharply decreased by the addition of DG44/CD20 antibody. In addition,
even
when antibody concentration of the antibody composition was increased 100-fold
or
- 102 -
CA 02542121 2006-04-07
more while keeping the existence ratio of Ms704/CD20 antibody to DG44/CD20
antibody at 1:9, it was not equal to the ADCC activity of the 1 ng/ml
Ms704/CD20
antibody sample.
Based on the above, it was revealed that an antibody molecule having a
sugar chain in which fucose is bound inhibits ADCC activity of an antibody
molecule
having a sugar chain in which fucose is not bound, and that the conventional
antibody
compositions cannot exert the ADCC activity which is equivalent to the
antibody
composition of the present invention.
In this connection, similar results were obtained from other antibody
compositions produced by the production method of the present invention.
Industrial Applicability
The present invention provides a cell in which a genomic gene encoding an
enzyme relating to a sugar chain modification in which 1-position of fucose is
bound to
6-position of N-acetylglucosamine in the reducing end through a,-bond in a
complex
type N-glycoside-linked sugar chain is knocked out, wherein the cell is
naturalized in a
serum-free medium; a process for producing a glycoprotein composition using
the cell;
and a glycoprotein composition produced by the process.
2 0 Free Texts of Sequence Listing
SEQ ID NO:10 - Explanation of artificial: Synthetic
sequence DNA
SEQ ID NO:11 - Explanation of artificial: Synthetic
sequence DNA
SEQ ID N0:12 - Explanation of artificial: Synthetic
sequence DNA
SEQ 117 N0:13 - Explanation of artificial: Synthetic
sequence DNA
2 5 SEQ Il7 N0:14 - Explanation of artificial: Synthetic
sequence DNA
SEQ 117 NO:15 - Explanation of artificial: Synthetic
sequence DNA
SEQ ID N0:16 - Explanation of artificial: Synthetic
sequence DNA
SEQ D7 N0:17 - Explanation of artificial: Synthetic
sequence DNA
SEQ ID N0:20 - Explanation of artificialSynthetic
sequence: DNA
3 0 SEQ ID N0:21 - Explanation of artificialSynthetic
sequence: DNA
SEQ ID N0:22 - Explanation of artificialSynthetic
sequence: DNA
SEQ ID N0:23 - Explanation of artificialSynthetic
sequence: DNA
SEQ ID N0:24 - Explanation of artificialSynthetic
sequence: DNA
SEQ 117 N0:25 - Explanation of artificialSynthetic
sequence: DNA
3 5 SEQ 117 N0:26 - Explanation of artificialSynthetic
sequence: DNA
SEQ 11.7 N0:27 - Explanation of artificialSynthetic
sequence: DNA
- 103 -
CA 02542121 2006-04-07
SEQ >D N0:28 - Explanation of artificial sequence: Synthetic DNA
SEQ m N0:29 - Explanation of artificial sequence: Synthetic DNA
SEQ ID N0:30 - Explanation of artificial sequence: Synthetic DNA
SEQ ID N0:31 - Explanation of artificial sequence: Synthetic DNA
SEQ ID N0:32 - Explanation of artificial sequence: Synthetic DNA
- 104 -
DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPRI~:ND PLUS D'UN TOME.
CECI EST L,E TOME 1 DE 2
NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des
Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.
THIS IS VOLUME 1 OF 2
NOTE: For additional valumes please contact the Canadian Patent Office.
